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ABSTRACT 
 
Neuromodulation of the immune system has been described to be influenced by 
hemispheric lateralisation (HL), the stable tendency to relatively utilise one 
hemisphere or its functions over another. To date there has not been a systematic 
review of research in this phenomenon conducted, and only one study has examined 
the effects of HL on the progression of a disease – Human Immunodeficiency Virus 
(HIV). That research was conducted on a small sample with little control for 
confounders. The present work sought to compile a systematic review of literature 
concerning HL and immunity in humans, using effect size analysis. Further, the 
present work also describes an empirical advancement of this earlier HIV study with 
stricter control over confounds in a larger sample. The findings corroborated the 
theory of asymmetrical immune influence by HL via the systematic review showing 
clear, relatively consistent and strong relationships between left-HL and 
immunopotentiation. The empirical prospective study extended current knowledge of 
this relationship in HIV to identify a moderator – HAART treatment. Specifically, 
left-HL predicted better immunity in HIV-1 patients independent of confounders, with 
further findings of the same pattern in untreated patients, but not in HAART-treated 
patients. Further observations were made between HL and HIV-relevant behaviours, 
again adding to current knowledge. The finding of left-HL being associated with 
fewer sexual partners in Europeans presents new information of relevance to public 
health. The combined findings of the present work suggest that left-HL has predictive 
value in illness (HIV-1) and in general immunity. The present work adds to the 
existing knowledge new information concerning a moderating factor of the HL-
immunity relationship in HIV, and behavioural implications of HL which impact upon 
HIV disease. Potential explanations for moderation, proposals for neurobiological 
mechanisms and direction towards future, more rigourous study in the field, both in 
HIV and immunity, are discussed. 
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PSYCHONEUROIMMUNOLOGY AND THE BIDIRECTIONAL 
MANNER OF COMMUNICATION BETWEEN THE BRAIN AND 
IMMUNE SYSTEM 
 
Psychoneuroimmunology describes a bi-directional manner of communication 
between the central nervous system (CNS) and immune system in humans and other 
animals (Bellinger et al., 2008; Ferone et al., 2006; Webster et al., 2002) and how 
psychological factors influence immunity. The composite mechanisms of this bi-
directional communication rely on networks associated with neurological, endocrine 
and immune systems (Banks, 2004; Besedovsky & del Ray, 1996; 2007; Butts & 
Sternberg, 2008; Taub, 2008). The immune system communicates with the CNS once 
an infection has been encountered in the periphery to initiate a sequence of events 
termed sickness behaviour which serve to provide optimum behavioural conditions to 
facilitate immune defence and recovery (Hopkins, 2007; Konsman et al., 2002; 
Rivest, 2003; Vollmer-Conna et al. 2004). The CNS communication with the immune 
system largely comes in the form of modulating immune parameters, in ways which 
are still being discovered, including sympathetic and neuroendocrine pathways 
(Ferone et al., 2006; Neveu, 1988; Webster et al., 2002; Wrona, 2006). Evidence of 
cerebral influence on immune function also comes from neurophysiological 
observations concerning hemispheric lateralisation (HL), a phenomenon still under 
research which not only demonstrates CNS to immune system communication but 
also serves to explain some individual differences within this association (Neveu, 
1988; 1991; 1992). 
 
IMMUNE TO BRAIN COMMUNICATION 
Perhaps the most obvious illustration of the influence of the immune system on the 
CNS is the generation of sickness behaviour (Banks, 2004; Besedovsky & del Ray, 
1996, 2007; Konsman et al., 2002). Sickness behaviour is a collective term for 
behavioural responses to the increased circulation of proinflammatory cytokines 
resulting from peripheral illness, including somnolence, hyperalgesia, lethargy and 
anorexia, which facilitate convalescence (Banks, 2004; Hopkins, 2007; Rivest, 2003). 
On a biological level, there is further evidence for immune system influence on CNS 
functioning, most notably in stimulation of the hypothalamo-pituitary adrenal (HPA) 
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axis (in releasing corticotropin releasing hormone and vasopressin) by interleukin- 
(IL)1, IL-2, IL-3, IL-6, IL-8, IL-11, IL-12, tumour necrosis factor- (TNF) α, 
interferon- (IFN) γ, and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(Goncharova & Tarakanov, 2007; Guyon, et al., 2008; Hopkins, 2007). Transport of 
immune signals to the brain is largely considered to occur by three means; via the 
vagus nerve, the circumventricular organs (CVO) and through mediators on both sides 
of the blood brain barrier (BBB); which together make up the Dorsal Vagal Complex 
(Guyon et al., 2008; Quan & Banks, 2007; Rivest, 2003; Wrona, 2006).  
There is also evidence that immune cells can exude hormones, neuropeptides and 
neurotransmitters such as catecholamines, which are transmitted to the brain (either 
systemically or via neural pathways – most notably the vagus nerve) and ultimately 
create further neuroendocrine alterations (Banks, 2004; Besedovsky & Del Ray, 1996, 
2007; Hopkins, 2007; Wrona, 2006). These observations have led to the immune 
system being characterised as another sensory organ used by the brain to ensure 
survival of the organism (Besedovsky & Del Ray, 1996, 2007; Goncharova & 
Tarakanov, 2007; Hopkins, 2007; Wrona, 2006).  
Finally, there is evidence for centrally located receptors for immune signals and for 
cytokines such as IL-1(α and β), IL-2, IL-4, IL-6, TNF-α, IFN-γ, macrophage colony 
stimulating factor (M-CSF), and stem cell factor (SCF) (Besedovsky & Del Ray, 
1996; Goncharova & Tarakanov, 2007; Hopkins, 2007; Rivest, 2003; Wrona, 2006), 
indicating that such immune signals operate in the CNS.  
 
CENTRAL NERVOUS SYSTEM COMMUNICATION WITH THE IMMUNE 
SYSTEM 
One of the first demonstrations of a neural influence on immune system function 
came in the form of a conditioning experiment by Ader & Cohen in 1975 (Ader, 
2003; Ader & Cohen, 1975). They demonstrated an immune response to a drug or 
antigen could, by classical conditioning, become associated with a taste stimulus 
(Ader, 2003; Ader & Cohen, 1975). Since this discovery much research has been 
undertaken to elucidate the nature of this relationship and the mechanisms by which 
these influences take place. This very large field of research can be largely split into 
two groups based on the mechanism of communication; communication to organs and 
communication to immune cells (Banks, 2004; Bellinger et al., 2006, 2008; 
Besedovsky & Del Ray, 1996; Butts & Sternberg, 2008; Ferone et al., 2006).  
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CNS communication with immune organs 
Organs of the lymphatic system, such as bone marrow, thymus, spleen, mucosal 
lymphoid tissues and lymph nodes, are innervated by autonomic fibres – mainly of the 
sympathetic division, but parasympathetic involvement has recently been described 
(Bellinger et al. 2006; 2008; Quan & Banks, 2007; Wrona 2006). The main regions of 
the brain which feed into these communication pathways are: the HPA axis, most 
notably the anterior, medial, lateral aspects and paraventricular nucleus of the 
hypothalamus; the CVO; certain limbic structures, most notably the amygdala and 
hippocampus; the cortex; the cerebellum; the dorsal vagal complex and the midbrain 
periaqueductal grey matter (Banks, 2004; Bellinger et al. 2006; 2008; Quan & Banks, 
2007; Webster et al., 2002; Wrona 2006). The purpose of these innervations ranges 
from direct regulation of function, such as haematopoiesis, lymphopoeisis and 
vasomotor function; following the provision of neurotransmitters (NT), neuropeptides 
(NP) and hormonal signalling (Banks, 2004; Bellinger et al. 2006; 2008; Quan & 
Banks, 2007; Wrona 2006).    
 
CNS communication with immune cells 
The main means of direct communication with immune cells comes in the form of 
neurochemical signalling, using NTs, NPs and hormones (Bellinger et al., 2008; 
Besedovsky & Del Ray, 1996; 2007; Butts & Sternberg, 2008; Levite, 2008; Taub, 
2008). Receptors for various hormones, NPs and NTs have been found to be 
expressed on the surface of many immune cell types, making a main “meeting point” 
for CNS-immune communication (Basu & Dasgupta, 2000; Ferone et al., 2006; 
Levite, 2008; McKenna et al., 2002; Wrona, 2006). These NPs, NTs and hormone 
receptors include, but are not limited to, receptors for: acetylcholine, β-adrenergic 
agents, dopamine, vasointestinal peptide, prolactin, growth hormone, glutamate, 
serotonin, corticosteroids, neuropeptide Y, somatostatin, cortistatin, estradiol, insulin, 
testosterone, endorphins, substance P, µ- δ- and κ-opioids and enkephalins, but are not 
equally expressed across all immune cells (Levite, 2008; Taub, 2008; Wrona, 2006).  
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DIFFERENTIAL CNS INFLUENCES ON THE IMMUNE SYSTEM: 
HEMISPHERIC LATERALISATION 
The nature of the effects of the CNS on the immune system can be dependent upon 
many factors, including hemispheric lateralisation (HL); the stable tendency to 
relatively activate or utilise the functions of one hemisphere versus the other. The two 
hemispheres of the human brain have different functional specialisations, and it is 
well known that one of the hemispheres will be functionally dominant to the other 
(Cerqueira et al., 2008; Hugdahl, 2000; Neveu, 1988, 1991, 1992). The two 
hemispheres of the brain are known to act differentially upon behaviour, and mood, 
manifested in psychiatric and neurological disorders and act differentially on 
immunity (Coan & Allen, 2004; Davidson, 2003; Neveu, 1992). Experimental studies 
in animals across the last two decades have demonstrated that damage to the left or 
right hemispheres of the brain results in opposite immunological reactions (Neveu, 
1988, 1991, 1992). Damage to the left hemisphere results in the depression of 
immunological parameters; such as T-lymphocyte proliferation, natural killer cell 
activity (NKCA), IL-2, and Immunoglobulin G antibody production (Neveu, 1988, 
1991, 1992). Damage to the right hemisphere can produce either no immunological 
change, or even enhance certain immune parameters (Neveu, 1988, 1991, 1992).  
 
In 1982, one research group developed a theory based on the association of prenatal 
testosterone exposure, what they termed “anomalous dominance” (i.e. abnormal 
language lateralisation, left handedness) (Geschwind & Behan, 1982). In observing 
higher incidences of left-handedness amongst populations of individuals with 
developmental and immune disorders, Geschwind and Behan hypothesised that this 
anomalous dominance was partly responsible for the variation observed across 
individuals in susceptibility to illnesses (Geschwind & Behan, 1982; Morfit & 
Weekes, 2001). This proposal was supported through large population surveys of left-
handed individuals, along with population surveys of sinistrality in patients with 
migraine and immune disorders (Geschwind & Behan, 1982). Whilst this research 
was vital to the initiation of investigation of HL effects on immune function, it was 
fraught with conceptual and methodological flaws. Most notable of which was 
“anomalous dominance”, which cannot be determined by handedness alone, since also 
among right handed people alone, many have a right (and not left) stronger 
hemisphere activity, and “anomalous dominance” is too broad a concept in itself to be 
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used as a definition of cerebral dominance pattern (McManus & Bryden, 1991). 
Indeed, handedness is very poorly, if at all, correlated with HL, but rather may be 
indicative of language lateralisation only (Jung et al., 2003; Toga & Thompson, 
2003). Moreover, research with animals has suggested that “handedness” effects on 
the immune system can be abolished with unilateral cortical ablation to the left 
hemisphere (Neveu et al., 1991), and may therefore not be a stable index of HL 
activation.  
 
Studies of Lateralisation and Immunity: The present and the future 
Since the landmark research of Geschwind and Behan (1982), more research groups 
have begun to examine the relationship between HL and immune function in humans. 
The emphasis of research in this field is now centred upon activational HL (i.e. the 
overall lateralisation of hemispheric activation) and on relative utility of certain 
functions associated with one hemisphere, rather than on the psychomotor concept of 
handedness (i.e. specialisation).  With the developments in science which have 
occurred in the last two decades it is now possible to easily view individuals’ brain 
activation patterns, assess neuropsychological functioning via multitudes of tests and 
perform sophisticated laboratory testing to analyse the components of blood and 
immunity. These developments have made the examination of the brain and immune 
relationships infinitely more feasible and accurate, yet more complex as well.  
 
Whilst the study of the HL-immunity relationship has continued, there has not been a 
synthesised examination of the cumulative data. Considering data in this area has 
been generated for almost 30 years, an evaluation of the combined associations of the 
literature is both timely and important. Moreover, only one study to date has 
examined the implications of this relationship on the progression of a disease. This 
study explored the predictive capability of HL on the prognostic immune markers of 
T-cells in Human Immunodeficiency Virus (HIV) and provided support for the 
relationship between laterality and immunity (Gruzelier et al., 1996). Further, this 
study provided support for the theory that HL has opposite effects on immunity, 
insomuch as left HL provides immunopotentiation and right HL elicits 
immunosuppression. These findings echo previous findings in both animal and human 
studies (Ivashkova et al., 2002; Neveu, 1992), but – crucially - apply these findings to 
a disease.  However, this study had several critical limitations, including lack of 
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statistical control for baseline immunity, a modest sample size and type, and nearly no 
methodological or statistical control for variables which create interference in the 
general functioning of the immune system (e.g. other illnesses such as cancer), or the 
modulation of HIV disease course (e.g. psychological morbidity, duration of illness). 
Therefore, despite the initial encouraging results of this study, the findings need to be 
replicated in a larger sample of HIV patients, with more advanced statistical and 
methodological control.  
 
THESIS AIMS & OBJECTIVES 
The role of HL in immunity 
Given the wealth of literature available concerning the relationship between HL and 
immunity in humans there is a need for compilation and assessment of the data. As 
this is a relatively new field of research, it is important to evaluate the strengths of 
evidence and identify gaps in knowledge and future methodological requirements. 
Systematic reviews provide a synthesized appraisal of data to guide future research 
and best-practice in parallel investigations, and are vital to assess generalisability of 
existing findings (Cook et al., 1997; Mulrow, 1994). Further, they are essential for the 
identification of methodological limitations inherent within that field, and can guide 
research to overcome these limitations. In order to substantially posit that HL impacts 
immunity, it is necessary to statistically evaluate the strength of the current evidence. 
If such a postulation can be corroborated by the combined findings of the available 
literature, this could provide a validation for this proposal in assessing the modulation 
of the immune system by the brain. Moreover, the implications of such a relationship 
could be applied to many areas of research; in identifying individual differences in 
disease course, potential targets for interventions and considerations in the treatment 
of disease.  
It is therefore one of the aims of the present work to conduct a systematic review of 
available literature on humans. This review will summarise the data, statistically 
evaluate the strengths of the data through effect size analysis, and provide detailed 
quality analysis of the research methodological quality, with guidelines for future 
directions. By analysing the data in such a way, this provides a unique opportunity to 
establish and formulate a research advancement guided by the cumulative knowledge 
of studies thus far conducted. 
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The role of HL in HIV 
To provide a practical application of the present theory, and to advance the currently 
available evidence in a disease model, a study was designed and executed to advance 
the findings of Gruzelier and colleagues. Inclusion of the Gruzelier et al. study in the 
aforementioned systematic review provides guidance on the methodological 
limitations and potential for expansion of the findings. Detailed exploration of 
literature concerning the biological aspects of HIV pathogenesis and those variables 
already known to influence disease course will be conducted in order to provide a 
thorough and considered approach to the research. Furthermore, the addition of 
exploring behavioural aspects of HL and HIV will add new data to the existing body 
of literature in these research areas. Moreover, analysis will be conducted to identify 
potential moderating factors in the relationship between HL and HIV immunity to 
help understand those factors which drive or facilitate the relationship.  
Thus, the second objective of the present thesis was to conduct an investigation in to 
the predictive capabilities of HL in relation to the outcome of HIV-specific immunity. 
This was done using the basic framework from the Gruzelier study, with the addition 
of statistical and methodological control for those variables known to modulate HIV 
disease course, to increase inferential validity, and to allow the generalising of the 
findings to larger groups of HIV patients.  
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CLASSIFICATION 
Human immunodeficiency virus (HIV) is of the genus Lentivirus, family 
Retroviridae, termed a retrovirus due to its ability to genetically reproduce with a 
reverse template (i.e., transcribing DNA from RNA) (Butler et al., 2007; Klimas, et 
al., 2008).  It is suggested that HIV was zoonotically transferred from non-human 
primates (in the form of Simian Immunodeficiency Virus: SIV) to humans, where it 
has flourished and spread for over 30 years (Butler et al., 2007; Lever, 2005; Reeves 
& Doms, 2002). HIV infiltrates the immune system of the host and proliferates, 
exhausting the host’s immune system until the host reaches total immune failure and 
subsequently dies from infection or neoplasia (Graham, 1998; Sierra et al.,2005; 
Weber, 2001; Wilkinson & Gotch, 2001). The period of immune failure is known as 
Acquired Immune Deficiency Syndrome (AIDS) and is unequivocally related to HIV 
infection (Harris & Bolus, 2008; Levy, 2006).   
Two genetically distinct species of HIV exist; HIV-1 and HIV-2; and both can lead to 
AIDS (Grant & De Cock, 2001; Levy, 2006; Lewthwaite & Wilkins, 2005; Reeves & 
Doms, 2002). The two types are pathogenically similar (although HIV-2 appears to be 
less virulent), but differ in terms of epidemiology (Grant & De Cock, 2001; Lever, 
2005; Lewthwaite & Wilkins, 2005; Reeves & Doms, 2002). HIV-1 is now 
considered to be pandemic, whereas HIV-2 is relatively endemic; being broadly 
confined to the geographical regions of West Africa, southern Europe and in the 
Southwest area of India (Grant & De Cock, 2001; Levy, 2006; Reeves & Doms, 2002; 
Roquebert et al., 2009). Due to its reduced virulence, confined areas of infection and 
similarity of medical treatment, HIV-2 receives less attention from the scientific 
community than HIV-1, which is responsible for many more new infections and 
AIDS-related deaths worldwide (Reeves & Doms, 2002).  
HIV-1 is further subdivided in to strains (by nucleotide sequence), subtypes within the 
strains, and combinations of subtypes (circulating recombinant forms: CRF) each 
representing different pathogenic speeds and risk factors (Roquebert et al., 2009; 
Spira et al., 2003). HIV-1 is split in to three groups (strains); M (main group); O 
(outlier); and N (non-M, non-O) (Butler et al., 2007; Klimas et al., 2008; Roquebert et 
al., 2009; Simon et al.,2006). Amongst group M there are 9 main subtypes (A, B, C, 
D, F, G, H, J and K), as well as many genetically distinct CRFs, derived from the 
combination of at least two of these subtypes (Klimas et al., 2008; Roquebert et al., 
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2009; Skar et al.,2011). At least 40 CRFs have been identified so far, with two 
emerging frequently in genotypic analyses worldwide: CRF01_AE and CRF02_AG 
(Skar et al, 2011). Within HIV-1, non-B subtypes represent 90% of circulating virus 
strains, with subtype C (most common in Southern Africa and Asia) being responsible 
for approximately 50% of global infections (Roquebert et al., 2009). Subtypes A and 
D are most commonly found in East Africa, CRF02_AG in West Africa, and subtype 
B in North America, Australia and Western Europe (Klimas et al., 2008; Roquebert et 
al., 2009). 
 
EPIDEMIOLOGY 
HIV/AIDS is one of the most frequent causes of death across the world, ranking 7th in 
the worldwide statistics, rising to 6th and 3rd in middle and low income countries 
respectively (WHO, 2011). Recent statistics from the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) and World Health Organisation (WHO) 
epidemic update show that at the end of 2010 there were approximately 34 million 
people living with HIV across the world (UNAIDS, 2011). The estimates of new 
infections in that year are 2.7 million (UNAIDS, 2011), an average of over 7000 new 
infections every day. It is estimated that 1.8 million people died from AIDS in 2010 
(UNAIDS, 2011), bringing a daily figure of nearly 5000 people. 
Of these global statistics, the overwhelming majority of infections, deaths and 
numbers of people living with HIV are observed in the region of Sub-Saharan Africa 
(SSA; see Figure 1) (UNAIDS, 2011). The largest singular contribution of this 
epidemic in SSA, and indeed the global pandemic, comes from South Africa, which is 
now estimated to have 5.6 million people living with HIV/AIDS (UNAIDS, 2010). 
The estimated number of children living with HIV increased to 2.5 million in 2009; 
however the number of children being born with HIV is decreasing overall (UNAIDS, 
2010). The geographical region (designated by UNAIDS) that seconds SSA in terms 
of people living with HIV is Asia, which stands at 4.8 million as compared to the 22.9 
million in SSA (UNAIDS, 2011), which illustrates the relative severity of the 
situation in Africa. One country in SSA has a devastatingly high saturation of HIV 
infections; Swaziland now has a 25.9% adult prevalence (UNAIDS, 2010).  
A recent upsurge of HIV infections in the region of Eastern Europe and Central Asia 
has seen the number of people living with the disease increase by over 250% since 
2001 (UNAIDS, 2011). The two countries within this region that have the highest 
 13 
prevalence rates (>1%) are the Russian Federation and Ukraine, which combined 
account for over 90% of new infections in the region (UNAIDS, 2010; 2011). The 
comparably affluent UNAIDS region of North America & Western and Central 
Europe was estimated to have 2.2 million people living with HIV/AIDS in 2010, an 
increase of 34% since 2001 (UNAIDS, 2011). The largest proportion of these 
infections are reported to be amongst men who have sex with men (MSM), with data 
from 23 European countries reporting an 86% rise in HIV diagnoses in this 
demographic between 2000 and 2006 (UNAIDS, 2010). In 2007 there were 3160 new 
diagnoses among MSM in the UK alone, the highest ever reported at that time 
(UNAIDS, 2010). New diagnoses have risen by more than 50% in the UK between 
2000 and 2009 (UNAIDS, 2011). Similarly, new diagnoses have doubled in other 
European countries in that time; in Bulgaria, Czech Republic, Hungary, Lithuania, 
Slovakia and Slovenia (UNAIDS, 2011). Disparities within the countries in this 
global region abound, with reports of African-American women in the US thought to 
be 19 times more likely to contract HIV in comparison to corresponding Caucasian 
women (UNAIDS, 2010).   
 
 
Figure 1. Global prevalence of HIV, 2009. (UNAIDS, 2010) The darker areas show highest 
concentration of prevalence (15-28%)    
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TRANSMISSION 
When AIDS was first discovered in 1981 in the US, it was in a demographic of 
homosexual men and was considered, at that time, to be related to homosexual 
activity (Levy, 2006; WHO, 2007). It was another two years before HIV was 
discovered and implicated as the cause of AIDS (Levy, 2006; WHO, 2007). By 1984 
a heterosexual epidemic of AIDS had been discovered across the Atlantic in Africa 
(WHO, 2007) suggesting that the disease was communicable beyond homosexual 
demographic groups. Today, the vast majority of new infections in the developing 
world are borne from heterosexual contact, seconded by vertical perinatal and breast-
milk transmission (Grant & De Cock, 2001; Hansasuta & Rowland-Jones, 2001; 
Simon et al., 2006). Homosexual transmission is the main mode of transmission in 
Latin America and Southeast Asia, but is more rarely reported in Africa (Grant & De 
Cock, 2001). New infections are most likely to occur by transmission from someone 
who is also recently infected, with the estimates of such causality being suggested to 
be as much as 50% (Skar et al., 2011). This elevated risk of transmission could be due 
to the exponential viraemia experienced in early infection, or the individual’s lack of 
knowledge of their serostatus (Skar et al., 2011). In developing countries there is also 
significant risk of transmission via blood donation, particularly in those countries 
where donation is remunerated. This transmission can be as a result of the receipt of 
infected blood products or during donation from insufficiently sterile equipment 
(Grant & De Cock, 2001; Hansasuta & Rowland-Jones, 2001). In industrialised 
countries the main mode of transmission remains through homosexual contact 
between MSM (Wolitski et al., 2001; UNAIDS, 2010).  Injection drug use is another 
important mode of transmission across many geographical regions, accounting for 
approximately one third of all HIV-1 infections outside SSA, being mostly localised 
to Eastern Europe and central and southeastern regions of Asia (Simon et al., 2006; 
UNAIDS, 2010).  
 
 
Transmission Dynamics 
In heterosexual contact, transmission from man to woman is approximated to be eight 
times more likely than from woman to man (Hansasuta & Rowland-Jones, 2001). 
Vertical perinatal transmission is more prominent in developing countries than 
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industrialised regions mainly due to the quality of health care as it can be avoided 
through antiretroviral treatment (ART) and a good standard of obstetric management 
(Hansasuta & Rowland-Jones, 2001). Vertical transmission via breast-milk is highest 
in the early months of breastfeeding (Miotti et al., 1999), which is a particular issue in 
developing countries where alternatives such as formula are expensive and difficult to 
obtain. This high vulnerability could stem from the child’s immature immune system 
at this point. In homosexual contact, the majority of infections are observed in 
populations of MSM but have been observed in women who have sex with women; 
this is mainly thought to be due to be injection drug use and bisexual contact and there 
has been no evidence, thus far, of direct female-to-female transmission (Bevier et al., 
1995). 
 
HIV PATHOGENESIS 
There are four clinically definable stages to HIV infection; these are primary HIV 
infection (PHI), the chronic asymptomatic phase, symptomatic HIV infection, and 
AIDS (Hansasuta & Rowland-Jones, 2001; Harris & Bolus, 2008; Weber, 2001). 
These groups have been further broken down into diagnostically meaningful criteria 
by both the WHO (Harris & Bolus, 2008) and the United States Centres for Disease 
Control (CDC) (Mindel & Tenant-Flowers, 2001). Each stage is characterised by 
unique symptomology and viraemia; but may present differently in different 
geographical areas due to variations in opportunistic infections that are acquired 
during immunosuppression, and due to individual factors of the host (Grant & De 
Cock, 2001; Mindel & Tenant-Flowers, 2001). 
 
Unless HIV is directly introduced to the blood stream (as in cases of needle-sharing, 
infected medical equipment, or in utero transmission), HIV is generally introduced to 
a new host through a mucosal barrier (Hansasuta & Rowland-Jones, 2001; Larsson, 
2005; Lever, 2005; Weber, 2001). The cells that are most frequently and easily 
targeted by the virus are CD4+ and CD8+ T lymphocytes, macrophages and dendritic 
cells (Clapham & McKnight, 2001; Donaghy et al., 2006; Hel et al., 2006; Verani, et 
al., 2005). Thus, major players in cellular immunity and in antigenic presentation are 
the targets of HIV, two main aspects of immunity. At the mucosal barrier the virus is 
most likely to directly infect CD4+ T-cells, or attach to dendritic cells (DC); most 
notably Langerhan’s Cells (Derdeyn & Silvestri, 2005; Donaghy et al., 2006; 
 16 
Hansasuta & Rowland- Jones, 2001; Larsson, 2005; Weber, 2001). If DC become 
infected, they then carry the virus to CD4+ T-cells for eradication, but instead of 
eradicating the antigen, the CD4+ T-cells then also become infected and then carry the 
virus to local lymph nodes where the virus replicates within other target immune cells 
(Donaghy et al., 2006; Hansasuta & Rowland-Jones, 2001; Weber, 2001). HIV enters 
target cells by interacting with CD4+ glycoprotein and a co-receptor of the seven 
transmembrane group, which are chemokine coreceptors; most notable of these are 
CCR5 and CXCR4 (Clapham & McKnight, 2001; Larsson, 2005; Lever, 2005; 
Reeves & Doms, 2002; Simon et al., 2006). Once in the cell, HIV replicates by using 
reverse-transcriptase to transcribe its viral ribonucleic acid (RNA) into proviral 
deoxyribonucleic acid (DNA).  This proviral DNA is then inserted into the DNA of 
the host by a protein called integrase which is present in the HIV viral bundle along 
with protease (see figure two) (Lever, 2005; Harris & Bolus, 2008; Sierra et al., 
2005).  After several weeks of this viral replication (between two and six weeks) a 
replication threshold is reached and viraemia proliferates through the body: inducing 
PHI (Hansasuta & Rowland-Jones, 2001; Weber, 2001).  
Initially the viral population of HIV will be largely homogenous, although the virus is 
highly mutation-prone (Lawn, 2004). Once an HIV-specific T-cell response (CD8+) 
has been initiated, any mutated virions that can evade cytotoxic T lymphocyte 
responses will proliferate (Lawn, 2004; Leslie et al., 2004). CD8+ T-cells are vital in 
the immune response to control the replication of HIV; however there is a constant 
battle between these cells and the rapid evolution of HIV virions (Derdeyn & 
Silvestri, 2005; Sierra et al., 2005). Mutations also occur due to the “error-prone” 
viral protein reverse-transcriptase (RT), key to the retroviral reproduction of RNA to 
DNA (Lever, 2005; Roquebert et al., 2009; Skar et al., 2011).  It is estimated that 
approximately 10 billion virions are produced each day in an infected individual, with 
each viral replication potentially diverging from the original wild-type to the point of 
one of 9600 nucleotides, or 0.1-0.3 mutations per genome and replication cycle 
(Lever, 2005; Roquebert et al., 2009; Skar et al., 2011). These mutations can be 
harmless, and may in fact reduce the viral fitness of the virion; but equally they could 
confer the virus to a state of increased fitness – and ultimately allow the virus to adapt 
extremely quickly to its environment (Lever, 2005; Roquebert et al., 2009).  
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Figure 2. The internal structure of the HIV virion 
Courtesy: National Institute of Allergy and Infectious Diseases 
 
 
HIV is a lentivirus, like Epstein-Barr or Cytomegalovirus (CMV), but unlike these 
viruses, which live within the body without necessarily being fatal to the host, HIV 
causes catastrophic damage to the immune system resulting in death (Hel et al., 2006; 
Levy, 2006). Healthy human immune systems can keep these other lentiviral 
infections in a latent, or dormant, state with the cellular immune response (mainly 
through CD8+ T-cells); however HIV actively attacks and depletes this arm of 
immunity, making control of the infection impossible (Hel et al., 2006; Levy, 2006). 
These other lentiviruses have been part of human virology for centuries, and it is 
thought that the reason HIV is deadly to humans is that it is relatively young, 
therefore neither humans nor the virus have had the chance to co-evolve in such away 
as to ensure mutual survival (Hel et al.,  2006; Levy, 2006). 
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Primary HIV Infection (PHI) 
During this period HIV proliferates throughout the system by continuously invading 
CD4+ immune cells and rapidly replicating (Harris & Bolus, 2008; Weber, 2001). 
This stage has presenting symptoms, which are usually characterised as fever, rash, 
swollen lymph nodes (lymphadenopathy), headaches, arthropathy, pharyngitis and 
weight loss (Hansasuta & Rowland-Jones, 2001; Harris & Bolus, 2008; Lewthwaite & 
Wilkins, 2005; Sierra et al., 2005; Weber, 2001). These symptoms may be 
experienced in varying degrees of severity and will usually persist from a period of 
several days to several weeks (Hansasuta & Rowland-Jones, 2001; Harris & Bolus, 
2008). Some patients will experience no symptoms at all, although the relative 
proportions of those who do not varies between studies (Lewthwaite & Wilkins, 2005; 
Sierra et al., 2005; Weber, 2001). The symptoms that are presented in this phase are 
geographically specific, as are many of the symptoms presented in subsequent phases 
of HIV infection (Grant & DeCock, 2001; Hansasuta & Rowland-Jones, 2001).  
The severity of symptoms during PHI has been positively associated with a higher 
rate of disease progression, and extreme cases may require temporary hospitalisation; 
particularly if the rate of CD4+ T-cell destruction experienced in this phase causes 
immunosuppression leading to the acquisition of opportunistic infections (Hansasuta 
& Rowland-Jones, 2001; Harris & Bolus, 2008; Lewthwaite & Wilkins, 2005; Mindel 
& Tenant-Flowers, 2001).  During this phase there is a massive activation and 
attrition of CD4+ T-cells particularly in mucosal lymphoid tissues, and an extensive 
proliferation of virus within the plasma (Derdeyn & Silvestri, 2005; Hansasuta & 
Rowland-Jones, 2001; Hel et al., 2006; Sierra et al., 2005; Weber, 2001). There is 
also a large increase in activated circulating CD8+ T-cells, with reports of virus-
specific cytotoxic T-cells being evident as early as two days post-infection (Hansasuta 
& Rowland-Jones, 2001; Wilkinson & Gotch, 2001). The abnormal levels of CD4+ 
and CD8+ T-cells usually resolves after two to four weeks post-seroconversion 
whereby the levels return to an almost normal, but usually less than pre-infection, 
level (Hansasuta & Rowland-Jones, 2001; Harris & Bolus, 2008; Lewthwaite & 
Wilkins, 2005; Weber, 2001). Once an HIV-specific cellular immune response has 
been established by CD8+ cytotoxic T-cells, the virus begins to come under control by 
the immune system (Simon et al., 2006; Yamamoto & Matano, 2008). The plasma 
viraemia abates several weeks after seroconversion and then establishes a “set-point” 
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where it will remain more or less stable for a protracted period of time (Hansasuta & 
Rowland-Jones, 2001; Harris & Bolus, 2008; Sierra et al., 2005; Weber, 2001). This 
stage may be particularly sensitive to cerebral influence, since the antibody-
production has been repeatedly shown to be related to psychological factors (Cohen et 
al., 2001), a topic which will be fully discussed later. 
 
The Chronic Asymptomatic Phase  
This period of pathogenesis is variable from individual to individual, but can range 
from two to more than ten years after PHI (Derdeyn & Silvestri, 2005; Harris & 
Bolus, 2008; Lewthwaite & Wilkins, 2005; Mindel & Tenant-Flowers, 2001). During 
this phase of infection the individual continues to have a slow and steady rate of CD4+ 
and CD8+ T-cell decline with viral load (VL) remaining relatively stable, as viral 
replication still continues but at a slow rate due to high virion turnover (Lever, 2005; 
Sierra et al., 2005; Weber, 2001).  
The CD4+ T-cell count during this phase is usually above 350/mm3 and the immune 
system is in a state of persistent activation thus providing the virus with a constant 
supply of infection targets (Derdeyn & Silvestri, 2005; Mindel & Tenant-Flowers, 
2001). In some individuals, CD4+ T-cell count has a rapid decline in the 12 months 
following PHI; this is thought to be caused by an R4 virus (i.e. a virus with CXCR4 
tropism), rather than an R5 virus (CCR5 tropic virus) (Harris & Bolus, 2008; 
Lewthwaite & Wilkins, 2005).  CD8+ T-cells display a shorter half-life and higher 
turnover in HIV patients, particularly during this phase (Weber, 2001). Progression of 
the asymptomatic phase may be characterized by the individual feeling well but 
experiencing persistent generalised lymphadenopathy which can continue for several 
months, bilaterally across the body (Lewthwaite & Wilkins, 2005; Mindel & Tenant-
Flowers, 2001). In the advance to symptomatic HIV infection the immunocompetency 
of the host begins to collapse, with the immune system growing increasingly unable to 
produce the cytokines (IL-2, interferon (IFN)) that are required to support T-cell 
generation (Harris & Bolus, 2008; Hel et al., 2006; Weber, 2001).  
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Symptomatic HIV Infection  
Before the status of HIV is replaced by that of AIDS, symptomatic HIV infection 
occurs. Here symptoms begin to appear and the host becomes susceptible to 
opportunistic pathogens (Mindel & Tenant-Flowers, 2001; Weber, 2001). The CD4+ 
T-cell count of patients in the symptomatic phase will usually be between 200/mm3 
and 500/mm3 (Harris & Bolus, 2008). Turnover of both CD4+ and CD8+ T-cells 
accelerates exponentially during this phase as the virus begins to replicate beyond the 
control of the immune system (Weber, 2001). Opportunistic infections take place due 
to the exhaustion of CD4+ T-cell regeneration as a consequence of chronic T-cell 
activation, destroying T-cell homeostatic capabilities of the immune system (Hel et 
al., 2006). The opportunistic infections that are experienced by the patient are 
geographically specific, with the access and effective use of highly active 
antiretroviral therapy (HAART) being another factor in this variance (Grant & De 
Cock, 2001; Mindel & Tenant-Flowers, 2001). The United States CDC has broken 
down this latter phase of HIV infection into clinically meaningful stages which are 
used for the diagnosis of AIDS with indicators of “AIDS defining illness”. This is 
particularly useful in locations where sophisticated laboratory analyses may be 
difficult or impossible, so partial reliance on a clinical presentation can be an 
alternative (Grant & De Cock, 2001; Mindel & Tenant-Flowers, 2001).  
Before AIDS defining illnesses occur, a number of opportunistic infections may 
present themselves. These are typically haematologic disorders, skin and mouth 
problems, and constitutional illnesses: usually diarrhoea, fever, weight loss and 
lethargy (Harris & Bolus, 2008; Lewthwaite & Wilkins, 2005; Mindel & Tenant-
Flowers, 2001). The weight loss experienced during this stage is clinically distinct 
from HIV wasting syndrome, which is indicative of AIDS. AIDS-related HIV wasting 
syndrome is characterised by an at least 10% loss of body mass and either persistent 
fever or diarrhoea lasting for at least one month (Mindel & Tenant-Flowers, 2001).  
 
AIDS 
The stage of full-blown AIDS is characterised by a CD4+ T-cell count of less than 
200/mm3 or the presence of at least one AIDS defining illness; any one of which 
could cause fatality in the immunocompromised patient (Harris & Bolus, 2008). 
AIDS defining illnesses that occur most commonly across all groups of HIV+ patients 
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are; HIV wasting syndrome; HIV encephalopathy; tuberculosis; pneumococcal 
pneumonia; persistent oral, oesophageal and/or vaginal candidiasis; oral hairy 
leukoplakia (caused by active Epstein-Barr virus); pneumocystis jirovecii pneumonia; 
cerebral toxoplasmosis; Kaposi’s sarcoma (herpes-derived neoplastic dermal lesions); 
severe diarrhoeal disease; mycobacterium avium intracellulare; systemic fungal 
infections; CMV infection; high-grade B-cell non-Hodgkin’s lymphoma; and 
progressive multifocal leukoencephalopathy (cerebral viral infection caused by JC 
virus) (Davaro & Thirumalai, 2007; Grant & De Cock, 2001; Levine et al., 2001; 
Lewthwaite & Wilkins, 2005; Mindel & Tenant-Flowers, 2001).  
 
Coinfection 
Coinfection in the HIV patient is very common, and varies according to geography. It 
is possible for an individual to become infected with more than one strain of HIV. 
Dual infections with HIV-1 and HIV-2, as well as with two variants of HIV-1 have 
already been well reported in the history of HIV, whereas dual infection with two 
forms of HIV-2 has not (Smith et al., 2005; van der Kuyl & Cornelissen, 2007). 
Triple HIV-1 infections have also been observed in patients from Africa and Europe 
(van der Kuyl & Cornelissen, 2007), however these events are rare. HIV 
superinfection can also lead to viral recombination to create a new recombinant form, 
which can then be passed on to another individual (Blackard et al., 2002; Smith et al., 
2005). Observations of coinfection with two distinct main groups of HIV (i.e. group 
M and group O) have been reported in several continents (Blackard et al., 2002). 
Frequently in cases of dual HIV infection, the CD4+ T-cell attrition is accelerated, 
along with viral load proliferation (Blackard et al., 2002; Smith et al., 2005; van der 
Kuyl & Cornelissen, 2007). Perhaps the most serious consequence of HIV dual- and 
super-infection is the scope for the virus to become drug-resistant or even multi-drug 
resistant (MDR) (van der Kuyl & Cornelissen, 2007). Two HIV virus strains can 
recombine to become a unique recombinant form (URF), which can be transmitted to 
others (van der Kuyl & Cornelissen, 2007). There have already been reports of 
patients with dual infection of MDR HIV strains (Smith et al., 2005), along with the 
transmission of a MDR URF from a dual infected patient (dual infected with two 
MDR strains) to another individual (van der Kuyl & Cornelissen, 2007).   
Additionally, accelerated pathogenicity of HIV has been observed with coinfections 
of bacterial (mycobacterium tuberculosis: TB), viral (hepatitis B and C viruses; 
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human T-cell lymphotropic virus), and parasitic (plasmodium falciparum malaria; 
leishmania; schistosoma mansoni; hookworm; lymphatic filariasis) origins; to name 
only a few (Brites et al., 2009; Djoba Siawaya et al., 2007; Harms & Feldmeier, 2002; 
Lawn, 2004; Nikolopoulos et al., 2009; Petrovic, 2007; Rénia & Potter, 2006; Soriano 
et al., 2010; Talaat et al., 2008). These infections appear to create an additive effect, 
whereby the immune system is compromised further by HIV from mounting a 
response to these various infections – which can result in faster disease progression 
(Harms & Feldmeier, 2002). The immune system mounts a pro-inflammatory 
response (Th2) to these infections, which not only provides target cells for HIV 
infection, but also inhibits anti-inflammatory (Th1) responses required to control HIV 
viraemia (Djoba Siawaya et al., 2007; Harms & Feldmeier, 2002; Lawn, 2004; Talaat 
et al., 2008).  
These infections pose a real threat to HIV+ populations around the world. Hepatitis 
(both B and C variants) and Human T-cell Lymphotropic Virus are commonly found 
in HIV+ patients, due to shared modes of transmission (Brites et al., 2009; 
Nikolopoulos et al., 2009; Soriano et al., 2010). Recent estimates have placed the 
number of chronic Hepatitis C and HIV coinfections at 7 million (20% prevalence); 
with coincidence of chronic Hepatitis B and HIV estimated at 3 million, ranging 
between 5% prevalence in Western regions up to 20% in developing regions such as 
SSA and South East Asia (Soriano et al., 2010). TB is both an opportunistic infection 
associated with HIV infection (a leading cause of HIV mortality), and a coinfection 
observed frequently in HIV+ patient populations (Djoba Siawaya et al., 2007; Lawn, 
2004). Parasitic infections are common in tropical and desert areas, making the 
interactions of these infections particularly pertinent to the millions of HIV+ people 
living in these areas (Harms & Feldmeier, 2002; Lawn, 2004; Talaat et al., 2008). It is 
also important to note that the areas where these parasitic infections are commonly 
found are also usually areas of lower income, with less access to healthcare and 
medications – yet another addition to the relative disadvantages experienced by HIV+ 
patients in these locales compared to those from industrialised nations.  
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FACTORS RELATING TO SUSCEPTIBILITY & RESISTANCE 
Susceptibility  
Mucosal Immune Status & Genetics 
It is supposed that most sexual exposures to HIV do not result in infection (Kaul et 
al., 2008) and therefore there must be specific factors involved in the risk of 
transmission of the virus from one body to another. There are two perspectives to 
increased susceptibility; that of increased likelihood of the donor transmitting the 
virus, and that of increased likelihood of the individual receiving the virus (Hansasuta 
& Rowland-Jones, 2001; Kaul et al., 2008).  
 
Transmission Probability 
Increased infectivity of an HIV donor is most influenced by the plasma HIV RNA VL 
of the infected individual. Higher VL indicates increased likelihood of transmission, 
which is thought to be due to a high correlation between plasma and genital secretion 
VLs (Hansasuta & Rowland-Jones, 2001; Kaul et el., 2008). It is also thought that co-
infections with other sexually transmitted infections (STIs) and vitamin A deficiency 
increases the VL of genital secretions (Hansasuta & Rowland-Jones, 2001; Kaul et 
al., 2008). For example, genital ulceration caused by STIs (i.e. gonorrhoea, syphilis 
and genital herpes (HSV2)) is likely to increase the amount of viral shedding in 
genital secretions (Hansasuta & Rowland-Jones, 2001; Kaul et al., 2008; Lawn, 
2004). CMV is another STI that is associated with increased VL in genital secretions, 
an infection that is often found in those with HIV (Kaul et al., 2008).   
 
Contraction Susceptibility 
In terms of enhanced susceptibility to HIV infection, the main factors involved are 
related to mucosal immune status and genetic factors (Derdeyn & Silvestri, 2005; 
Hansasuta & Rowland-Jones, 2001; Kaul et al., 2008; Lama & Planelles, 2007; Spear 
et al., 2007). Increased susceptibility related to mucosal immune status is directly 
associated with co-infections of STIs such as CMV, syphilis, HSV2, gonorrhoea and 
bacterial vaginosis (Hansasuta & Rowland-Jones, 2001; Kaul et al., 2008; Spear et 
al., 2007). This is largely supposed to be due to an increase in HIV target immune 
 24 
cells in the genital mucosae, as the immune system attempts to control these local 
infections (Hansasuta & Rowland-Jones, 2001; Kaul et al., 2008; Spear et al., 2007). 
Hormonal changes also affect mucosal immune status in women. During the follicular 
phase of the menstrual cycle, when ovarian oestrogen levels increase, higher numbers 
of immature DCs can be found on the cervix making women more vulnerable to 
infection during this time (Kaul et al., 2008). Additionally, during the secretory phase 
when progesterone is abundant (but DC levels have diminished), CCR5 is expressed 
in higher numbers across the cervical tissues, also increasing transmission 
susceptibility in viruses that use this co-receptor (Kaul et al., 2008). This increase in 
susceptibility related to increased levels of progesterone is also thought to explain the 
observed associations between increased HIV infection susceptibility and hormonal 
contraception, which is usually through the introduction of progesterone (Hansasuta 
& Rowland-Jones, 2001; Kaul et al., 2008).  
 
Genetic Factors 
Genetic factors that impact on the susceptibility and resistance to HIV infection are 
still being discovered. Thus far the majority of genetic studies have uncovered factors 
relating to resistance, but there have been some key discoveries relating to 
susceptibility (Derdeyn & Silvestri, 2005; Hansasuta & Rowland-Jones, 2001). 
Research in Africa has uncovered that enhanced transmission and susceptibility have 
been associated with the sharing of the class I HLA-B (Human Leukocyte Antigen B) 
allele between partners (Derdeyn & Silvestri, 2005; Dorak et al., 2004; Hansasuta & 
Rowland-Jones, 2001). These probably depend on the resemblance between the 
virus’s and the host’s HLA. Conversely, there is also a protective factor associated 
with the HLA alleles insomuch as the foreign HLA molecules on the virus may 
trigger a rejection reaction (similar to that observed in failed organ transplant), 
allowing resistance, or may make infection more efficient if the virus evades the 
initial cytotoxic T-lymphocyte (CD8+) response (Derdeyn & Silvestri, 2005; 
Hansasuta & Rowland-Jones, 2001).  
In a similar dichotomous fashion, polymorphisms in the promoter region of RANTES 
(a gene coding for an HIV suppressing chemokine) have been found to influence 
susceptibility and resistance (Hansasuta & Rowland-Jones, 2001). It is suggested that 
the polymorphism leads to increased expression of RANTES which can lead to 
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increased inflammation of mucosae, thus leading to increased susceptibility, but can 
also lead to higher suppression of the virus if infection takes place (Hansasuta & 
Rowland-Jones, 2001; Lama & Planelles, 2007). Thus, the RANTES polymorphysim 
can affect risk of infection, depending on the level of elicited immune responses and 
its timing in relation to HIV-infection.  
Variations in the CCL3L1 gene may also account for decreased susceptibility, as this 
gene encodes for MIPα (macrophage inflammatory protein α), and greater amounts of 
this chemokine may exhibit competitive usage of the CCR5 co-receptor, weakening 
HIV’s bonding to CD4+ immune cells (Simon et al., 2006). Another finding concerns 
a polymorphism in the promoter region of CCR5, which, if apparent, is associated 
with increased susceptibility of children contracting HIV from their mothers during 
gestation (Hansasuta & Rowland-Jones, 2001). 
 
Resistance  
Genetics 
The study of resistance factors relating to HIV infection has been greatly aided by the 
research of two groups of individuals; long-term non-progressors (LTNPs) and 
highly-exposed persistently-seronegative (HEPS) individuals (Hansasuta & Rowland-
Jones, 2001; Lama & Planelles, 2007). LTNPs represent approximately two to four 
percent of the HIV infected population. They are infected with HIV but live for a 
protracted period of time (over ten years) without any symptoms even in the absence 
of treatment and typically have CD4+ T-cell counts of over 500/mm3 with plasma VL 
below 10,000 RNA copies per millilitre (Lama & Planelles, 2007; Wilkinson & 
Gotch, 2001). HEPS are individuals who fail to contract HIV despite either numerous 
or persistent exposures to the disease. They have been found in populations of HIV- 
children of HIV+ mothers, injection drug users, sex workers, those having high levels 
of unprotected sex, and health workers who have undergone accidental exposure to 
the virus (Lama & Planelles, 2007).  
 
The most significant finding in the genetic studies has been the identification of 
polymorphisms of the 32 base pair of the CCR5 gene (i.e. CCR5∆32) which enables 
protection from HIV in homozygotes (i.e. those with the full pair deleted) and 
protection from HIV progression in heterozygotes (i.e. those with one of the pair 
deleted) (Clapham & McKnight, 2001; Donaghy et al., 2006; Hansasuta & Rowland-
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Jones, 2001; Lama & Planelles, 2007; Sierra et al., 2005; Simon et al., 2006). Those 
who are CCR5∆32+ have been known to acquire HIV, but it is thought that these 
viruses are CXCR4-tropic (R4) strains, which are more rare than the CCR5-tropic 
(R5) strains (Clapham & McKnight, 2001; Hansasuta & Rowland-Jones, 2001; Lama 
& Planelles, 2007). It has been observed that HEPS are over-represented as a group in 
those who are CCR5∆32 homozygous, and LTNPs are similarly so in those who are 
CCR5∆32 heterozygous, but this is not universal, so there may be other factors 
involved that are as yet undiscovered (Lama & Planelles, 2007).  CCR5∆32 
polymorphisms are found most commonly in Caucasian groups, particularly those 
from northern Europe, and are almost never found in African or Asian groups, further 
explaining the high prevalence of HIV and AIDS in the latter regions (Hansasuta & 
Rowland-Jones, 2001; Lama & Planelles, 2007). LTNPs have also been found to 
possess a polymorphism of the CCR2 allele V63I phenotype, which appears to slow 
the progression to AIDS (Sierra et al., 2005). HLA molecules are also implicated in 
the phenomenon of long-term non-progression. LTNPs have been found to have 
increased amounts of HLA classes I and II molecules (Sierra et al., 2005). This 
suggests that antigen-presentation, the main role of HLA, is important in protecting 
against the progression of HIV, either by more frequent/efficient antigen-presentation 
or more frequent/efficient activation of healthy CD4+ T-cells. 
 
 
TREATMENT OF HIV INFECTION 
 
HIV Surveillance & Pharmacotherapy 
Medical care of HIV patients in developed countries is mostly comparable, with 
patients being seen every three to six months, and their CD4+ T-cell count, VL and 
weight being checked at each visit (Mindel & Tenant-Flowers, 2001). This may not 
be possible in more economically-strained regions, where the recommendation is for 
the patient to attend medical monitoring as often as is possible for that region’s 
resources (Grant & De Cock, 2001). The selection of the type of treatment, and when 
it should begin is often highly individual and can depend on the particular case and 
the health resources of the geographical setting (Grant & De Cock, 2001; Harris & 
Bolus, 2008; Simon et al., 2006). Hammer et al. have published guidelines as part of 
the International AIDS Society, stating that treatment should be started in all 
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symptomatic patients, and in those asymptomatic patients who have CD4+ T-cell 
counts of between 350/mm3 and 200/mm3 (Hammer et al., 2006; Harris & Bolus, 
2007; Simon et al., 2006).  
Treatment for HIV first started with simple Antiretroviral Treatment (ART), but due 
to the ability of the virus to form drug-resistant recombinants and to replicate at a high 
rate (Paredes & Clotet, 2010), a race often ensues between the development of safe 
and effective drugs and the evolution of the virus to resist them. Developments in the 
last decade that have seen combinations of antiretrovirals (ARVs) being used to great 
benefit, and these combinations are now referred to as Highly Active Antiretroviral 
Treatment (HAART) (Harris & Bolus, 2008; Simon et al., 2006; Weller & Williams, 
2001). To date there are so far six different drug classes used in HAART; nucleoside 
reverse-transcriptase inhibitors (NRTIs), nucleotide reverse-transcriptase inhibitors 
(NtRTIs), non-nucleoside reverse-transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), fusion inhibitors (FIs) and co-receptor inhibitors (CRI) (see table one) 
(De Clercq, 2010; Deeks, 2006; Orsega, 2007; Wilkinson & Gotch, 2001). Today 
these drugs now also come in fixed-dose combinations, allowing a vast reduction in 
pill-burden, and easy combination with other drug classes (Cihlar & Ray, 2010; 
Ganguli et al., 2011). The goal of antiretroviral treatment is to control viral 
replication, which in turn helps to repopulate CD4+ T lymphocyte levels (Deeks, 
2006; Simon et al., 2006) The efficacy of these treatments is evaluated through the 
monitoring of both T-cell levels and VL assay. See table one for a summary of the 
currently approved HAART medications available within the European Union.  
 
Nucleoside Reverse-Transcriptase Inhibitors (NRTIs) 
NRTIs and, more recently, NtRTIs (described below) form the staple of modern 
combination ARV therapy (Cihlar & Ray, 2010). NRTIs prevent viral replication by 
both inhibiting the protein RT, which is required to translate HIV RNA into DNA, 
and terminating the DNA chain by interrupting its synthesis (Deeks, 2006; Harris & 
Bolus, 2008; Weller & Williams, 2001). However HIV has adapted to this, the oldest 
form of antiretroviral therapy, and new strains have emerged which are less 
vulnerable to RT inhibition (Deeks, 2006; Weller & Williams, 2001). The use of these 
drugs is also limited due to polydrug interactions and the numerous and diverse 
adverse side-effects experienced by patients (Cihlar & Ray, 2010).  
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Nucleotide Reverse-Transcriptase Inhibitors (NtRTIs) 
Tenofovir, marketed as Viread, is the only approved drug in this class to date, has 
been formulated as a component of two fixed-dose combination drugs (Truvada and 
Atripla) and is now one of the most frequently prescribed drugs in HAART today (De 
Clercq, 2009; Pozniak, 2008).  The compound has the same mechanism of action as 
NRTIs, but it is based on nucleotide analogues as opposed to nucleoside, making it 
effective in activated and resting cells (De Clercq, 2009; Pozniac, 2008). The drug is 
comparatively well tolerated, and as it has a relatively long half-life there are fewer 
implications if the patient does not take the drug exactly on time (Pozniac, 2008). As 
well as being approved for use in HIV-1 and HIV-2, it has also been approved for use 
in Hepatitis B infection (De Clercq, 2009; Pozniac, 2008) making this drug 
exceptionally useful for those coinfected with both viruses.  
 
Non-Nucleoside Reverse-Transcriptase Inhibitors (NNRTIs) 
NNRTIs work in a similar fashion, targeting RT, but these are distinct in their ability 
to bind to the catalytic non-active site of the enzyme, disrupting the enzyme activity 
from creating conformational changes (Harris & Bolus, 2008; Weller & Williams, 
2001). These agents are highly effective at disrupting viral replication and have 
relatively low toxicity to the patient, but they are only effective at this action with 
HIV-1 and not HIV-2 (Weller & Williams, 2001). NNRTIs can be used well with 
other classes of HAART, but again suffer in efficacy from HIV mutations which are 
resistant to their action and so often require combination with other chemical agents 
(Weller & Williams, 2001).  
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Table 1. A summary of currently available drugs within the HAART repertoire of the European Union. 
Drug class, name(s) and mechanism of action (HIV target) are provided.  
Drug Class Generic Name(s) Trade Name(s) Target 
Zidovudine (AZT) Retrovir 
Lamivudine (3TC) Epivir 
Abacavir Ziagen 
Stavudine (d4T) Zerit 
Didanosine (ddl) VidexEC 
 
Nucleoside Reverse 
Transcriptase Inhibitors 
(NRTIs) 
Emtracitibine (FTC) Emtriva 
 
 
Viral Reverse 
Transcriptase 
 
Nucelotide Reverse 
Transcriptase Inhibitor (NtRTI) 
 
 
Tenofovir 
 
Viread 
 
Viral Reverse 
Transcriptase 
Efavirenz Sustiva/Stocrin 
Etravirine Intelence 
 
Non-Nucleoside Reverse 
Transcriptase Inhibitors 
(NNRTIs) 
Nevirapine Viramune 
 
Viral Reverse 
Transcriptase 
FTC/Tenofovir Truvada 
3TC/AZT Combivir 
3TC/Abacavir Kivexa 
 
NRTI/NtRTI Fixed-Dose 
combinations 
3TC/Abacavir/AZT Trizivir 
 
Viral Reverse 
Transcriptase 
 
NRTI/NtRTI/NNRTI Fixed-
Dose combination 
 
 
FTC/Tenofovir/Efavirenz 
 
Atripla 
 
Viral Reverse 
Transcriptase 
Atazanavir Reyataz 
Darunavir Prezista 
Fosamprenavir Telzir 
Indinavir Crixivan 
Lopinavir/Ritonavir Kaletra 
Ritonavir Norvir 
Saquinavir Invirase 
 
 
 
 
Protease Inhibitors (PIs) 
Tipranavir Aptivus 
 
 
 
 
Viral Protease 
 
Fusion Inhibitor (FI) 
 
Enfuviritide (T-20) 
 
Fuzeon 
Viral integration 
in to host cell 
DNA 
 
 
 
CCR5 Inhibitor 
 
 
 
Maraviroc 
 
 
 
Celsentri 
Disruption of 
the interaction 
between CCR5 
and HIV protein 
gp120 
(“docking” 
protein) 
Integrase Inhibitor Raltegravir Isentress Viral Integrase 
protein 
 
 
Protease Inhibitors (PIs) 
PIs target the protease enzyme in the viral bundle of HIV that is used to let the virus 
“bud” out of an infected cell once it has successfully invaded and replicated in the 
target cell cytoplasm (Harris & Bolus, 2008; Lever, 2005; Weller & Williams, 2001). 
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As protease is inhibited, it cannot break down the strands of viral proteins that mature 
the virions (a process known as protein catabolism), and so only immature, inert viral 
proteins are released (Harris & Bolus, 2008; Simon, Ho & Karim, 2006; Weller & 
Williams, 2001). PIs are very efficient in preventing viral proliferation, and their 
introduction to mainstream medicine was associated with significant decreases in both 
morbidity and mortality in HIV patients (Weller & Williams, 2001). As with the RT 
inhibitors, HIV has evolved and developed some degree of resistance to PIs, and that 
in combination with the tolerability of the drug class have created problems in recent 
years (Weller & Williams, 2001).  
 
Fusion Inhibitors (FIs) 
FIs are one of the newest classes of HAART drugs and work by preventing the fusion 
and entry to target cell membranes (Harris & Bolus, 2008; Orsega, 2007; Rockstroh & 
Mauss, 2004; Simon, Ho & Karim, 2006). The purpose of FIs is to effectively block 
HIV binding to chemokine coreceptors (CD4, CCR5, CXCR4), and also disrupt the 
fusion mechanics of the HIV virion, preventing bonding between the two cell 
membranes (Harris & Bolus, 2008; Rockstroh & Mauss, 2004). To date there is only 
one approved drug in this class, enfuvirtide (fuzeon), its administration requires twice-
daily injections and is usually reserved for those patients who have developed 
resistance to other drug classes as it can help to overcome this resistance (Deeks, 
2006; Orsega, 2007; Rockstroh & Mauss, 2004; Simon, Ho & Karim, 2006).     
 
Integrase Inhibitors (INIs) 
So far there has only been one INI developed beyond stage III clinical trials and 
approved for use in humans; raltegravir (Isentress) (De Clercq, 2010; Hicks & Gulick, 
2009; Ramkumar et al., 2010). This class of drug is designed to target the integration 
of the proviral DNA into the host genome, but is only approved for use in HIV-1 (De 
Clercq, 2010; Hicks & Gulick, 2009). It is currently only recommended for use in 
patients who are treatment-experienced, with particular emphasis towards those who 
have contracted or developed MDR virus (De Clercq, 2010; Ramkumar et al., 2010). 
Raltegravir has been relatively well tolerated by patients, and does not involve 
polydrug interactions like so many other ARV drugs (Hicks & Gulick, 2009; 
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Ramkumar et al., 2010). Unfortunately resistance to raltegravir has been observed, in 
relatively low opposition (due to just a few mutations in HIV integrase) (De Clercq, 
2010).  
 
Co-Receptor Inhibitors (CRIs) 
Maraviroc (Cesentri) is the first CRI available worldwide, working in the same 
fashion as INIs, but specifically targeting the chemokine coreceptor CCR5 (Gilliam et 
al., 2010; Ray, 2008). Due to its unique chemical target, this drug is only effective for 
R5 HIV strains, and offers no effect for those strains that target CXCR4 or both 
chemokine coreceptors, however R4 and R4R5 viruses are rare by comparison (Ray, 
2008). Maraviroc essentially works as a receptor antagonist; thereby blocking the 
receptor (Gilliam et al., 2010; Ray, 2008). Currently Maraviroc is reserved for 
treatment-experienced patients, used largely as a “salvage” regimen, but is tolerated 
well and can be used in combination with other drugs for the treatment of viruses 
other than HIV (Gilliam et al., 2010; Ray, 2008). The resistance to this drug is an 
issue currently being researched, with suggestions that its use may trigger a de novo 
receptor-tropism switch (i.e. R5 to R4), however this switch does occur naturally in 
more advanced cases of HIV and use of Maraviroc does not so far appear to have 
accelerated these findings (Ray, 2008).  
 
Efficacy Issues 
As effective as these drugs are at combating the progression of HIV disease, they also 
present problems in terms of tolerance and toxicity, which can lead to difficulties in 
patient adherence – an aspect which is vital for clinical efficacy (Deeks, 2006; 
Lewthwaite & Wilkins, 2005; Simon et al., 2006; Weller & Williams, 2001). 
Resistance of the virus to every drug has been observed so far, once it has become 
tolerant to its effects; but there have also been some completely drug-resistant strains 
of the virus which have been found in up to 20% of new infections in countries with 
good access to antiretroviral agents (Simon et al., 2006). Each class of drugs has 
associated toxicities, but some are also drug-specific (Deeks, 2006; Weller & 
Williams, 2001). Immune reconstitution inflammatory syndrome is being increasingly 
seen amongst those who are in the early stages of HAART and is still not properly 
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understood, but it is thought to be a reaction from a sudden increase in immune cells 
(Davaro & Thirumalai, 2007; Deeks, 2006).  
Among NRTIs the class-associated toxicities are lactic acidosis, lypodystrophy and 
hepatic steatosis (fatty liver disease) (Davaro & Thirumalai, 2007; Deeks, 2006; 
Simon et al., 2006; Weller & Williams, 2001). The more severe of the drug-related 
toxicities in this class are peripheral neuropathy (stavudine; zalcitibine; didanosine), 
nausea (zidovudine; abacavir), hepatitis (stavudine), pancreatitis (didanosine) and 
myopathy (zidovudine) (Deeks, 2006; Weller & Williams, 2001). NNRTIs have class-
associated toxicities similar to NRTIs, the more severe drug-specific toxicities are 
hepatitis (nevirapine), mood disturbances (efavirenz) and Stevens-Johnson syndrome 
(a necrotising skin condition) (nevirapine) (Deeks, 2006; Weller & Williams, 2001). 
PIs are associated with hyperlipidaemia (high blood lipid content), lypodystrophy and 
diabetes mellitus as a class (Deeks, 2006; Weller & Williams, 2001). The more severe 
drug-associated toxicities of this group include chronic diarrhoea (nelfinavir; 
ritanovir; amprenavir; lopinavir), hepatitis (ritanovir), and nephrolithiasis (kidney or 
bladder stones) (indinavir) (Deeks, 2006; Weller & Williams, 2001). FIs are generally 
well accepted by the patient, but they do have adverse effects in terms of their 
parenteral administration, which can cause severe reactions at injection sites (Deeks, 
2006; Rockstroh & Mauss, 2004). 
 
Therapeutic Recommendations 
The therapeutic strategy that is recommended for these drugs is the use of at least one 
drug from at least two of the agent classes but these guidelines can differ according to 
the individual, particularly in cases of pregnancy, infection in children and co-
infection with hepatitis (Deeks, 2006; Lewthwaite & Wilkins, 2005; Sierra et al., 
2005). In order to combat the difficulties experienced with drug toxicity and 
resistance, structured treatment interruptions can be implemented (Deeks, 2006; 
Simon et al., 2006; Wilkinson & Gotch, 2001). This is generally only recommended 
in those patients who have well-controlled viraemia or who would benefit physically 
more from stopping than from continuing with treatment (Deeks, 2006; Simon et al., 
2006; Wilkinson & Gotch, 2001). This treatment strategy is still being investigated as 
it is thought that interruptions may encourage the re-constitution of viral reservoirs 
within the body that will ultimately make the condition more difficult to treat 
(Wilkinson & Gotch, 2001).  
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FUTURE DIRECTIONS IN HIV RESEARCH 
Vaccine Development  
As with all communicable diseases, one of the ultimate goals for HIV medicine is a 
vaccine. There have been many vaccine trials to date in both HIV and SIV, but none 
have yielded sufficiently positive efficacy to be brought to market (Virgin & Walker, 
2010). Most importantly, the correct immunological pattern has not yet been 
discovered which will allow the blanket recognition and defense against HIV 
(Burgers et al., 2011; Virgin & Walker, 2010). It has also not been decided whether 
the most feasible or appropriate end-goal would be immunity against contracting HIV, 
or prevention of disease development to AIDS (Virgin & Walker, 2010).  
General vaccine strategy involves the programming of memory T and B cells to 
recognise an antigen, however this approach is redundant in the case of HIV due to 
the aforementioned “error-prone” reverse-transcriptase (RT) enzyme of HIV (Virgin 
& Walker, 2010). The HIV protein RT is relatively unstable, and as the virus is 
transcribed and reproduced, the encoding of this enzyme is prone to mutation, making 
each virion potentially different (Lever, 2005; Roquebert et al., 2009; Skar et al., 
2011).  Another hurdle to surmount in vaccine research comes from the latent 
reservoirs of infected cells, characteristic of lentiviruses, which allow the evasion of 
infected cells from immune surveillance (Virgin & Walker, 2010). Nonetheless, 
vaccine developments and trials continue to be conducted in the hopes that a 
successful vaccine can be developed, and to date one trial has provided cautious 
optimism in the field. A vaccine study in Thailand in a large sample of volunteers 
showed a modest level (31%) of protection against HIV-1 infection as compared to a 
placebo group (Rerks-Ngam et al., 2009).  
 
Pre-Exposure Prophylaxis (PrEP) 
One of the most recent avenues of interest in HIV medicine is that of pre-exposure 
prophylaxis (PrEP), or the ability to prevent infection before exposure occurs (Naswa 
& Marfatia, 2011). Two trials of PrEP have been conducted so far, with encouraging 
results. The first study employed a tenofovir (NtRTI) based gel, to be applied 
topically before sexual contact. This study used an experimental group (N=445) 
versus control placebo group (N=444) of women in South Africa (Karim et al., 2010). 
They found an overall reduction in HIV infection of 39%, ranging between 28-54% 
depending on adherence (Karim et al, 2010). The second study was conducted using 
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2499 MSM and transgender women who have sex with men in samples on four 
continents (South and North America, South East Asia and Africa) (Grant et al., 
2010). The study employed a PrEP strategy in HIV seronegative participants, versus a 
placebo, using Emtracitibine (a NRTI) and tenofovir (NtRTI) in pill form, and found 
that this regimen provided a 44% reduction in infection rates (Grant et al., 2010).  
 
 
SUMMARY 
The management of HIV has been part of mainstream medicine for 30 years now, and 
although the scientific community has developed a wealth of knowledge about the 
disease, there is still much to be uncovered. It is a very complex virus, creating an 
even more complex somatic experience, highly variable across individuals. By 
effectively hijacking the immune system, using its innate mechanisms for antigen 
control, it has proved to be a formidable foe in medicine. The fact that it proliferates 
and thrives using the same system used and developed to control viral spread; and the 
fact that each new virion can be potentially different to the parent strain, thus evading 
antibody strategy, provide challenging conditions in pharmacy and vaccine 
development. Additional complexities are apparent when considering the impact that 
host genetics and immunity have on the tremendous variability of the pathogenicity of 
the virus.  
Despite the exponential advances made in the treatment of the infection, a cure still 
remains elusive. It is, however, a remarkable feat of contemporary research and 
scientific understanding that such a relatively young disease has been met with the 
development of over 25 different approved pharmacotherapies, prolonging wellness 
and life far beyond that which was the norm at the beginning of the epidemic. In the 
absence of remedy or vaccine it is necessary that interventions, both medical and 
behavioural, be developed and implemented on a wide scale that target prevention of 
infection and effective management of illness. Pharmacotherapy is being continually 
developed and different approaches to a vaccine are still being considered and tested, 
but in the absence of a unilateral cure, efforts must be continued to ensure that those 
living with the disease have adequate access to treatment and can continue to live with 
a maximum quality of life.  
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Host Psychosocial Predictors of Prognosis in HIV Infection 
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Human Immunodeficiency Virus (HIV) infection is a chronic, progressive illness, 
which results in the development of Acquired Immune Deficiency Syndrome (AIDS), 
and subsequently death (Graham, 1998; Harris & Bolus, 2008; Levy, 2006). Whilst 
the progression from HIV infection to a clinical AIDS status is characterised by a 
distinct and discrete categorisation of disease stages, the rate at which the illness 
progresses is highly variable and is still not fully understood (Ashton et al., 2005; 
Farinpour et al., 2003; Lama & Planelles, 2007; Langford et al., 2007; Leserman, 
2003). Those factors that are thus far understood to determine the trajectory of the 
disease progression are: viral factors (Derdeyn & Silvestri, 2005; Simon et al., 2006); 
host genetic and biological factors (Derdeyn & Silvestri, 2005; Donaghy et al., 2006), 
and host psychosocial factors, which can modulate pathogenesis through 
psychoneuroimmunological mechanisms (Langford et al., 2007; Leserman, 2003; 
Soloman et al., 2000). 
 
The plethora of host psychosocial HIV disease progression modulators have received 
broad attention in recent years, particularly since the advent of Highly Active 
Antiretrovial Treatment (HAART) which has led to much more stable medical 
management of HIV pathogenesis and morbidity (Hartzell et al., 2008; Ironson et al., 
2005b). Since HAART has become widely available in the developed world, the life 
expectancy of those with HIV has become greatly increased, although there still exists 
a large heterogeneity in this life expectancy (The Antiretroviral Therapy Cohort 
Collaboration, 2008; Balbin et al., 1999; Farinpour et al., 2003). This has led to the 
increased focus on host psychosocial factors on both morbidity and mortality in HIV 
and the predictors of HAART adherence, a factor that is vital to its efficacy and 
therefore survival in HIV (Harris & Bolus, 2008; Simon et al., 2006). Demographic 
differences have been related to variations in prognosis, with factors such as younger 
age, higher IQ and being female associated with slower disease progression 
(Farinpour et al., 2003; Langford et al., 2007). These demographic factors are useful 
in our understanding of the variance of the disease course, but cannot be changed and 
so in terms of identifying variables susceptible to invertention in HIV, psychosocial 
predictors provide valid basis for research and intervention.  
Broadly speaking, the main components of host psychosocial influences on HIV 
progression fall in to three categories; psychological (e.g. depression, anxiety, 
optimism), social (e.g. social support, social identity), and behavioural (e.g. 
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abuse/dependence of drugs and/or alcohol, HAART adherence, health behaviour). 
These components influence each other to some degree, for example lack of social 
support may induce depression, which can in turn impact on adherence; but can also 
exert their effects independently. 
 
 
PSYCHOLOGICAL FACTORS 
Psychological Morbidity 
The diagnosis of a life-limiting illness such as HIV is highly associated with the 
development of psychological morbidities, such as depression, anxiety and sometimes 
Post Traumatic Stress Disorder (PTSD) (Gibbie et al., 2006; McCain et al., 2003; 
Milam, 2006). Even if an individual manages to receive such a diagnosis without 
developing a psychological condition, the process of living with HIV and its 
associated physical wellness, lifestyle and social changes leave the individual more 
vulnerable to experiencing psychological morbidity (Chippindale & French, 2001). It 
is also suggested that those people who become infected with HIV are more likely to 
come from backgrounds associated with psychological morbidity, such as a history of 
sexual and/or physical abuse and drug or alcohol dependence, which is reported 
significantly more in HIV-seropositive (HIV+) individuals than in the general 
population (Cohen et al., 2000; Dévieux et al., 2007; Kimerling, et al., 1999; 
Mugavero et al., 2007; Pence, 2009). As the mechanisms by which these 
psychological morbidity factors impact on HIV disease are often shared amongst 
these factors, they will be discussed after the summary.  
 
Depression 
It is estimated that up to 50% of the HIV+ population are also living with some sort of 
depressive disorder (Evans et al., 2002; Gibbie et al., 2006; Hartzell et al., 2008; 
Pence, 2009). Depression in HIV+ patients has been reported to be five to ten times 
more prevalent than in the general population (Pence, 2009). This prevalence rate 
constitutes a significant health problem, particularly in view of the adverse effects of 
some HAART medications, which can elicit depression in otherwise mentally healthy 
patients (e.g. Efavirenz, Zidovudine) (Hartzell et al., 2008; Kopnisky et al., 2004; 
Montessori et al., 2004). Furthermore, it is estimated that nearly 50% of HIV+ patients 
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who meet diagnostic criteria for a depressive disorder are undiagnosed (Asch et al., 
2002; Pence, 2009). This further highlights health care problems in these patient 
groups if depression is a contributor to disease course, or, indeed, a barrier to 
optimum treatment efficacy. 
The current consensus is that depression in HIV+ patients has a negative effect on 
mortality, neurocognitive functioning, HIV-related immune response and disease 
severity (subjective experience), and faster progression toward an AIDS diagnosis or 
diagnosis of an AIDS-defining condition, which is proportionately more pronounced 
in those with more chronic and severe depression than those with more mild or 
intermittent depression (Greeson et al., 2008; Hartzell et al., 2008; Ironson, et al., 
2005b; Leserman, 2003; Pence, 2009). There has been some evidence to suggest that 
HIV pathogenesis may influence mood via inflammation. Inflammation is a key 
aspect of HIV disease and contributes largely to non-opportunistic morbidity and 
mortality (i.e. morbidity and mortality unrelated to opportunistic infections or 
neoplasia) (Lane, 2010). Further, systemic inflammation has been demonstrated to 
cause negative affectivity (both anxiety and depression); with these effects being 
suggested to be driven by the increase in proinflammatory cytokines such as tumour 
necrosis factor (TNF) (Reichenberg et al., 2001). Therefore, the characteristic 
inflammation experienced in HIV may contribute to both psychological and 
physiological morbidity.   
 
 
Anxiety & Stress 
Anxiety and stress have been known to affect immune functioning across a variety of 
illness states for many years (Balbin et al., 1999; Hassan & Douglas, 1990; Leserman, 
2003; Stein & Rotheram-Borus, 2004; Vassend & Eskild, 1998; Vassend et al., 1997). 
HIV is an illness that is highly associated with stressors, such as social stigma, 
victimisation, excessive medication burdens, changes in personal relationships and 
shortened life expectancy (Hassan & Douglas, 1990; Kimerling et al., 1999; Stein & 
Rotheram-Borus, 2004). This means being able to understand the effect that anxiety 
exerts on HIV disease course is essential.  
The link between excessive stress and HIV disease progression is by far the most 
supported in the spectrum of psychosocial disease prognostics in this field (Balbin et 
al., 1999). Research has suggested that those experiencing higher levels of life stress 
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can progress through HIV disease at up to four times the rate of those with 
intermediate or low levels of life stress will (Balbin et al., 1999; Leserman, 2003). It 
has been observed that several immune parameters are related to increased experience 
of life stressors in HIV disease; CD4+ (helper) T-lymphocyte decline, CD8+ 
(cytotoxic) T-lymphocyte population and functional decline, and natural killer (NK) 
cell decreased number, activity and function (Balbin et al., 1999; Greeson et al., 2008; 
Soloman et al., 2000).  
As anxiety and stress are associated with rises in cortisol secretion and proliferation; 
there is also a direct correlation between the levels of stress-associated plasma cortisol 
and prognostic indicators of HIV disease (progression to AIDS, to clinical 
progression, and to death) (Leserman et al., 2002). One common theme amongst the 
literature is bereavement-associated anxiety; which has been shown to have very 
strong links to CD4+ T-cell decline and HIV disease progression (Balbin et al., 1999; 
Kopnisky et al., 2004; Leserman, 2003). Another specific type of stressor has been 
identified in a study involving HIV+ women. Here “victim status” was identified as 
being strongly related to subjective health status, with those women who had reported 
at least three types of victimisation (e.g., burglary, rape, mugging) being shown to 
experience higher rates of AIDS defining conditions (by self-report and medical 
evaluation) in comparison to HIV+ women who had not reported victimisation 
(Kimerling et al., 1999).  
 
 
Post-Traumatic Stress Disorder (PTSD) 
PTSD has been observed as a reaction to HIV diagnosis up to eight years post-
diagnosis (Delahanty et al., 2004; Kelly et al., 1998; Milam, 2006; Safren et al., 
2003) and has been reported in HIV+ populations irrespective of its origins (Kimerling 
et al., 1999; Pence, 2009). Because of the difficulties in forming a diagnosis of PTSD 
that is clinically distinct from sustained anxiety, there is a paucity of studies 
concerning the disease modulating effects of PTSD (Kelly et al., 1998; Pence, 2009).  
With this in mind, the findings of high prevalence rates of PTSD in HIV+ samples 
(approximately 30-50%) indicate the importance of further research in this topic area 
(Boarts et al., 2006; Kelly et al., 1998; Safren et al., 2003). As with studies 
concentrating on depression, the literature describes disparate findings, which are 
 40 
usually explained by methodological issues such as insufficient follow-up time 
(Boarts et al., 2006; Evans et al., 2002; Kopnisky et al., 2004). 
Despite these difficulties, there is evidence amongst the literature that PTSD has a 
deleterious effect on HIV disease (Kelly et al., 1998; Leserman, 2003; Reilly et al., 
2009). Exposure to traumatic events has been demonstrated to impact on CD4+/CD8+ 
T-cell ratio at one-year follow-up (Leserman, 2003), with PTSD-associated death 
anxiety correlating strongly with HIV symptom experience (Safren et al., 2003). An 
interesting finding to emerge is that those with PTSD, unlike those with chronic 
anxiety, have lower morning salivary cortisol and less diurnal cortisol difference than 
those without symptoms of PTSD (Delahanty et al., 2004). Furthermore, this study 
also revealed that those with PTSD had higher levels of CD4+ T-cells, which is 
suggested to be due to the stunted cortisol response as cortisol increase is associated 
with CD4+ T-cell decline (Chida & Vedhara, 2009; Delahanty, Bogart & Figler, 2004; 
Kopnisky et al., 2004; Leserman, 2003).  However, despite the higher CD4+ T-cell 
counts being observed in PTSD HIV+ samples, there is also an association between 
PTSD and higher (or detectable) viral load (VL) (Boarts et al., 2006). This effect was 
more strongly observed in a population of participants who were suffering from PTSD 
as a direct cause of a natural disaster, as opposed to other samples whose origins of 
PTSD traced back to HIV or related issues (Reilly et al., 2009). Using HIV+ survivors 
of hurricane Katrina in New Orleans, Reilly and colleagues followed participants for 
two years post-event and found participants with PTSD had detectable VL levels at 
both the one- and two-year follow-up junctures, and also documented a decrease in 
CD4+ levels at the two-year follow-up (Reilly et al., 2009) suggesting that PTSD in 
reaction to non-illness based situations could elicit a stronger response. The literature 
presents an overriding association between PTSD and medication adherence, with 
some study groups suggesting that PTSD only has an indirect affect on HIV disease 
course via adherence (Boarts et al., 2006; Delahanty et al., 2004). It is therefore 
possible that in HIV-related PTSD that adhering to the medication regimens may 
serve as a reminder to their serostatus and therefore result in more distress (Delahanty 
et al., 2004). This is a factor that may not be observed in groups of HIV patients with 
PTSD that is unrelated to their diagnosis (e.g. Reilly et al., 2009). Psychosocial 
impact on medication adherence will be discussed later.   
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Individual Differences 
Psychological morbidity constitutes a significant problem for those with HIV, but 
there are still issues concerning variation in these findings (Evans et al., 2002; 
Kopnisky et al., 2004). One way of understanding these disparities is by examining 
the individual differences in areas such as coping, personality and disposition, which 
potentially could explain some of the variance within and without psychological 
morbidity data (Temoshok et al., 2008a, 2008b).  
 
Coping Styles 
The analysis of coping style as a factor in itself is very difficult, particularly in the 
health psychology setting, due to the interactions that coping style has with other 
factors such as personality, disposition, psychological morbidity, social support 
structures and patterns of behaviour (Balbin et al., 1999; Vassend & Eskild, 1998). 
There is also the issue that different coping styles may be effective at specific times in 
a progressive illness, but not in others, which means that temporally consistent coping 
styles could elicit both positive and negative effects (in either order) (Ironson et al., 
2005b; Temoshok et al., 2008a; Vassend & Eskild, 1998).  Nonetheless, coping styles 
have been shown to produce some of the strongest host relationships to HIV disease 
progression amongst the literature of psychosocial prognostic indicators (Chida & 
Vedhara, 2009).  
One of the most studied styles of coping is that of Type C coping, which is defined as 
a difficulty in recognising, processing and communicating those physiological and 
psychological cues of stress or emotional difficulty (Solano et al., 2002; Temoshok et 
al., 2008a; 2008b). Type C coping is usually characterised as a personality factor, but 
the current discussion relates exclusively to the coping styles characterised by Type C 
personality. Historically, Type C coping has been used to assess prognostics in 
cancer, but has recently been applied to HIV (Solano et al., 2002; Temoshok et al., 
2008a; 2008b). Stronger Type C coping has been associated with higher interleukin 
(IL) -6 production and increased disease progression in HIV (Temoshok et al., 2008a; 
2008b). This observed increase in IL-6 production has a direct impact on the 
replication of HIV, as it is a proinflammatory cytokine that upregulates the expression 
of CCR5 coreceptor on human immune cells, which facilitates R5-tropic HIV viruses 
in binding to and infiltrating healthy cells (Langford et al., 2007; Temoshok et al., 
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2008a) An increased presence of IL-6 also increases the apoptosis (programmed cell-
death) of CD8+ T-cells, meaning that IL-6 and other proinflammatory cytokines have 
an HIV facilitating action irrespective of the HIV virus strain (both R5- and X4-
tropic) (Langford et al., 2007).  
However, as aforementioned, there may be temporal effects in this relationship 
(Solano et al., 2002; Temoshok et al., 2008a). One study, which observed the 
relationship between Type C coping and HIV disease progression, categorised their 
participants into their CDC classification of HIV disease stages (Solano et al., 2002). 
With this categorisation, the deleterious effect between higher levels of Type C 
coping and HIV progression was only observed in those with more advanced HIV 
disease (CDC category A2; with CD4+ T-cell counts between 200 and 499 
cells/mm3), and not in those within the prior categorisation (CDC category A1; with 
CD4+ T-cell counts over 500 cells/mm3) (Solano et al., 2002). This finding suggests 
that whilst CD4+ T-cell counts are over 500 cells/mm3, and physiological HIV 
symptoms are at a minimum, Type C coping is not particularly destructive. However, 
once CD4+ T-cell levels drop, and symptoms develop and feelings of illness increase, 
this coping pattern, which is characterised by a lack of ability to process those 
feelings, becomes detrimental (Solano et al., 2002; Temoshok et al., 2008a).  
Further coping styles that have been found to impact on HIV disease progression are 
those which are reactionary to HIV diagnosis; posttraumatic growth (Milam, 2006) 
and increases in spirituality or religiousness (Ironson et al., 2006). Both posttraumatic 
growth and an increase in spirituality/religiousness have shown to be protective 
factors for CD4+ T-cell counts in HIV (Ironson et al., 2006; Milam, 2006), with a 
decrease in spirituality or religiousness post-diagnosis suggested to increase the speed 
of CD4+ T-cell loss by four and a half times (Ironson et al., 2006). Those other coping 
styles which have been suggested to negatively impact on HIV disease are passive 
coping, which has been shown to increase the reports of AIDS symptoms in HIV+ 
youth (Stein & Rotherum-Borus, 2004); the practice of “venting” (immediately 
expressing emotions without processing them) which has been suggested to increase 
the report of HIV symptoms in adults (Ashton et al., 2005); and denial or avoidant 
coping which has associations with increased viral load and decreased CD4+ T-cell 
counts prospectively (Ironson et al., 2005b). A coping style termed “planful problem 
solving” (i.e. that which requires cognitive processing of problems, and planning of 
resolutions) has been observed to be a protective factor in HIV disease, with a slower 
 43 
clinical progression than those who do not adopt this coping style (Vassend & Eskild, 
1998; Vassend et al., 1997). Adaptive coping is also a factor involved in attenuating 
disease progression in HIV. A study involving long-term survivors (those with a 
symptom-defined AIDS status for over four years) showed adaptive coping to 
increase NK cell cytotoxicity and decrease VL (Soloman et al., 2002). 
Further support for these findings comes from intervention studies that have been 
targeted to ameliorate emotional expression of stress and grievances. One such study 
employed a brief intervention based on written emotional expression. This required 
randomised participants to write for half an hour a day for four consecutive days, with 
the experimental group being asked to write about their most emotional or traumatic 
life experiences and the control group being asked to write about a neutral topic 
(Petrie et al., 2004). Six months after this intervention, an increase in CD4+ T-cell 
count was still being observed in those from the experimental group, which 
considering the brief nature of the intervention is a strong support for the effects of 
active coping and emotional disclosure (Petrie et al., 2004).  
 
Personality and Disposition 
Personality as a psychological construct has been applied to the understanding of 
health and disease across many patient groups (Kubzansky et al., 2009). As explained 
above, Type C coping is an aspect of Type C personality and has been explored in 
terms of its effects on both HIV and cancer (Ironson et al., 2008; Solano et al., 2002; 
Temoshok et al., 2008a; 2008b). In basic terms personality, as a construct, influences 
behaviour, beliefs and cognitions, coping mechanisms, information processing and 
contextual interpretation, and decision-making (Ironson et al., 2008). As such, 
personality (and its composites) is an important host factor in understanding the 
individual differences of HIV disease progression. 
Examination of personality traits and HIV progression is still a relatively new field, 
but the initial findings appear to be promising. A one-year study conducted with HIV 
patients looked at the trait of conscientiousness (e.g. competence, order, dutifulness, 
achievement striving, self-discipline and deliberation) and found that it was related to 
both CD4+ T-cell count and VL measures longitudinally (O’Cleirigh et al., 2007). 
Those participants who scored high in levels of conscientiousness were observed to 
experience a mean increase of 59 in CD4+ T-cell counts and a mean decrease of 1,727 
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in VL, compared to those low in conscientiousness who experienced a mean decrease 
in CD4+ T-cells of 27 counts and a mean increase in VL of 13,000 (O’Cleirigh et al., 
2007). This finding is particularly impressive given that in HIV, even if the patient is 
using HAART, a steady decline in CD4+ T-cell count is usually observed over time 
(O’Cleirigh et al., 2007). A follow-up to this study was conducted a year later, using 
more personality traits to evaluate the effect of broader aspects of personality on HIV 
disease progression (Ironson et al., 2008). This study observed similar trends in 
conscientiousness, but also expanded to show both openness and extraversion, and 
performed a four-year follow-up to establish longer-term correlates of personality 
(Ironson et al., 2008). Both openness and extraversion were associated with an 
increase in CD4+ T-cell count over four years, and variations in conscientiousness 
were shown to predict the increase in VL normally observed over such a time period 
(Ironson et al., 2008). The authors explained these results by surmising that those who 
were high in extraversion would be more likely to sustain their social relationships 
and those high in openness would be more optimistic (Ironson et al., 2008). 
 
Further personality factors that have received attention in the research community are 
optimism and pessimism. Optimism and pessimism are dispositional factors, which 
are characterised as the ability to create positive or negative interpretations to life 
events and the maintenance or lack of hope in situations of adversity (Ironson et al., 
2005a; Milam et al., 2004). Optimism has been associated with increases in CD4+ T-
cell counts over time in those with HIV (Ironson et al., 2005a; Milam et al., 2004). 
However, this relationship is suggested to be curvilinear as those with moderate levels 
of optimism have higher CD4+ T-cell counts than both low and high optimism groups 
(Milam et al., 2004). This curvilinear relationship between optimism and CD4+ T-cell 
counts suggests that there is a point where optimism becomes unrealistic and 
ultimately detrimental. In effect, those with very high expectations that are eventually 
not realised will experience more stress than those with lower expectations that are 
realised (Milam et al., 2004; Temoshok et al., 2008a). Therefore optimism must be 
metered with a sense of realistic expectation to be effective in promoting health in 
HIV. Those with above average levels of optimism have been shown to experience 
above average increases in CD4+ T-cell counts and slower VL increase, whereas those 
with lower levels of optimism see above average decreases in CD4+ T-cells and 
higher VL increase over a two year follow-up period (Ironson et al., 2005a). However 
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a study examining both optimism and pessimism found no such relationship for 
optimism and VL, in fact optimism was only related to CD4+ T-cell count and 
pessimism was related to VL only (Milam et al., 2004).  
 
As the impact of personality factors on HIV is still a relatively new field, no research 
to date has examined the possible mechanisms that underlie the relationship. 
However, it stands to reason that as personality factors have associated behaviours 
and cognitions that relate to them, it is very likely that these may serve as facilitative 
factors (Ironson et al., 2005a). However, in their study of the effects of different 
levels of optimism and pessimism on HIV prognosis, Milam et al. observed no 
differential relationships with health behaviours on HAART adherence (Milam et al., 
2004), which suggests there should be other underlying causes for this interaction. It 
is also quite possible that pessimism may be a factor of depression, as it is a 
characteristic of depressed affect, and it should be noted that depression has been 
suggested to be a mediator in the findings of Ironson et al., who examined varying 
levels of optimism and its effects on CD4+ and VL (Ironson et al., 2005a).  
 
SOCIAL FACTORS 
The host social elements of being HIV+ are multi-factorial. A diagnosis of HIV not 
only has health consequences, but due to its communicability and related stigma, it 
leads to significant social change for the patient (Pakenham & Rinaldis, 2001; Pryor 
et al., 1999; Ullrich et al., 2004). Social resources can help to manage the changes 
involved in an HIV diagnosis as well as facilitating adaptive coping to new challenges 
and difficulties (Burgoyne, 2005). Two of the main social factors involved in disease 
progression are social support and social identity 
 
Social Support 
Social support is one of the most well established social factors responsible for 
impacting on disease progression and is defined as resources for emotional, practical 
and informational problems from family, friends, partners or organisations (Ashton et 
al., 2005; Young et al., 2004). The examination of social support in HIV has 
classically been regarding issues such as health-related quality of life, but has more 
recently been reviewed in regard to its impact on disease progression (Burgoyne, 
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2005). As previously discussed, prevalence rates of psychological morbidity in HIV+ 
patients are very high, but these psychological difficulties can indeed be buffered by 
social factors, provided that social support is satisfactory and accessible (Ashton et 
al., 2005; Young et al., 2004). The literature surrounding this relationship has 
classically been more related to social support as this buffering factor for distress, but 
is beginning to be examined as a risk factor in itself (Burgoyne, 2005).  
The data concerning this relationship has also been contradictory, with some studies 
outlining a high level of social support as a protective factor and some as a damaging 
factor (Balbin et al., 1999; Burgoyne, 2005; Chida & Vedhara, 2009). Studies that 
have shown a relationship between higher social support and decreased HIV 
progression have observed this relationship in terms of suppressed VL (Burgoyne, 
2005). Another perspective of viewing this relationship has been in the form of 
perceived satisfaction with social support, which in itself provides a more salient 
measurement for such a highly subjective construct. Subjective satisfaction with 
social support has been found to predict HIV symptoms at one year follow-up, with 
lower levels of social support satisfaction being related to higher levels of HIV 
symptom experience (Ashton et al., 2005) and faster progression through CDC stages 
(Leserman et al., 2002).  
Social inhibition has also been examined as a component of social support, with those 
with higher levels of social inhibition displaying higher baseline levels of VL and 
poorer immunologic responses to HAART prospectively (Cole et al., 2003). 
Moreover, this study related social inhibition to autonomic nervous system (ANS) 
activity, concluding that ANS activity is a mechanistic factor between social 
inhibition and HIV immunologic outcome and is independent of a variety of 
psychosocial, biological and HIV-related variables (Cole et al., 2003).  
A further facet of social support researched in relation to HIV prognostics is affects of 
a stable partnership (Young et al., 2004). Stable partnership can be a protective factor 
in HIV disease progression in terms of immunologic and physiologic HIV-related 
outcomes, but was also reported to decline with increasing disease (Young et al., 
2004).  
Several studies have, however, failed to support these findings, and have found either 
no discernable relationship between social support and HIV pathogenesis (Balbin et 
al., 1999) or have found trends in the opposite direction, with findings of higher 
baseline social support predicting faster CD4+ T-cell decline (Ironson et al., 2005b). 
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Suggested reasons for this harmful relationship have been postulated as occurring via 
behavioural and social mechanisms, whereby good social networks foster either risky 
health behaviours or repeated exposure to traumatic circumstances such as AIDS-
related bereavement or caregiving (Miller & Cole, 1998). A recent meta-analysis of 
psychosocial prognostic factors in HIV concluded that there is currently not enough 
evidence, either in strength or number, to support a direct relationship between social 
support and HIV prognosis (Chida & Vedhara, 2009). This is proposed to be due to a 
number of factors, most notably the conceptualisation of social support, its component 
factors and their relevance to the individual (Chida & Vedhara, 2009). The authors 
also raise an interesting point which requires further study; namely that women may 
benefit from social support more than men - and propose that further research be 
conducted with female samples to assess the relationship (Chida & Vedhara, 2009). 
There is also the issue that social support in itself may indeed be affected by HIV, as 
the disease worsens and the individual feels more ill and requires more time at rest, so 
social relationships may weaken or dissipate (Burgoyne, 2005). It is therefore difficult 
to review the effects of social support on HIV prognosis if the disease has developed 
to the point where the patient’s social life is impacted significantly, and this could 
account for some of the discrepant findings in the literature.  
 
Social Identity and Inhibition 
How individuals relate to their social systems can be a more difficult issue win HIV 
patients (Cole et al., 1997; Fekete et al., 2009). One of the highest proportions of HIV 
infections globally is transmission amongst men who have sex with men (UNAIDS, 
2010), which makes homosexual HIV+ populations doubly sensitive to social issues. 
Social identity in HIV populations refers to the disclosure of HIV status and 
homosexual identity (Cole et al., 1997). The act of disclosing homosexuality (or 
“coming out”) is a psychosocial milestone for gay people: with the possibility of this 
disclosure being met with hostility, disappointment, prejudice or other negative 
attitudes and behaviours (Cole et al., 1997; Ullrich et al., 2003).  Equally the 
disclosure of an HIV+ status has the potential to be met by similar negative social 
reactions due to the stigma heavily laden on the condition since its discovery (Fekete 
et al., 2009; Pryor et al., 1999). Whilst some may choose to disclose these issues to 
their immediate social network, and sometimes beyond, others may choose to conceal 
them from even their closest family and friends, which can result in this type of 
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inhibitory behaviour “spilling” over to other aspects of their lives (Eisenberger et al., 
2003; Ullrich et al., 2003). Social inhibition has been associated with increased ANS 
activation; which, in turn, was also associated with elevated VL and decreased 
response to HIV treatment (Cole et al., 2003).  
 
Concealment of Sexual Identity 
The concealment of homosexuality from one’s social network has been associated 
with faster HIV disease progression (Cole et al., 1997; Ullrich, et al., 2003). 
Additionally, the relationship between concealment and disease progression also 
appears to be influenced by satisfaction with social support (Ullrich et al., 2003). 
Further, the effects of concealment may be less pronounced amongst those who are 
rejection-sensitive (Cole et al., 1997). This suggests that although there is a 
relationship between the concealment of homosexual identity and faster HIV disease 
progression, it is highly likely to be relative to that individual’s social and personal 
context. The data suggest that in those who are less sensitive to rejection and who 
have higher levels of self-regard and satisfaction with social support, the concealment 
of homosexuality would be a damaging factor for HIV prognosis (Cole et al., 1997; 
Ullrich et al., 2003; 2004). However, concealment of homosexuality can serve as a 
protective factor in those with lower levels of self-regard and who are more rejection-
sensitive, as they are not risking negative social consequences, which they may be 
less equipped to deal with (Cole et al., 1997; Ullrich et al., 2004).  
 
Concealment of HIV Status 
Two studies to date have assessed the impact of disclosing HIV+ status on the 
progress of the illness (Fekete et al., 2009; Sherman et al., 2000). One study of HIV+ 
children categorised them into those who had recently disclosed their HIV status to 
their friends, those who had previously disclosed and those who had not disclosed and 
compared their CD4+ T-cell percentage decline over one year (Sherman et al., 2000). 
Amongst the children, those who had disclosed their HIV status showed a significant 
increase in CD4+ T-cell percentage over one year (Sherman et al., 2000). In contrast, 
those who had not previously disclosed their HIV status did not experience CD4+ T-
cell increase (Sherman et al., 2000). The percentage increase was greater in those 
recently disclosing serostatus than that observed in those who had previously 
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disclosed, which suggests that the most pronounced effects of this disclosure are 
immediate, but that they can endure (Sherman et al., 2000).  
In adults HIV status disclosure has also been associated with a slower disease 
progression and has also been described culturally (Fekete et al., 2009). In a study 
analysing the differences in CD4+ T-cells and VL amongst men who divulged their 
HIV serostatus to their mothers, these changes were assessed differentially in 
Caucasian and Latino cultures and across those with different levels of perceived 
HIV-related family support (Fekete et al., 2009). The results showed that amongst 
Caucasian men who disclosed their HIV status to their mothers, those who had higher 
levels of perceived support had lower VL and higher CD4+ T-cells than did those who 
reported low perceived levels of support (Fekete et al., 2009). Inversely, Latino men 
who disclosed their serostatus to their mothers only showed an improvement in HIV 
progression markers (VL) if they reported low levels of perceived support, whereas 
those who reported high levels of support showed no relationship between disclosure 
and CD4+ T-cell count or VL (Fekete, 2009). Equally no associations could be found 
amongst men who disclosed their HIV status to their fathers (Fekete, 2009). 
Caucasian men only display a difference in prognostic markers (CD4+ T-cell count 
and VL) if they perceive higher levels of HIV-specific family support, and do not 
appear to be at a detriment if they have lower levels of support (Fekete, 2009). 
However, Latino men do not experience any increase in HIV suppression even if they 
report high levels of perceived support but rather do appear to be at a detriment if 
their disclosure results in low levels of HIV-related family support (Fekete, 2009). 
These findings suggest that familial disinhibition is culturally relevant and further 
differences could be observed across other racial and ethnic demographics. It also 
appears to be relevant to the individual in terms of how much support they receive 
once they have made this disclosure.  
 
On a more general level of social inhibition, a recent study using interviews with 
HIV+ women has described an association between the use of language related to 
inhibition when undergoing a “coping with HIV” interview, and CD4+ T-cells. The 
study revealed that those who display higher levels of inhibition have lower CD4+ T-
cell counts (Eisenberger et al., 2003). Even when controlling for a broad variety of 
physiological, psychological and behavioural covariables, levels of social inhibition 
still contributed to 8% of the variance observed in CD4+ T-cell count across the 
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participants (Eisenberger et al., 2003). This observation was still maintained when 
accounting for emotional expression, which suggests that the relationship between 
inhibition and HIV suppression is not influenced by emotional expression as one 
might expect. It is therefore possible that the deleterious effects of inhibition are 
exerted through other behavioural or interpersonal mechanisms such as decreased 
socialisation, increased stress due to the withholding of pertinent personal information 
or decreased self-care due to the denial or suppression of HIV-relevant physiological 
cues. 
 
BEHAVIOURAL FACTORS 
The behaviours of the individual that impact upon HIV progression can exist 
independently or can be resultant from the previously discussed psychological or 
social factors (see figure three). The three main areas in which behavioural factors 
decrease HIV suppression are HAART medication adherence, the abuse or 
dependence of alcohol or addictive substances and health behaviours. Whilst these 
behaviours can serve as mechanisms from other areas of psychosocial prognostic 
indicators and disease progression, they are concepts within themselves, and their 
prevalence and predispositions have been studied well in recent years. 
HAART Adherence 
Since its widespread availability in the late 1990s, HAART use has been associated 
with an estimated two-thirds decrease in mortality amongst those with end-stage HIV 
disease (CD4+ T-cells<100 copies/mm3) (Weller & Williams, 2001). The combination 
of drugs that act on various stages of the virus’ replication has resulted in the ability to 
suppress HIV viraemia to near undetectable levels (the “gold standard” of 
combination therapy) (Deeks, 2006). With this optimum suppression, the immune 
system can then reconstitute and function to its highest capacity (Deeks, 2006; Weller 
& Williams, 2001). The development and widespread availability of HAART now 
means that HIV can be considered more a chronic illness rather than a terminal one 
(Parruti et al., 2006; Pence, 2009). This means understanding the reasons why patients 
do not adhere to their medication is an important issue in treating the global problem 
of HIV.  
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Those who do not adhere to their HAART medication regimes may do so for several 
reasons, and can be loosely categorised into three groups: erratic, unwitting and 
intentional (Van Servellen et al., 2002). Those who are erratic non-adherents are 
characterised by circumstantial barriers to adherence. Although they understand how 
and why to take their medications there may be situations in which they miss doses 
(for example if they forget, run out or are too busy) (Van Servellan et al., 2002). 
Unwitting non-adherents are those people who have a poor understanding of the 
schedule of their medication regimes and intentional non-adherents are those who 
actively choose not to adhere (Van Servellen et al., 2002). Intentional non-adherence 
is an issue particularly pertinent to HIV not just because adherence is required for 
optimum viral suppression and prevention of viral mutation (to a drug-resistant state), 
but because there is a heavy pill-burden in HAART with drugs which elicit numerous 
side-effects and serve as a constant reminder of illness (Langford et al., 2007; Pence, 
2009; Parruti et al., 2006; Van Servellan et al., 2002). 
Optimum adherence to HAART has been related first and foremost with good 
tolerance of the drugs being taken, with the experience of side-effects from the 
medications being cited as the most common reason for non-adherence (Parruti et al., 
2006; Applebaum et al., 2009). Stressful life events and depressive symptoms have 
also been observed to have an inverse relationship with medication adherence 
(Leserman et al., 2008). Married people are reported to be twice as likely to retain 
good levels of adherence in comparison to single people, irrespective of the HIV 
serostatus of the spouse (Parruti et al., 2006). Psychosocial predictors of poor 
adherence include the experience of trauma, depression, substance abuse, 
homelessness and stress (Leserman et al., 2008; Mugavero et al., 2007; Parruti et al., 
2006; Uldall et al., 2004). On a more global scale, access to health care and the 
attitude with which health professionals treat patients also has a predictive 
significance on medication adherence (Schneider et al., 2004; Van Servellen et al., 
2002).  
 
Alcohol or Addictive Substance Abuse & Dependence 
Substance use and abuse is commonly found amongst HIV+ populations and 
constitutes a significant problem in relation to HIV treatment (Cabral, 2006; Fiellin, 
2004; Uldall et al., 2004). The use or abuse of addictive substances carries with it an 
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inherent impact upon HIV progress in the form of medication adherence, as 
intoxication is associated with negligent behaviour and the primary prioritisation of 
maintaining the addictive behaviour (Gore-Felton & Koopman, 2008). However, once 
someone has received treatment for substance dependence they may still experience 
faster HIV disease progression and greater adherence problems than patients who 
have never had dependency problems, which is thought to be attributable to the social 
and psychiatric circumstances of such populations (Spire et al., 2007). The routes of 
administration of certain drugs can also have an impact on HIV. Those drugs that are 
commonly injected (e.g. opiates, cocaine, and methamphetamine) not only facilitate 
the spread HIV, but also other blood-borne pathogens (Donahoe & Vlahov, 1998). 
Coinfection with other pathogens may impede the immune system, and can also 
create multiple HIV exposures in an individual with the possibilities of multiple viral 
subtype infections, which results in more virulent HIV infection and more 
complicated treatment (Donahoe & Vlahov, 1998; Gore-Felton & Koopman, 2008).  
Longitudinal research by the United States CDC has suggested that injection drug 
users (IDU) as a group show extraordinarily fast conversion from HIV diagnosis to 
AIDS, with around 40% IDU experiencing this transition in just 12 months 
(Grigoryan et al.,  2009). The introduction of some of these substances to the body 
can also change the general functioning of the immune system and can interact with 
HAART (Fiellin, 2004; Gore-Felton & Koopman, 2008). Whilst research into the 
effects of drugs of abuse on HIV progression is still ongoing, only that which has 
provided consistent support throughout the literature will be presented here. Other 
avenues of interest that are still being debated are marijuana and tobacco.  
 
Alcohol 
Alcohol consumption has been associated with enhanced HIV viraemia, decreased 
HAART uptake and adherence, and increased cerebral atrophy (which has been 
related to the neuropathogenensis of HIV) (Fiellin, 2004; Pfefferbaum et al., 2007; 
Samet et al., 2007). Some studies have argued that alcohol dependency or abuse has 
no direct biological action on HIV, and only results in accelerated pathogenesis by its 
behavioural effects on adherence (Chander et al., 2006). However, the wealth of the 
literature on this subject suggests that there are direct biological consequences of 
alcohol abuse in HIV disease.  Physiologically, alcohol is supposed to have additive 
effects to HIV in immunodegeneration and neurological damage, over and above that 
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observed for either condition in exclusion (Fiellin, 2004; Pfefferbaum et al., 2007; 
Samet et al., 2007).  
In trying to extract the biological from the behavioural, one study examined heavy 
alcohol use and its effects on CD4+ T-cell count and VL in HIV+ participants (Samet 
et al., 2007). In this study, heavy alcohol use still correlated with lower VL in those 
taking HAART once adherence was controlled for, and correlated with lower CD4+ 
T-cell counts but only in those who were not taking HAART (Samet et al., 2007). 
These findings suggest that although there are some effects that may be attributable to 
adherence, alcohol abuse still exerts a negative effect on HIV pathogenesis. In light of 
the fact that alcohol abuse correlated with VL in HAART users and not in non-
HAART users, it is possible that alcohol use has an interactive effect on HAART 
medications (which are primarily responsible for curtailing VL).  
 
Amphetamines 
The use of methamphetamines can be found quite commonly amongst samples of 
HIV+ men who have sex with men (MSM) due to the social associations of 
methamphetamine use in the MSM demographic, and its consequential effects on high 
risk sexual behaviour (Marquez et al., 2009; Nakamura et al., 2009). The use of 
methamphetamine has been associated with the dysfunction and neuroadaptation of 
the dopamine and serotonin pathway network systems within the brain, which is 
known to cause immunomodulation and compromise the blood brain barrier, 
facilitating neuro-infection of HIV and therefore overall disease progression (Cabral, 
2006; Chang et al., 2005; Mahajan et al., 2008). As with alcohol, there is a suggestion 
that methamphetamine use has an additive effect to HIV in the degradation of brain 
matter volumes, including the compromised integrity of the blood brain barrier, both 
of which contribute to the neuropathogenesis of HIV (Chang et al., 2005; Mahajan et 
al., 2008).  
 
Cocaine 
Cocaine and crack-cocaine are another sub-section of drugs of abuse that have been 
suggested to impact upon the progression of HIV (Cook et al., 2008; Fiellin, 2004). 
Cocaine use has been associated with immunomodulation, with changes in T-cell 
activity and the balance between Th1 and Th2 immunity patterns, which may impact 
on the immune system’s ability to control HIV and its associated opportunistic 
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infections (Cabral, 2006; Fiellin, 2004). Crack cocaine is commonly smoked, and 
there have been strong associations found between the smoking of crack and the 
incidence of pulmonary-associated HIV-related diseases, which may contribute to the 
associations between cocaine use and HIV disease progression (Webber et al., 1999).  
As with other illicit drugs whose use has been investigated in relation to the 
progression of HIV, it is broadly understood that cocaine and crack-cocaine use exerts 
its effect on pathogenesis by interfering with HAART adherence (Baum et al., 2009; 
Fiellin, 2004; Webber et al., 1999). However, in recent years more research has been 
conducted to examine these effects whilst controlling for adherence, and crack-
cocaine has been independently associated with markers of disease progression 
(Baum et al., 2009; Cook et al., 2008). In a longitudinal study examining the effects 
on disease progression in crack-using women, use was demonstrated to relate to 
increased HIV viraemia and immune deterioration, the diagnosis of an AIDS-defining 
condition and AIDS-related mortality independent of HAART use or adherence 
(Cook et al., 2008). In a recent study, Baum et al. have demonstrated not only an 
impact of crack-cocaine use on VL, but also on CD4+ T-cell count, again independent 
of HAART use or adherence over a prospective data collection period of 30 months 
(Baum et al., 2009).  
 
Opioids 
Research into the effects of opioid use on HIV progression is relatively sparse and 
inconclusive, which is surprising considering the strong relationship between injection 
drug use and HIV infection (Fiellin, 2004). Much is known about the effects of 
opioids on the immune system, yet comparatively little is understood about their 
effects in HIV+ patients. This is supposedly due to the difficulties in isolating opiate 
use as a predictor from other issues such as adherence, polydrug use and toxic 
poisoning by excipient substances (Donahoe & Vlahov, 1998; Roy et al., 2006). One 
of the most pressing issues in HIV+ opioid addiction is that of the availability of 
HAART, as many IDU may not be provided this treatment until they are receiving 
treatment for their addiction (Fiellin, 2004; Spire et al., 2007). That said, it has been 
suggested that opiate replacement therapy (with agents such as methadone or 
buprenorphine) is associated with better adherence in opiate addicted samples (Spire 
et al., 2007; Uldall et al., 2004).  
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HIV aside, the use of opioids is known to decrease the volume of both the thymus and 
spleen; secondary lymphoid organs vital to the production of lymphocytes and the 
differentiation of immature T-cells to CD4+ T-helper cells or CD8+ cytotoxic T-cells 
(Cabral, 2006; Roy & Loh, 1996; Roy et al., 2006). Chronic opioid use is also 
suggested to affect NK cell function and cytotoxicity, as well as suppressing cellular 
immunity (Cabral, 2006; Roy & Loh, 1996; Roy et al., 2006). Evidence from in vitro 
research suggests that opioids upregulate HIV (Donahoe & Vlahov, 1998; Gore-
Felton & Koopman, 2008). However, some recent research into Simian 
Immunodeficiency Virus (SIV) has suggested that opioid exposure helps to slow 
down the progression of SIV (Donahoe et al., 2009). It is possible that these 
differences observed in the simian model may have occurred through the different 
levels of stress. The authors posit that as the opiate dependence of the laboratory 
monkeys was well maintained, that they may not experience the physiological and 
psychological stress that human opiate dependents may do (Donahoe et al., 2009). 
Further, it is this stress that elicits the activation of latently infected HIV cells, thereby 
increasing circulating virus.  
 
 
Figure 3. Host psychosocial contributers to accelerated HIV progression 
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PNI PATHWAYS OF DIFFERENTIAL HIV PROGRESSION 
Whilst the mechanisms from one phenomenon to another can be explained through 
behaviour (i.e. social support to HIV acceleration, via HAART adherence (see figure 
three), there are some direct biological pathways that allow psychological states to 
exert effect upon immune system actions. These pathways serve to explain some of 
the differences observed from person to person in HIV disease, although more 
research is required in order to fully understand these mechanisms. 
Recent clinical evidence has sought to elucidate the mechanisms that may serve to 
explain the relationship between psychological morbidities and increased HIV 
progression. NK cells and CD8+ (cytotoxic) T-lymphocytes are two of the leading 
cells impacted by the depression-disease progression relationship in HIV, with a 
relatively decreased number of NK cells being observed in HIV+ patients with 
depression compared to those without (Alciati et al., 2007; Evans et al., 2002; 
Greeson et al., 2008; Ironson et al., 2005a; Pence, 2009). In HAART-naïve patients, it 
has been suggested that major depression only relates to NK cell count and 
percentage, in contrast to non-depressed matched HIV+ controls (Alciati et al., 2001). 
This suggests that the findings of depression’s impact upon CD8+ T-cells observed in 
HAART using samples may be due to the modulation of HAART action by the 
neurophysiological consequences of depression. One study conducted by Evans and 
colleagues (2002) describes a functional alteration in lymphocyte activity, with lower 
levels of NK cell activity and higher levels of activated CD8+ T-lymphocytes being 
observed in HIV+ women with symptoms of depression and anxiety (Evans et al., 
2002). 
Other theories include modulation of the sympathetic nervous system (SNS) in 
depression and stress, with the biogenic amine Noradrenaline being cited as a likely 
perpetrator (Chida & Vedhara, 2009; Cole, 2008; Greeson et al., 2008; Hassan & 
Douglas, 1990; Kopnisky et al., 2004; Leserman, 2003). Receptors for this 
neurotransmitter have been found on the cell surface of many cell classes within the 
immune system and can alter the way in which the immune system functions at rest or 
in response to infection (Besedovsky & Del Ray, 2007; Taub, 2008).  
A recent suggestion is that Substance P (SP) may be involved as a mechanism by 
which depression (and other psychosocial factors) may impact in disease progression. 
Evidence for this postulation comes from observations of high levels of SP in the 
plasma of HIV+ patients, the effectiveness of SP receptor antagonists in treating 
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depression, and the role of SP in immunoregulation (Cole, 2008; Ho & Douglas, 
2004; Kopnisky et al., 2003; Leserman, 2003; Li et al., 2001). It is proposed that SP 
facilitates HIV replication through several means. Firstly, SP elicits the activation of 
NF-κB (a genetic transcription factor), which activates CCR5 expression on immune 
cells allowing R5-tropic HIV virus more receptors to target for cell invasion (Li et al., 
2001). Secondly, SP stimulates the release of pro-inflammatory cytokines, including 
Tumor Necrosis Factor (TNF)-α, which is known to facilitate the upregulation of 
HIV-1 infection in T-cells and monocytes (Ho & Douglas, 2004; Kopnisky et al., 
2004; Li et al., 2001). Thirdly, SP has been demonstrated to activate latent HIV-1 
virus in infected cell lines, most notably T-lymphocytes, thereby exponentially 
increasing host VL (Ho & Douglas, 2004; Li et al., 2001). Evidence for this direct 
link comes in the form of exerting SP receptor antagonists on the relevant cells, where 
the effect of SP on HIV-1 cells is abrogated as binding of SP is blocked by the 
antagonist (Ho & Douglas, 2004; Kopnisky et al., 2004; Li et al., 2001). Moreover, 
HIV has been suggested to increase serum levels of SP, thereby creating what is 
termed a feed-forward cycle where both HIV and SP promote each other 
symbiotically (Ho et al., 2002; Kopnisky et al.,, 2004; Leserman, 2003).  
 
Anxiety’s detrimental effects on HIV are thought to be driven by the increased 
activity of the Hypothalamic-Pituitary-Adrenal (HPA) axis, and production of cortisol 
(Chida & Vedhara, 2009; Cole, 2008; Ironson et al., 2005b; Kopnisky et al., 2004; 
Leserman, 2003; Leserman et al., 2002). The stress-induced over production of 
cortisol is thought to affect HIV pathogenesis by switching immune response patterns 
from Th1 to Th2 (Chida & Vedhara, 2009; Kopnisky et al., 2004; Leserman, 2003). 
This switch diminishes the attack response to HIV and accelerates apoptosis of 
antiviral immune cells, and possibly also accelerates HIV replication further as there 
have been some suggestions that HIV-infected cell lines respond to cortisol and 
dexamethasone (Chida & Vedhara, 2009; Kopnisky et al., 2004; Leserman, 2003). 
However, research into the effects of glucocorticoids on HIV has suggested that they 
may actually suppress HIV replication by bonding to and suppressing long-terminal 
repeat activity (that which enables the virus to enter a host cell) (Kino et al., 2000), so 
this requires more research.  
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CONCLUSION 
The ways in which psychosocial aspects of the individual impact upon HIV 
progression are multifactorial and often interlinked (see figure three). Although we 
understand much about how certain conditions affect HIV disease, there is still much 
we do not know.  
Intervention studies have afforded us the opportunity to assess our ability to 
ameliorate or reverse some of the adverse effects of psychosocial circumstance on 
HIV, and have underlined the importance of psychosocial support during illness. For 
example, the intervention for emotional expression by Petrie and colleagues 
delineated the longitudinal efficacy of simple, brief strategies, which can be employed 
universally to HIV patients due to their simplicity (Petrie et al., 2004). Such 
interventions also aid in improving the patients' experiencing of living with their 
illness, as well as trying to prolong their lives. The present identified factors are all 
fraught with theoretical contention, and it is immediately apparent that observational 
breadth and good covariable control are essential to furthering our knowledge. 
However, there are some conditions under which we may not be able to accurately 
isolate prognostic indicators from extraneous variables, such as is seen with analysing 
the effects of drug and alcohol dependence on HIV progression.  
 
In summary, although there is still much to be studied and learned, the literature 
surrounding the non-viral host-related precedents of HIV progression has allowed us 
to understand more about the individual variation of HIV disease experience, how to 
help prolong peoples’ lives by targeting these variations and to identify those areas in 
which our knowledge is still wanting. In the HAART era, whereby patients can live 
with HIV for much longer than the early years of the epidemic, whilst it is still of vital 
importance that efforts are made to find a cure, the research into those factors which 
speed up the progression of the illness helps HIV+ patients every day and this research 
should continue.  
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Abstract 
 
Past studies examined relationships between hemispheric lateralisation (HL) and 
immune system functioning. However, there has been no up-dated systematic review 
of this research area. This article reviews relevant published studies, evaluates study 
quality and effect sizes. Eleven studies were selected: three revealing a relationship 
between weaker left hemisphere function and poorer immune function, three 
describing a relationship between weaker right hemisphere function and stronger 
immune functioning, and five describing both relationships. Mean effect-size of the 
studies was r = 0.536 (range 0.280-0.866). Collectively, studies point at left-HL and 
stronger immunity relationships. Limitations, mechanisms and clinical implications 
are discussed. 
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INTRODUCTION 
Neuroimmunology has uncovered progressively over the last 3 decades the bi-
directional manner of communication between the central nervous system (CNS) and 
immune system (Banks, 2004; Bellinger et al., 2008; Besedovsky & del Ray, 1996; 
Butts & Sternberg, 2008; Ferone et al., 2006; Tracey, 2002; Webster et al., 2002; 
Wrona, 2006). The immune system communicates with the CNS once an infection has 
been encountered in the periphery, initiating sickness behaviour, providing optimum 
behavioural conditions to facilitate immune defence and recovery (Banks, 2004; 
Besedovsky & del Ray, 1996, 2007; Hopkins, 2007; Konsman et al., 2002; Rivest, 
2003; Vollmer-Conna et al. 2004; Wrona, 2006). One important form of immune-to-
brain communication is via the vagal nerve, especially in low levels of peripheral 
inflammation (Tracey, 2002). The CNS-immune communication is mainly achieved 
via autonomic and neuroendocrine pathways, (Bellinger et al., 2008; Besedovsky & 
del Ray, 1996; Butts & Sternberg, 2008; Ferone et al., 2006; Neveu, 1988; Webster et 
al., 2002; Wrona, 2006). Receptors for various hormones, neuropeptides and 
neurotransmitters have been found to be expressed on the surface of many immune 
cell types (Basu & Dasgupta, 2000; Ferone et al., 2006; McKenna et al., 2002; 
Webster et al., 2002). Organs of the lymphatic system; such as bone marrow, thymus, 
spleen, mucosal lymphoid tissues and lymph nodes; have been demonstrated to be 
innervated by autonomic fibers – mainly of the sympathetic division, but 
parasympathetic involvement has also been described (Bellinger et al. 2006; 2008; 
Quan & Banks, 2007; Tracey, 2002; Wrona 2006). Evidence of CNS-immune 
relations also comes from neurophysiological observations concerning hemispheric 
lateralisation (HL), which may help explain some individual differences in brain-
immune associations (Neveu, 1988; 1991; 1992). The HL-immune relationship is the 
topic of this article. 
 
Differential CNS communication with the Immune System – Hemispheric 
Lateralisation 
How the CNS influences the immune system can depend on many factors, one of 
which is hemispheric lateralisation (HL). The two hemispheres of the human brain 
have different functional specialisations, and it is well known that one of the 
hemispheres will be activationally or functionally dominant to the other (Cerqueira et 
al., 2008; Hugdahl, 2000; Neveu, 1988, 1991, 1992). The two hemispheres of the 
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brain are known to act differentially upon behaviour, psychiatric and neurological 
disorders and immunity (Neveu, 1992; Sackeim et al., 1984; Wittling et al., 1998). 
Experimental studies in animals across the last two decades have demonstrated that 
unilateral damage or stimulation to either the left or right hemispheres of the brain 
result in opposite immunological reactions (Moshel et al., 2005; Neveu, 1988, 1991, 
1992; Neveu et al., 1991). Damage to the left hemisphere results in the depression of 
immunological parameters such as T-lymphocyte proliferation, natural killer cell 
activity (NKCA), IL-2 production and production of Immunoglobulin G antibodies 
(Goldstein et al., 2002; Neveu, 1988, 1991, 1992, Neveu et al., 1991). Damage to the 
right hemisphere can produce either no immunological change, or even enhance 
activity of certain immune parameters (Goldstein et al., 2002; Neveu, 1988, 1991, 
1992). Furthermore, a study using rats with implanted electrical cortical stimulation 
revealed that stimulation of the left temporo-parieto-occipital cortex temporarily 
increased production of thymic CD4+ and CD8+ lymphocytes, while stimulation of the 
right hemisphere decreased their levels (Moshel et al., 2005).  
Geschwind and Behan (1982) developed a theory based on the association of prenatal 
testosterone exposure and termed this “anomalous dominance” (i.e. right sided 
“abnormal” language lateralisation). Observing higher incidences of left-handedness 
amongst individuals with developmental and immune disorders, they hypothesised 
that this anomalous dominance was a contributor for variation in susceptibility to 
illnesses (Geschwind & Behan, 1982; Morfit & Weekes, 2001). This theory was 
supported through large population surveys of left handed individuals, and studies of 
sinistrality in patients with migraine and immune disorders (Geschwind & Behan, 
1982). Whilst vital to the investigation of effects of HL on immune function, this 
research had conceptual and methodological flaws, most notably the definition of 
“anomalous dominance”. The latter cannot be determined by handedness alone, and is 
too broad a concept in itself to be used as a definition of cerebral dominance pattern. 
Handedness is only one of many activities and behaviours that are lateralised and 
cannot comprise a total asymmetry index (McManus & Bryden, 1991). Furthermore, 
handedness is very poorly correlated with HL, but rather may be indicative of 
language lateralisation only, as language lateralisation in sinistrals is heterogeneous, 
whereas with dextrals it is almost exclusively in the left hemisphere (Gruzelier et al., 
1996; Jung et al., 2003; Knecht et al., 2000; Toga & Thompson, 2003). Moreover, a 
study using mice showed that handedness effects on immunity were abolished with 
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left, but not right, cortical ablation (Neveu et al., 1991), suggesting the involvement of 
more complex brain organisation factors in the HL-immunity relationships. While 
handedness is related to hemispheric specialisation (e.g., left hemisphere specialising 
in certain linguistic abilities), people may differ in their relative levels of hemispheric 
activation (Davidson et al., 1999), which we refer to here as hemispheric 
lateralisation (HL) or cerebral activation asymmetry. Below we provide a more 
comprehensive definition of HL. 
 
The purpose of this review 
Using electroencephalograms (EEG) and neuroimaging techniques, as well as 
neuropsychological tests assessing specific brain functions, we can test more precise 
relationships between the CNS and immune systems, with particular emphasis on HL 
and immunity. To date, there have been no systematic reviews of the research on the 
relationship between HL and immunity in humans, nor do we know the magnitude of 
such a relationship. This could be, at least in part, due to the fact that laterality itself is 
difficult to define – with the term being mostly applied to cognitive attributes. The 
present review aims to synthesize the currently available research, assess its 
methodological quality and effect sizes, delineate study limitations, and interpret the 
findings with a view to future advancements in the research area and its clinical 
implications. 
Definition of Hemispheric Lateralisation in Neuroimmunology 
For the purposes of this review, the definition of HL for neuroimmunology should be 
separated from that used in cognitive neuroscience. The latter uses HL in the context 
of hemispheric specialisation, whereas the broader concept of hemispheric activation 
is the basis for this area of neuroimmune theory. It has been suggested that 
hemispheric activation can actually influence hemispheric specialisation (Davidson et 
al., 1999; Davidson & Hugdahl, 1996; Kang et al.¸1991), which means that focusing 
on the cognitive terms of specialisation alone may not reflect the true antecedents of 
the immunological influence. Moreover, activation can be independent of hemispheric 
specialisation (Davidson & Hugdahl, 1996). 
 
 64 
METHOD 
Literature Search 
A computer-based search was conducted for the present review from the following 
databases; OVID, CINAHL, EBSCOhost EJS, Ingenta Journals, NCBI PubMed, 
Science Direct, Highwire Press, Scopus, Springer Link, Taylor & Francis Journals 
and Wiley Interscience. The key search terms of “lateralisation” and “lateralization” 
were combined with the Boolean operator OR; in conjunction with AND for the 
secondary terms of “immune function”, “T cells”, “natural killer cells”, “immunity”, 
“cytokines”, “lymphocytes”. Another strategy of using as keywords “cerebral 
asymmetry”, “stroke”, “epilepsy”, “traumatic brain injury”, and “cerebral lesion” 
were combined with the Boolean operator OR, in conjunction with AND for the 
secondary terms listed previously. The time period selected was to encompass the 
years from 1982 (the year of the Geschwind & Behan study) to 2010. Only full text 
articles were identified for inclusion into the review. There were no systematic 
reviews or meta-analyses currently available on this topic in humans. All identified 
articles were scrutinized for other relevant articles in their reference lists.  
 
Selection Criteria 
Selection of studies was based upon their relevance to humans, and their relevance to 
relationships between lateralisation and aspects of immune functions, using either a 
cross-sectional or experimental design. Studies that did not primarily assess this 
relationship were also considered if their data examined this as a secondary analysis. 
This systematic review was limited to papers published in English or French. Studies 
that were excluded include those not employing functional or activational assessments 
of laterality (such as handedness), and those using clinical conditions that resulted in 
more complications than just lateralisation (e.g. cerebral palsy). Studies that did not 
employ direct immunological measures as an outcome measure (i.e. self-report health 
surveys) were excluded.  
 
Quality Assessment 
In the absence of a standardised checklist for such heterogeneous data, a quality 
assessment scale was developed from quality assessment frames such as can be found 
in Mols et al. (2005) and Borghouts et al. (1998). The quality of each of the articles 
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was assessed using a five-item checklist, with scores ranging from 0 to 18, with 
relevant predefined criteria (see figure 1). The categories viewed essential to ensuring 
a good standard of methodological quality (internal validity) concerned control over 
third variables and the statistical treatment. Those third variables that can affect the 
relationship between the brain and the immune system were demographic (e.g., age), 
psychological (e.g., chronic stress), physiological or neurological (e.g., inflammatory 
diseases), and an extensive list of these variables was established. Another essential 
criterion of quality assessment was the study conclusions: whether correctly derived 
from the study design and results. One investigator (RS) assessed all articles and 
another (YG) assessed five of the articles for inter-rater reliability. The quality criteria 
are presented in Figure four. 
 
Extracted information 
Summary of extracted details from the studies included: research team, year of 
publication, sample details, types of HL and immunological tests, research design and 
results. 
Effect Size Assessment 
Effect size calculations were undertaken only on the main tests of the relationship 
between HL and immune functions. These were calculated utilising the reported 
information relevant to the statistical tests used for each main relationship or effect 
studied. Mean effect sizes across study type (cross-sectional, semi-experimental) and 
across all studies were calculated to yield a single scale for comparison across studies. 
This procedure was again employed to assess across groups of activation and 
functional analysis.  
 
RESULTS 
Study Characteristics   
After all exclusion criteria were applied to the identified literature, 11 articles were 
eligible for inclusion in the present review. Eight studies used clinical samples (e.g. 
stroke, epilepsy patients) and three used healthy samples.  Eight of the studies used 
quasi-experimental or experimental methodologies; and three used cross-sectional or 
prospective methodology. A summary of the reviewed studies can be found in Table 
two. 
 66 
1) Design (scoring 0-2) 
0= cross-sectional 
1= quasi-experimental (e.g. using clinical groups as 
“experimental” conditions) 
2= experimental 
An additional point is offered if the results are compared 
between two or more groups 
2) Sample (scoring 0-2) 
0= small (<40) 
1= moderate (40-79) 
2= large (80+) 
3) Third Variables (scoring 0-5) 
0= none considered 
1= a total of 1 or 2 (from one or more groups) (see below) 
2= a total of 2-4 (from one group) 
3= a total of 2-4 (from two or more groups) 
4= a total of 4+ (from one group) 
5= a total of 4+ (from two or more groups) 
Groups: 
• Psychological – Anxiety/depression, current mood, 
life events, family, sexuality, employment status and 
type, IQ. 
• Physiological – Comorbid illness, medications, 
activity/lifestyle, prior dependence of drugs/alcohol, 
current use of nicotine and caffeine. 
• Neurological – ANS interactions, handedness, 
language lateralisation, previous TBI or 
neurological disorder.  
• Background – SES, age, education, gender. 
4) Statistics  (scoring 0-4) 
0= 0/4 suitability criteria 
1= 1/4 
2= 2/4 
3= 3/4 
4= 4/4 
Criteria: 
• Appropriate choice (parametric assumptions, 
degrees of freedom, prospective power analyses, 
bivariate vs multivariate, data transformations) 
• Control for third variables (baseline adjustments, 
missing data, sphericity adjustments etc.) 
• Setting of p value to .01 
• Post-hoc analyses (further stat testing, power 
analyses, mediating/moderating effects, prospective 
assessment for further testing if applicable) 
5) Conclusions (scoring 0-4) 
0= 0/4 suitability criteria 
1= 1/4 
2= 2/4 
3= 3/4 
4=4/4 
Criteria: 
• Conclusion validity 
• Limitations 
• Contextual evaluation 
• Indications for future research 
Figure 4. Quality assessment criteria for the review of studies examining hemispheric lateralisation and 
immunity 
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Table 2. Overview of studies on the relationship between hemispheric lateralisation and immune function 
 
Paper Sample Brain 
Measures 
Immune Measures Design Results Quality 
Score  
0-17 
Kang et al. 
1991 
20 (11 extreme stable right 
activation; 100% f, 17-20 
years) 
Right handed in top or 
bottom 25th percentile of 
activation asymmetry. 
EEG 
 
Also state-trait 
anxiety scale, 
BDI and 
Derogatis Stress  
Profile. 
 
 
(Activity) 
NK, lymphocyte 
proliferation (ConA, PHA, 
PW), T cell subset, plasma 
immunoglobulins and 
plasma cortisol. 
Also self-made 
questionnaire detailing 
frequency of common 
illnesses in preceding 2 and 
12 months, family history 
of autoimmune diseases. 
Cross-
sectional  
Lower levels of NKCA and IgM found in s’ with 
frontal right activation as opposed to left. – not 
extended to T cell subset profile or lymphocyte 
proliferative response to ConA or PW. 
Proliferation to PHA was in the same direction as 
NKCA.  
Magnitude of difference in NKCA across both L 
and R groups was similar to the magnitude of 
difference in NKCA in stressful events.  
Immune patterns not accounted for by health 
survey, plasma cortisol levels, anxiety or 
depression.   
9 
Tarkowski 
et al. 1995 
80 (51.25% f) stroke 
patients. 
Hachinski 
method of 
assessing minor, 
major or 
progressive 
stroke. 
Lateralisation of 
stroke assessed 
by physical 
exam and CT 
scan.  
 
(Activity) 
 
 
 
 
Tuberculin for skin 
reaction. Histamine 
injection for T-cell 
mediated immune response. 
Axon reflex vasodilation. 
Stimulation of PBMCs to 
PPD, PHA and ConA to 
yield production of IFN-γ. 
Quasi-
experiment
al 
Lateralisation of DTH response dependent on 
stroke clinical categorisation, motor function and 
side of lesion. 
Those with lesion on the right side had 
significantly larger DTH responses than those 
with left lesions which is independent of clinical 
categorisation of stroke.  
7 
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Paper Sample Brain 
Measures 
Immune Measures Design Results Quality 
Score  
0-17 
Gruzelier et 
al. 1996 
36 (27 with longitudinal 
assessments) asymptomatic 
HIV-1 infected patients, 
100% male, 11.1% non-
dextral.  
EEG, WRMT, 
controlled verbal 
fluency, 
semantic 
processing test, 
finger tapping, 
grooved peg-
board test, 
HADS, POMS. 
 
 
 
(Activity & 
Function) 
CD4 and CD8 taken at 
study onset and at 6 month 
intervals for 30 months.  
Cross-
sectional 
Superior left hemisphere functioning associated 
with higher CD4 count at baseline and through to 
study end.  
No relationship found between EEG activation 
asymmetry and CD4 count.  
Superior right functioning in WRMT indicated 
increased immune suppression (CD8).  
Higher POMS at onset predictive of poorer 
immune outcomes throughout study.  
7 
Tarkowski 
et al. 1998 
 
 
 
 
 
 
 
 
117 in total split into 3 
groups: 
1) 44 early stroke patients 
(47.8% f, 23-81yrs) 
2) 24 early stroke with retest 
(45.8% f, 23-76yrs) 
3) 49 chronic stroke (40.8% 
f, 23-88yrs). 
 
 
 
 
 
 
 
 
 
 
Hachinski 
method of 
assessing minor, 
major or 
progressive 
stroke. 
Lateralisation of 
stroke assessed 
by physical 
exam and CT 
scan. 
 
 
 
(Activity) 
 
 
 
Tuberculin for skin 
reaction. Histamine 
injection for T-cell 
mediated immune response. 
Axon reflex vasodilation. 
Stimulation of PBMCs to 
PPD, PHA and ConA to 
yield production of IFN-γ. 
Quasi-
experiment
al 
Replicated former findings that DTH responses 
stronger in patients with right localised ischemic 
trauma, but also that those with right side trauma 
showed significantly different effects with time. 
The later challenges created greater immune 
effects on the paretic side later in the post-stroke 
period compared to those in the earlier challenges. 
6 
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Paper Sample Brain 
Measures 
Immune Measures Design Results Quality 
Score  
0-17 
Davidson 
et al. 1999 
24 healthy s’, 37.5% female, 
17-21 years 
EEG 
Separately 
validated 
emotion eliciting 
film clips. 
 
 
(Activity) 
NKCA approximately 4 
weeks after EEG data 
taken. 
Experiment
al 
Superior anterior left sided activation predicted 
higher NKCA (mid-frontal, lateral frontal and 
anterior temporal regions). Differences in 
posterior activation unrelated to NKCA measures. 
Lateral prefrontal activation asymmetry accounted 
for 21% of the variance in NKCA at final exam 
time, even when accounted for by baseline 
measures.  
S’ with greater left frontal activation showed 
higher levels of NKCA after the positive film clip, 
this was exceeded by final exam effects which 
were three times greater.  
10 
Meador et 
al. 1999 
11 surgical epilepsy 
patients: 20-48 years; 18.1% 
f; 8 R handed with L 
language dominance, 1 
ambidextrous with L 
language dominance, 1 R 
handed with bilateral 
language representation 
(excluded from statistical 
analysis), 1 L handed with R 
language dominance (R 
temporal resection).   
5 right, 5 left temporal 
lobectomies, 1 left frontal 
lobe resection. 
 
Clinical 
diagnosis of 
epilepsy location 
and language 
lateralisation 
(language 
dominant 
resection = 
DOM; language 
non-dominant 
resection = 
NDOM).  
 
 
(Function) 
 
 
Complete Blood Count 
(CBC): 
Total White Blood Cells 
(WBCs) 
Total CD3+ 
CD3+4+ 
CD3+8+ 
CD8+ 
Total lymphocytes 
 
Blood taken the day before 
surgery and a mean of 6 
days after surgery. 
Quasi-
experiment
al 
No significant main effects found aside from an 
elevation in WBCs in pre- to postoperative states 
across all patients. Interactions for DOM and 
NDOM groups for pre-/postop states were found 
for absolute lymphocyte, CD3+4+, CD3+8+, and 
total CD8+. Follow-up contrast t tests performed 
showed significant results for increase in WBCs 
and decline in CD8+ for the DOM group. The 
NDOM group showed significant increase in 
CD3+4+. All other t tests for the DOM group were 
non-significant, but were in the trend of the non-
significant main effects; absolute lymphocyte 
decline, CD3+4+ decline, CD3+8+ decline, and 
total CD8+ decline. The pre- and postoperative 
changes were in opposite directions for NDOM 
(increase) and DOM (decline) groups, aside for 
WBCs which were universal increase.   
 
 
 
8 
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Paper Sample Brain 
Measures 
Immune Measures Design Results Quality 
Score  
0-17 
Ivashkova 
et al. 2002 
Clinical group – 38 subacute 
stage stroke patients 
receiving TMS, 44-64yrs, 
52.6% right hemisphere 
location. 
Control group – 30 healthy  
Reference group – 35 
subacute stage stroke 
patients not receiving TMS, 
54.3% right hemisphere. 
None mentioned 
aside from stroke 
assessment.  
 
 
 
 
(Activity) 
CD3+, CD4+, CD8+ and 
CD22+ 
BTR of human leukocytes 
(ConA, PHA, PW) 
Lymphocyte suppressor 
activity 
Phagocytic activity of 
neutrophils (NTR) 
Leukocyte adhesion 
suppression. 
Quasi-
experiment
al 
The type and degree of immune alterations was 
dependent on the lateral location of the lesion.  
Right hemispheric stroke resulted in CD3+ and 
CD8+ decrease, and CD4+/CD8+ ratio increase and 
disturbances in lymphocyte proliferation activity 
compared to healthy controls. 
Left hemispheric stroke resulted in CD3+, 
CD4+ and CD8+ decrease as well as 
disturbances to lymphocyte proliferative 
activity in comparison to healthy controls. 
TMS of sensory and motor regions of the 
cortex of right hemispheric stroke patients 
caused normalisation of immune values. 
Change less pronounced after TMS for 
left hemispheric patients.  
8 
Clow et al. 
2003 
16 healthy participants, 
37.5% f. 
Two males and one female 
studied twice. 
TMS to both 
hemispheres 
separately.  
 
(Activity) 
Salivary S-IgA and salivary 
volume.  
Experiment
al 
TMS to the left hemisphere causes upregulation of 
S-IgA. TMS to the right causes reduction in saliva 
volume. S-IgA rises after TMS on both sides but 
with salivary volume falling there is a significant 
increase after left TMS rather than right. 
8 
Dziedzic et 
al. 2003 
Reference Group – 26 right 
handed stroke patients; 11 
right lesion (45.5% f; mean 
age 63.7); 15 left lesion 
(46.7% f; mean age 60.6). 
Control group – 16 healthy 
s’ (43.8% f, mean age 62.3). 
Stroke location 
and size 
determined by 
CT scans. 
 
(Activity) 
Serum IL-10 and IL-6. Cross-
sectional 
Both left and right stroke patients had 
significantly higher levels of IL-10 and IL-6 than 
healthy controls.  
IL-10 was higher in left stroke patients and there 
was no difference in IL-6 in either patient group.  
 
 
 
 
 
9 
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Paper Sample Brain 
Measures 
Immune Measures Design Results Quality 
Score  
0-17 
Meador et 
al. 2004 
22 surgical epilepsy 
patients; 19-61 years, 45.5% 
f, 81.8% left language 
dominant (others mixed), 
half right resection half left. 
Healthy controls.  
Intracarotid 
amobarbital test 
for language 
dominance. 
 
POMS and daily 
stress inventory 
taken. 
 
 
 
(Activity) 
CBC 
Lymphocyte subset 
analyses 
Mitogen and microbial 
responses 
Histamine skin testing 
Cortisol 
Quasi-
experiment
al 
Lymphocytes, total T cells, cytotoxic T cells and 
T helper cells decreased with left and increased 
with right resections; these effects were unaltered 
when mood and cortisol accounted for. No 
differences in mitogen and microbial responses. 
Greater right arm histamine wheal responses 
found in left-brain dysfunction as compared to 
right and control. Histamine flare responses 
decreased after left resection and increased in 
right resection patients as compared to right sided 
patients and controls.The four patients with 
atypical language lateralisation had left lesions 
and surgery, cellular and skin responses differed 
from left resection patients with normal language 
lateralisation.  
 
7 
Koch et al. 
2006 
 
 
 
 
 
56 acute stroke patients (11 
TIA, 17 Lacunar, 20 
atherothrombotic, 8 cardio-
embolic). 
Mean age 58.9, 46.4% 
female, 31 left localisation 
of stroke, 25 right 
localisation. 
MRI/CT for 
localisation of 
stroke trauma. 
 
 
(Activity) 
C-Reactive Protein (CRP) 
and WBC (retrospective 
collection from medical 
notes) 
Quasi-
experiment
al 
Left hemispheric stroke resulted in increased 
variability in CRP and WBC, and higher absolute 
values of CRP and WBC. 
Correlation between CRP and WBC only 
observable in left-sided stroke patients.  
8 
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Quality Assessment 
To assess inter-rater reliability of quality assessment, scores were correlated using 
simple bivariate correlation with SPSS. The correlation between the two evaluators 
for the quality assessment of the five articles dually rated was 0.98. The quality 
assessment figures are presented in Table two. The mean quality assessment mark 
was under 50% (7.909, SD= 1.136) of the total possible score, 17. The general low 
level of methodological quality of the studies was mainly due to their lack of control 
over third variables, limited sample sizes and questionable inferential validity.  
 
Effect Sizes 
Effect sizes (r) were calculated for the main effects of nine of the reviewed studies for 
which relevant data were available for these calculations. A mean effect size for the 
HL-immunity relationship was calculated per study, across its various tests. The effect 
sizes were interpreted using Cohen’s (1988) criteria for small (r > 0.1), medium (r > 
0.3) and large (r > 0.5) effects. Using these criteria, five of the nine studies (67%) had 
large mean effect sizes for their main effects; two showed a medium effect size; and 
two a small effect (Table 2). The mean effect size (r) of the HL-immunity relationship 
for the main effects of the assessed studies was 0.532, which is designated as a large 
effect size. Of the three cross-sectional studies reviewed, two provided sufficient data 
to process effect size analyses; the mean effect size for these two studies was 0.533. 
Of the eight remaining studies that employed either experimental or quasi-
experimental designs, seven provided sufficient numerical data to conduct effect size 
calculations. The mean effect size for this group of studies was 0.537. This effect size 
refers to the overall differential effect of lateralisation on immunity. A summary of 
the effect sizes obtained for the assessed studies can be found in Table three.  
Each study was also classified as to whether HL was measured according to activity 
or function. Studies including patients after stroke or epilepsy, using EEG or brain 
stimulation, were classified into the activity HL group. Studies using 
neuropsychological tests or linguistic dominance were classified into the functional 
HL group. It is important to note that this classification is not perfect since lesions due 
to stroke or epilepsy could be construed as both reflecting changes in activity and 
function. Nevertheless, we related them to the activity group since changes following 
stroke, for example, are marked first by reductions in neuronal activity (Jiang et al., 
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2010). We then classified studies into activity versus functional measures of HL, since 
the studies utilized either or both types. Functional measures (2 studies alone) yielded 
an effect size of 0.63 while activity measures (8 studies) yielded an effect size of 
0.515. 
 
Quasi-Experimental and Experimental Data 
The studies in this group involved either direct manipulation of variables (Davidson et 
al., 1999; Clow et al., 2003) or used patient groups that demonstrated atypical 
lateralisation (Koch et al., 2006; Ivashkova et al., 2002; Meador et al., 1999; 2004; 
Tarkowski, et al., 1995; 1998). The articles are presented chronologically, according 
to the year of publication. 
  
Tarkowski et al., 1995 
Using patients of minor, major and progressive stroke, Tarkowski et al. (1995) 
assessed tuberculin skin reaction, histamine initiated T-cell response, and pokeweed 
(PW), phytohemagglutanin (PHA) and Concanavalin-A (Con-A) initiated lymphocyte 
distribution in those with left or right localised brain trauma. Lateralisation of skin 
response was relative to the clinical categorisation of the stroke, residual motor 
function and the lateral localisation of the lesion. Patients with left localised lesions 
(n=24) displayed smaller delayed type hypersensitivity (DTH) responses than those 
with right lesions (n=26), but those with right-sided lesions also demonstrated 
lateralised peripheral reactions (i.e. greater responses on ipsilateral side than 
contralateral side). The ability to find a HL-immune relationship in such a 
heterogeneous sample, compared to the more homogenous samples described below, 
supports the generalised effect of HL on immune function in humans. However, very 
little control over third variables was undertaken (e.g., age, hypertension, 
medications), which is particularly important in patients with cerebral ischemia. 
Stroke may be indicative of other illnesses that may affect the communication 
between the brain and immune system, and such illnesses could in themselves be 
indicative of atypical brain to immune communication (e.g. hypertension, diabetes), 
possibly affecting vagal immune-modulation. No control over psychological or 
cognitive variables relevant to stroke, that may be related with either HL or immune 
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function (e.g., executive functions, depression), was conducted either, limiting the 
inferential validity of the findings. It should also be noted that allergic responses in 
the skin can also be influenced by handedness (Bryden et al., 2005); which could have 
implications for the interpretation of the present findings.  
Classification: Activity 
 
Tarkowski  et al., 1998 
In a follow-up study, Tarkowski et al. (1995) employed the same methodology, but 
divided the clinical sample of stroke patients into three groups: early stroke, early 
stroke with retest of parameters in the subacute phase, and chronic stroke. This study 
replicated the former findings, but also showed that the early stroke group with 
localised right trauma exhibited larger DTH responses to immune challenges. This 
was observed in both the paretic and contralateral sides in comparison to those with 
left stroke. In the chronic phase of stroke, those with right localised ischemia showed 
a greater response than those with left stroke at the ipsilateral side. This study also 
considered a substantial number of third variables, although there were no controls for 
levels of depression, anxiety or general mood, which are related to immune function 
(Kemeny & Schedlowski, 2007), and are clinically relevant in such patient samples.  
Classification: Activity 
 
Davidson et al. 1999 
In a sample of healthy students Davidson et al. (1999) used emotionally evocative 
film clips to manipulate natural killer cell activity (NKCA) in left and right lateralised 
participants, as determined by electroencephalography (EEG). NKCA was assessed at 
an anxiety-neutral time (mid-semester) and at a high anxiety time (exam period). 
Participants with left frontal-anterior-temporal lateralization had greater NKCA in 
response to the positive film clips at both times than those with right lateralization. 
This study thoroughly considered third variables including handedness, caffeine, 
nicotine and alcohol consumption. However, there was no control for the use of 
prescription medications, or other illnesses, that may interfere with natural brain or 
immune system functioning, and this study had a relatively small sample size (n= 24) 
in comparison to the mean of all studies (n= 47.1). Nevertheless, using a naturalistic 
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stressor (exam stress) and finding higher NKCA in left-HL participants in two 
contexts suggests that this relationship may be generalisable to various contexts.  
Classification: Activity 
 
Meador et al., 1999 
Including patients waiting for epilepsy resection surgery, Meador et al. (1999) 
examined the differences in those receiving surgery at language dominant (DOM, left) 
and non-dominant (NDOM, right) hemispheres, in relation to several immunological 
outcomes. Resection surgery is employed with intractable epilepsy, whereby an area 
of the affected lobe is excised in order to diminish the epileptogenic activity. 
Increases in white blood cells (WBC) and decreases in CD8 post-surgery for the 
DOM group, and increases in CD4 post-surgery for the NDOM group were observed. 
Overall, aside from total WBC counts, the immune parameters decreased post-surgery 
for the DOM group and increased for the NDOM group, although many of the 
findings did not attain statistical significance. Of the main effects, only the total pre-
operative versus post-operative group analysis of WBC attained significance, the 
DOM versus NDOM main effect did not reach significance. A number of post-hoc 
tests were employed, although it is not clear whether statistical adjustments were 
made for these multiple comparisons. However, the overall observed trend was in line 
with right hemisphere functioning being indicative of poorer immune functions. The 
sample size for this study was relatively small (N=11), and it was heterogeneous due 
to its clinical nature. There was relatively little third variable control (e.g., comorbid 
illnesses). Whilst the use of the DOM/NDOM classification is useful to partly 
understand the HL of the patients; looking at resections in these categories as opposed 
to absolute left/right hemispheres, is conceptually problematic as it defines laterality 
in relation to function or specialisation, rather than to activity and side. It is known for 
example that not all individuals have a left side language dominance. 
Classification: function & activity 
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Table 3. Table of effect sizes for the main effects of the reviewed research concerning hemispheric lateralisation and immune function 
 
 
Paper Effect Effect Size  
(r) 
Mean r for 
the Study 
Natural Killer Cell Activity (NKCA) – Left vs Right – overall 0.678  
Lytic Units at 30% 0.559  
Kang et al., 1991 
IgM – Left vs Right 0.527 0.588 
Tarkowski et al., 1995 Lateralisation of stroke-induced lesion & DTH – Left vs Right 0.280 0.280 
Word fluency (Left) and CD4 0.610  
Semantic processing errors (Left) and CD4 0.480  
Finger tapping asymmetry (dominant hand) and CD4 0.540  
Gruzelier et al., 1996 
Memory for faces (Right) and CD8 0.530 0.540 
Early stroke & DTH – Left vs Right 0.862  Tarkowski et al., 1998 
Right subcortical lesions & DTH – Paretic vs Contralateral 0.675 0.769 
Baseline frontal asymmetry & baseline NKCA (11:1 ratio) 0.460  
Baseline frontal asymmetry & baseline NKCA (33:1 ratio) 0.510  
Baseline lateral frontal activation & baseline NKCA (11:1 ratio) 0.410  
Baseline anterior temporal activation & baseline NKCA (11:1 ratio) 0.480  
Davidson et al., 1999 
Baseline anterior asymmetry & NK reactivity to emotional film clips 0.440 0.460 
DOM vs NDOM group – Pre- to Post-op – Absolute Lymphocytes 0.647  
DOM vs NDOM group – Pre- to Post-op – Total CD3+ 0.675  
DOM vs NDOM group – Pre- to Post-op – CD3+CD4+ 0.666  
DOM vs NDOM group – Pre- to Post-op – CD3+CD8+ 0.675  
Meador et al., 1999 
DOM vs NDOM group – Pre- to Post-op – CD8+ 
 
 
0.678 0.669 
Right vs Left hemispheric stroke pre-TMS – cellular immunity (mean value) 0.794  Ivashkova et al., 2002* 
Right vs Left hemispheric stroke pre-TMS – neutrophil activity (mean value) 0.938 0.866 
Clow et al., 2003  Not Available  
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Dziedzic et al., 2003  Not Available  
Lymphocytes – Left vs Right across Pre/Post operative 0.535  
Total T cells – Left vs Right across Pre/Post operative 0.587  
Helper T cells – Left vs Right across Pre/Post operative 0.587  
Meador et al., 2004 
CD3+8+ – Left vs Right across Pre/Post operative 0.494 0.551 
C-Reactive Protein level – Left vs Right 0.125  Koch et al., 2006 
White Blood Cell level – Left vs Right 0.196 0.161 
 
 
Effect Size (r) designations (Cohen, 1988) 
Small = 0.1 
Medium = 0.3 
Large = 0.5 
 
* This study involved multiple interactions between 11 immune parameters (5 cellular immunity, 6 neutrophil activity) and four interactions 
(Left vs Right; Pre TMS vs Post TMS; Control vs Left and Right – Pre TMS; Right Pre & Post vs Left Pre & Post). To avoid reporting all 77 
calculated effect sizes, the mean effect size of all of those in that section (T cell or lymphocyte proliferation) was used to illustrate the main 
lateralisation finding of the study.
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Ivashkova  et al., 2002 
Ivashkova et al. (2002) used three groups of participants; a group of subacute stage 
stroke patients who received transcranial-electromagnetic stimulation (TeMS) 
therapy; a reference group of subacute staged stroke patients who did not receive 
TeMS, and a control group of healthy participants also receiving TeMS. A variety of 
immunological parameters were assessed, along with lymphocyte proliferation to 
Con-A, PW and PHA before and after TeMS, and proliferation changes were 
compared to the values observed in the control and reference groups. Right 
hemispheric stroke was shown to be related to T-cell deficit and disruption of 
lymphocyte proliferation, whereas left hemispheric stroke was associated with 
decrease in lymphocyte proliferation only. TeMS resulted in the normalisation of 
immune values in the group of clinical subjects with right localised lesions. The main 
finding of the study was that lateral localisation of the lesion was directly involved in 
the type and degree of observed immune alteration. The main limitation of this study 
is the disparity between study groups, making comparison between these groups more 
circumspect. The control group (N=30) was compared against two clinical groups 
(total N=73); and the TeMS and non-TeMS groups were equally disproportionate (N= 
68, 35 respectively).  Methodologically, the study is also limited by the use of 
multiple statistical tests, risking a type 1 error, without employing an appropriate 
correction. They report performing an extremely large number of t-tests (77), and if 
the standard Bonferoni correction for multiple comparisons, dividing the p critical 
value (0.05) by the number of t-tests (77), were applied it is unlikely that many (if 
any) of the results would survive. However, the use of a control group and a reference 
group was a methodological strength. Finally, the duration, frequency and precise 
location of the TeMS were not reported, which may impact the inferential validity of 
the findings as these factors affect immunity (Davidson et al., 1999). Analysis of 
confounder control either methodologically or statistically is difficult to infer, as there 
were no exclusion criteria or extraneous variable controls mentioned.  
Classification: Activity 
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Clow et al. 2003 
Healthy participants were selected for this study, which involved using repetitive 
transcranial magnetic stimulation (rTMS) to both hemispheres (on separate occasions) 
over the temporo-parieto-occipital (TPO) cortex, and assessing salivary 
Immunoglobulin A (S-IgA) changes before and after stimulation. The authors 
reported that initially rTMS to either hemisphere resulted in an increase in levels of S-
IgA. However after accounting for saliva volume, revealing the concentration of S-
IgA, the results were further elucidated: left hemispheric rTMS resulted in an increase 
in S-IgA whereas right resulted in decreases in S-IgA. Nonetheless, with a sample 
size of just 16 participants, with 3 participants being tested twice meant this 
preliminary study was relatively small in comparison to the rest under review. 
Furthermore, it is unclear as to how the data from those participants who were 
retested was dealt with, which makes validity difficult to assess. The only inclusion 
criteria mentioned were that the participants were healthy and right handed, with no 
mention of exclusion factors or control for third variables. Finally, there was also no 
“sham” rTMS condition, which could affect the results (Toschi et al., 2009), and the 
inferences concerning the effects of rTMS and HL on immunity.  
Classification: Activity 
 
Meador et al., 2004 
This research group again used surgical epilepsy patients to examine post-surgical 
changes in immune parameters. This study also used analyses of the same variables in 
a healthy control sample to control for variability in these measures. Using 
lymphocyte counts, responses to mitogen and microbes, and histamine skin testing, 
they also examined the effects of mood (Profile of Mood States; POMS) in the 
relationship between hemispheric surgery location and immune alteration. Left 
resection patients showed decreases in total lymphocytes, T cells, CD8 and CD4 after 
resection surgery, while the opposite was observed for the right resection patients. 
These effects remained stable when POMS was included in the statistical testing, 
suggesting that mood is not a moderator in the relationship. Histamine skin responses 
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showed that left resectioned patients displayed greater right arm wheal responses 
compared to the right resection patients and control group. Flare responses were 
reported to decrease after left resection, and increase after right resection. In 
comparison to the previous Meador et al. (1999) study, this research included twice as 
many participants (n=22), but is still below the mean for all of the studies reviewed. 
The change in methodology from examining differences between DOM and NDOM 
groups, to differences between left and right resection groups makes the findings 
more directly relevant to HL and more coherent. The use of cellular proliferation tests 
and histamine reaction in a control group to account for non-systematic variability in 
the clinical group, and the examination of psychological variables (mood) 
demonstrates carefully considered confounders and processes, although no exclusion 
criteria were detailed. The finding of left resection leading to both reduced cellular 
(Th1) immunity (decreased T-lymphocytes) and increased allergic responses (greater 
histamine reaction) is indicative of the left hemisphere being implicated in the 
modulation of immunity and possibly in certain immune-related illnesses. This 
association, however, may well be a conflicting one, as Th1 immunity involves the 
expression of pro-inflammatory cytokines, which would be decreased in this sub-
sample, but allergy requires an increase in Th1 immunological response (Webster et 
al., 2002). Further research is required to expand upon the different immunological 
consequences of left HL. Nevertheless, concerning only the lymphocyte data, these 
results are in line with a differential (and inverse) immunological function of HL.  
Classification: Activity 
 
Koch et al., 2006 
In the more recent of the reviewed studies, Koch et al. (2006) also used stroke 
patients to examine the effects of stroke lateralisation (as verified by magnetic 
resonance imaging or CT) on C-reactive protein (CRP) and WBC. The authors 
reported that left hemispheric stroke resulted in an increased variability in both CRP 
and WBC, and that correlations between these two parameters were only observable 
in the left-localised stroke patients, interpreted by the investigators as suggesting a 
deficit in immune control after left-sided ischemia. This study limited its examination 
to the immune parameters of WBC and CRP, which limits the comparison to similar 
 81 
studies under review here (e.g. Meador et al., 2004) due to the non-specificity of such 
markers. Furthermore, the immune measures were only conducted in the first 24 hours 
since stroke onset. Stroke in general, regardless of laterality, has been suggested to 
cause alterations to lymphocytes, granulocytes and leukocytes, particularly within the 
first 24 hours of onset (Miller et al., 1991; Vogelgesang et al., 2008), which would 
necessitate testing HL-immune relationships at periods beyond this phase, as these 
changes could be partly stroke-related rather than laterality-related. This is in stark 
contrast to the methods employed by the Tarkowski work groups (Tarkowski et al., 
1995; 1998); who assessed immune alterations longitudinally across the course of 
stroke clinical staging. In addition, no theoretical rationale for examining the 
relationship between CRP and WBC was provided. Does a greater variability in these 
two immune measures exist among left-hemisphere people, or does the left 
hemisphere in general regulate one or both parameters, possibly influencing the other 
one? Finally, what does lack of a correlation between CRP and WBC mean 
biologically? Thus, beyond methodological limitations, the interpretation and 
meaning of the observed results remain problematic. 
Classification: Activity 
 
Cross-Sectional or Prospective Data 
Three studies involved using healthy (Kang et al., 1991) and clinical (Dziedzic et al., 
2003; Gruzelier et al., 1996) participants; and they are presented in chronological 
order. 
 
Kang et al., 1991 
Using EEG measures, the researchers selected a group of healthy participants who 
displayed “extreme stable activation”; designated as those in the upper and lower 
quartile of prefrontal activation asymmetry. The researchers examined NKCA, 
lymphocyte proliferation (to Con-A, PHA and PW) and other immune parameters, 
whilst also obtaining self-report data concerning frequency of common illnesses in the 
past 12 months and family history of autoimmune diseases, as well as administering 
some psychometric scales (anxiety, depression and stress). They reported that higher 
right frontal activation (as opposed to higher left) resulted in lower levels of NKCA 
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and Immunoglobulin-M, as well as lower lymphocyte proliferation in response to 
PHA. The immune effects observed could not be accounted for by the health survey, 
plasma cortisol levels or the psychometric scales. The use of subjective self-report 
data concerning health may raise questions concerning validity of immune related 
illnesses. Nevertheless, the methodology was thorough including details about viral, 
fungal and respiratory infections as well as allergies and dermatological status. 
Control for confounding variables, the selection of participants in the top and bottom 
quartile for HL, taking details of drug use, including right-handed participants only, 
and conducting the immunological assessments at an anxiety-neutral time, are all 
evidence of relatively strict methodology. However, the small sample of female 
participants alone also has an impact on the generalisability of the findings, and 
leaving immunological assessment possibly subject to hormonal influences which 
were not fully tested or controlled for (Butts & Sternberg, 2008; Kovats & Carreras, 
2008; Taub, 2008). The observed lack of cortisol effects could mean that HL-
immunity relationships are dependent on other neuro-endocerine-immune pathways, 
unrelated to the HPA axis or only unrelated to cortisol. We shall discus this important 
issue below. 
Classification: Activity 
 
Gruzelier et al., 1996 
This study included asymptomatic HIV+ patients, and measured their immune 
outcomes (CD4, CD8) at a follow-up of 36 months in relation to baseline EEG 
recordings of cerebral laterality and performance on neuropsychological tests 
assessing right/left brain functions. The experimenters found that greater left 
hemisphere functioning predicted higher CD4 both at baseline and at follow-up, and 
that greater right functioning predicted greater immune suppression (CD8). The 
sample for this study was small (N=27) and was restricted to men of bisexual or 
homosexual orientation.  Today, the largest proportion of HIV transmission across the 
world occurs in heterosexual activity (Grant & De Cock, 2001; Hansasuta & 
Rowland-Jones, 2001). The pathogenesis of HIV may depend on biological 
parameters and socioculturally influenced health behaviours of individuals (i.e., 
comorbid illness, clinic attendance, heavy drug or alcohol use) which was not and 
cannot be accounted for in such a restricted sample, nor generalised to a wider 
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population (Derdeyn & Silvestri, 2005; Lama & Planelles, 2007; Gifford et al., 2002). 
Most importantly, the investigators did not statistically control for effects of baseline 
immune parameters and other confounders (e.g., education, mode of infection, other 
illnesses, medications) that may affect the autonomic, nerve or immune systems (Cole 
et al., 2003). All these limitations question the validity of their inferences. 
Nevertheless, reviewed here, the Gruzelier et al. (1996) study shows a prospective 
relationship between two different measures of HL, function and activity, with 
immunity in the context of an immune-related illness. However, to ensure these 
findings are valid, future studies must replicate it and address its many limitations. 
Classification – Activity & Function 
 
Dziedzic et al., 2003 
This study used stroke patients to examine the relationship between stroke location 
and interleukin (IL)-10, and IL-6. Stroke location and size were assessed using CT 
scans. An age- and gender-matched control group was used to compare general 
immunological parameters, but were not assessed for any form of lateralisation and so 
were not included in the analysis of the main effect. The stroke patients showed 
higher IL-10 and IL-6 levels than the control group. Within the stroke patient group, 
those with left localised stroke showed higher levels of IL-10, but there was no 
difference in IL-6. This study exhibited a good level of confounder control, with 
psychological, physiological and neurological factors all being considered, as well as 
including a healthy control group. However, as with Koch et al. (2006), the immune 
measures were taken at around 24 hours after hospital admission, which makes the 
reliability of the finding of abnormal IL-10 questionable, as this may not be due to 
laterality per se, but possibly also due to the stroke itself. Whilst IL-6 and IL-10 
reflect Th1 and Th2 immunity, respectively, a wider panel of immunological 
assessment including cytokines which clearly reflect cellular immunity activity (e.g., 
Interferon-gamma) would have been useful. Nevertheless, this is one of the only 
studies examining the relation between HL and cytokines, and results suggest that left 
HL is related to lower anti-inflammatory activity (IL-10). More studies need to 
replicate and extend this important issue. 
Classification - Activity 
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DISCUSSION 
General conclusions 
This systematic review summarises the results of 11 research articles investigating the 
relationship between hemispheric lateralisation (HL) and immune function. All of the 
reviewed studies show a relationship between HL and immune function. Three of the 
11 (27.3%) studies describe a relationship between poorer left versus right hemisphere 
function and decreased immunity in at least one immune parameter (Dziedzic et al., 
2003; Kang et al., 1991; Koch et al., 2006). Three of the 11 (27.3%) studies describe 
a relationship between poorer right versus left hemisphere function and increased 
immunity in at least one parameter (Davidson et al., 1999; Tarkowski et al., 1995, 
1998), in line with the finding of the first three studies. Five of the 11 (45.4%) studies 
describe both relationships of HL and immunity (Clow et al., 2003; Gruzelier et al., 
1996; Ivashkova et al., 2002; Meador et al., 1999, 2004). Despite the disparity in 
methodologies and outcome variables, this suggests a trend that HL, as a 
neuropsychological phenomenon, plays a key role in the functioning of the immune 
system in both health and sickness. However, the critical methodological limitations 
of this set of studies necessitates caution; and it is immediately apparent that research 
in to this relationship should be conducted with more control for confounding 
variables before any resolute conclusions can be ascertained. Importantly, the findings 
reviewed here suggest one direction; namely that the left hemisphere is 
immunopotentiating, the right is immunosuppressing. Although the mechanisms of 
this directionality cannot be ascertained by current knowledge; one possibility is by 
means of interhemispheric inhibition (IHI). IHI is thought to mainly take place via the 
corpus callosum (Geffen et al., 1994; Sullivan, 2004), and could explain the changes 
in immunoregulation following cerebral trauma such as stroke or surgery. 
 
The mean effect size (r=0.536) for the HL-immune relationship determined on the 
basis of the studies included here was large. Two of the nine studies studies reported 
mean effects in the upper quartile (r>0.65) (Ivashkova et al., 2002; Tarkowski et al., 
1998). These studies were both from the quasi-experimental/experimental category, 
which provides some encouragement for this relationship in the context of the many 
methodological flaws of this study set. The mean effect size (r=0.503) for those 
 85 
studies that described a relationship between poorer right versus left functioning and 
increased immunity (Davidson et al., 1999; Tarkowski  et al., 1995; 1998) was higher 
than the mean effect size (r=0.374) for the studies observing the opposite relationship 
(Dziedzic et al., 2003; Kang et al., 1991; Koch  et al., 2006). We then classified 
studies into activity versus functional measures of HL. Functional measures (2 studies 
alone) yielded an effect size of 0.63 while activity measures (8 studies) yielded an 
effect size of 0.515. The studies in the present review do show a high proportion of 
“large” effect sizes. However, attempting to compare studies that have such different 
independent and dependent variables, methods of data collection, methodological 
design and samples, can often cloud the main findings due to their disparities – and so 
these must be viewed with caution. Thus, we chose to focus on overall effect sizes, 
which can provide a standardised means of elucidating combined findings, by 
providing a combined perspective of the data. The fact that 55% of the effect sizes 
showed “large” effect sizes in the same direction is perhaps the most promising 
finding of the combined results, however it should be noted that many of the studies 
had small sample sizes – a factor which is known to increase effect size (Givens et al., 
1997). This indicates that despite the differences in methodology, the relationship 
between left-HL and enhanced immunity can be observed even under less than ideal 
conditions. 
 
Concerning quality assessment, there were three studies that received observed scores 
in the upper quartile (6-10) (Davidson et al., 1999; Dziedzic et al., 2003; Kang et al., 
1991). These studies are of both cross-sectional and experimental design. The 
common factor amongst these studies is control for third variables from at least two of 
the designated criteria. All three of these more methodologically rigorous studies 
supported the conclusion that left-HL is related to immune potentiation. The mean 
quality assessment score (7.9) of all studies was under 50% of the possible score, 
which suggests that methodology in this subject area is in need of improvement. The 
main areas that need improvement are control over third variables and inferential 
validity. More control is required to ensure that the HL-immune relation does not 
result from variables involving health behaviour (e.g., smoking), gender or co-
morbidities known to affect the immune or CNS systems (e.g., arthritis, infections, 
early dementia). Attention should also be paid to the immunological outcome 
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measures, and the reasons for choosing them. With regard to the conclusions, the 
main areas of improvement are the contextual evaluation - where each study fits 
amongst the current literature, and future theoretical and clinical implications.  
 
Possible mechanisms underlying the HL-immune relationships 
Cortisol does not appear to mediate or moderate the association between HL and 
immunity (Kang et al., 1991; Meador et al., 2004). This could mean that the HPA-
axis, at least as indexed by cortisol, does not play a role in the HL-immune 
relationship. There are also established relationships between HL and the stress 
response, with the right prefrontal cortex being associated with the modulation of the 
stress response (Cerqueira et al., 2008; Lewis et al., 2007; Sullivan, 2004). An 
alternative mechanism to explain the HL-immunity relationship may involve the 
sympathetic nervous system (SNS) since provision of beta-blockers reduced the HL-
immune relationship in rats (Moshel et al., 2005). There are also suggestions that 
there is hemispheric specialisation in autonomic control of the heart in humans, with 
the right hemisphere exerting sympathetic control and the left parasympathetic 
(Wittling et al., 1998). Future studies are needed to replicate and extend these 
findings, and must test the functional and health implications of such mediation.  
 
Clinical implications 
The study by Gruzelier et al. (1996), though with several limitations, shows that HL 
may be related to immunity in HIV. A more recent study found that right-HL 
predicted symptoms of upper respiratory tract infections, independent of multiple 
confounders (e.g., age, sex, IQ; Gidron et al., 2010). Both studies demonstrate that the 
HL-immune relationship has implications for immune-related diseases. This requires 
further research concerning both prediction of disease risk, prognosis and possible 
prevention using brain stimulation of the left-PFC for diseases originating from 
immune-suppression. The extent to which such illnesses may be prevented or 
ameliorated by left-PFC stimulation has important implications to understanding 
neuroimmunomodulation of diseases and to opening new therapeutic approaches that 
need to be tested. The study by Clow et al. (2003) using rTMS may be one promising 
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method for further investigation in relation to disease prevention. Yet, more sound 
research is needed to solidify the scientific ground for such interventions. 
Some research has uncovered an asymmetry in both peripheral immunity and in 
diseases. An asymmetry in peripheral cell-mediated immune diseases has been 
observed in a left-sided greater prevalence of herpes zoster presentation (Dane, 2009), 
as well as a greater left-sided reaction to bilateral tuberculin skin tests (Dane et al. 
2001). This peripheral cell-mediated asymmetry has also served as an explanation to 
findings of overall greater right-sided metastases in some gynaecological cancers 
(Borecki et al., 2007), as well as a higher prevalence of right-sided metastases in 
malignancies originating on both sides of the body (Borecki et al., 2007). It has been 
suggested that excessive left side immune reactions may be responsible for 
controlling left sided metastases, therefore increasing the prevalence of right side 
spread (Borecki et al., 2007; Dane et al., 2008). However, inconsistencies have been 
found as well when investigating paired organs. In a study that included over a quarter 
of a million cancer patients, Roychoudhuri et al. (2006) found lung and testicular 
cancer to have a right-sided prevalence, whereas breast cancer was suggested to be 
more common on the left (Roychoudhuri et al., 2006). There was very little difference 
observed bilaterally in kidney and ovarian cancer incidence, however five year 
survival was shown to be higher in women with left-sided ovarian cancer than those 
with right-sided tumours (Roychoudhuri et al., 2006). The discrepancy of the overall 
trend represented by breast cancer was theorized to be due to behavioural and 
diagnostic reasons, insomuch as the right-handed majority may be more aware of 
changes in the ipsilateral breast, or that right handedness may cause more movement 
in the breast, or preference in breast feeding, and therefore affect cancer risk 
(Roychoudhuri et al., 2006). The extent to which peripheral immune laterality, 
whether related to cerebral HL or not, is responsible for such laterality in disease risk, 
needs further investigation.  
 
Summary & Conclusions 
This review outlines 11 studies concerning the relationship between HL and immune 
function. To the best of our knowledge, it is the first of its kind. It is predominantly 
apparent that more research is required in this area to further elucidate findings, and 
uncover more aspects of this relationship. Further investigation into the specific areas 
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of the brain, as well as lateralisation effects (nature, duration, development, etc.), and 
their underlying mechanisms, is also clearly needed. The role of the SNS as well as 
neurotransmitters (e.g., acetylcholine, dopamine) in the HL-immunity relationship 
needs to be examined. The present literature also brings about interesting questions 
for neuroimmunology. For example, given the suggested differential 
immunomodulation by left versus right HL, could lateralisation predict the onset or 
prognosis of immune-related illness? The evidence from Gruzelier et al. (1996) and 
Gidron et al. (2010) indicate this may be possible. If such a relationship were 
discernable, then it would be reasonable to suggest that health may be improved by 
intervening in an unfavourable lateral balance, such as via rTMS (Clow et al., 2003). 
Furthermore, it is possible that neuropsychological interventions could be devised and 
tested, to see whether they prevent or ameliorate the effects of chronic immune-
related illnesses, as well as maintain good health in those unaffected by disease, 
particularly in people with poor left-HL. In a diagnostic setting, these findings could 
prove pertinent. Many chronic and life-limiting illnesses, such as HIV, show 
widespread individual differences in subjective symptomatic experience and 
prognosis (Balbin et al., 1999; Grant & De Cock, 2001; Mindel & Tenant-Flowers, 
2001), which could be explained, at least in part, by laterality effects. Moreover, 
research into this area of neuroimmunology could potentially allow us to understand 
more about the division of labour between the two hemispheres of the brain, 
particularly after trauma. From studies that have examined hemispheric trauma (i.e. 
epilepsy surgery or stroke) we can see the relationship between increased right 
hemisphere activity and functioning and poorer immunity. However, it is not clear 
whether this is caused by the effects of right-sided superiority, or left-sided inferiority, 
following a left-sided lesion. IHI can explain how HL influences immunity in this 
dichotic manner, but more research is required in order to understand its dynamics in 
this setting. In order to understand the clinical implications of laterality effects, 
investigation into which hemisphere exerts the most influence on immunity could be 
of vital importance, particularly given the suggestion by Lewis et al. (2007) that 
laterality can be essentially switched in certain psychological states.  Finally, could 
HL also partly explain variability in the effectiveness of vaccines? One study has 
found that higher levels of left prefrontal activation were related to a more effective 
antibody response to influenza vaccination (Davidson et al., 2003). Such questions 
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remain to be addressed in the next decade of research on HL, immunity and immune-
related diseases.  
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LATERALISATION-IMMUNITY THEORY: PRACTICAL 
APPLICATIONS AND THE NEED FOR DEVELOPMENT 
Of the recently reviewed literature concerning the effects of hemispheric lateralisation 
(HL) on immunity, only one study examined the prognostic applications of the 
hypothesis, by examining the effects of HL on prognosis in HIV. One of the studies 
examined the implications of the HL-immunity theory on HIV prognosis by 
examining the longitudinal correlates of HL and HIV-relevant biomarkers (Gruzelier 
et al., 1996). The Gruzelier workgroup provided the first perspective on the possible 
consequences of HL in immune-mediated illness. By examining the long-term 
consequences of HL on HIV, this study offered a meaningful application for the 
theory, providing a relevance to prognosis. Moreover, HIV disease course is highly 
variable, and the duration of each of the relevant stages of illness, as well as the 
overall time to mortality, varies greatly amongst individuals (Lama & Planelles, 2007; 
Langford et al., 2007). Some of the predictors of this variability have already been 
identified, and extensively researched.  
Amongst the factors already known to impact upon HIV prognosis, some of the most 
important are concerning biological and psychosocial factors, discussed previously. 
Of the biological factors, viral strain, dual- or superinfection, coinfection with another 
pathogen (viral, parasitic, and bacterial) and host genetics are some of the most 
implicated in accelerating HIV pathogenesis (Lawn, 2004; Spira et al., 2003; Van der 
Kuyl & Cornelissen, 2007). Psychosocial variables that are known to impact upon 
HIV pathogenesis are psychological morbidity, personality and coping styles, social 
support and behavioural factors such as medication adherence and addictive substance 
misuse or dependence (Burgoyne, 2005; Cabral, 2006; Cole, 2008; Pence, 2009; 
Temoshok et al., 2008b).  
 
Despite the vast wealth of knowledge accumulated over the last three decades 
concerning these predictors of prognosis, there still exists a variance in disease course 
so far unaccounted for. Given the strength of the studies evaluating the relationship 
between HL and immunity (Sumner et al., 2011), and the existence of research 
concerning this modulating variable and HIV progression (Gruzelier et al., 1996); it is 
possible that some of this variance may be explained by HL.  
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The research by Gruzelier et al. (1996) found that left HL (as measured by 
electroencephalograph (EEG) and neuropsychological tests) was associated with 
better immune outcomes (CD4+, CD8+ T-cells) at a 30 month follow up. Furthermore, 
the study also described a relatively poorer prognosis (by these same measurements) 
in those patients with right lateralisation. However, their sample was very small 
(N=26) and was restricted to men of bisexual or homosexual orientation.  Today, the 
largest proportion of HIV transmission across the world occurs in heterosexual 
activity (Grant & De Cock, 2001; Hansasuta & Rowland-Jones, 2001). The 
pathogenesis of HIV may depend on the biology and socioculturally influenced health 
behaviours of individuals, which cannot be accounted for in such a restricted sample, 
nor generalised to a wider population (Derdeyn & Silvestri, 2005; Gifford et al., 2002; 
Lama & Planelles, 2007). Most importantly, Gruzelier et al. (1996) did not control for 
effects of baseline immune parameters and other confounders (e.g., education, mode 
of infection, other illnesses) that may affect the autonomic nervous system (ANS) 
(Cole et al., 2003) or the course of HIV, either statistically or methodologically. 
Additionally, the study did not selectively recruit right handed participants, a measure 
which is central in HL research. Left handed individuals characterise atypical 
interhemispheric communication and hemispheric specialisation (Iwabuchi & Kirk, 
2009; Toga & Thompson, 2003), which contributes too much heterogeneity in this 
measure for an initial investigation. Moreover, the research was conducted before the 
advent of highly-active antiretroviral therapy (HAART), one of the most significant 
developments in the fight against the HIV epidemic (Simon et al., 2006). The study 
participant pool was drawn from the Zidovudine trials in 1996, and so some 
participants were receiving this treatment. However, this is one chemical agent in a 
repertoire of what now consists over 20 – a significant advance since these early 
trials. Whilst all of the participants were in the asymptomatic phase of HIV illness, it 
is still possible that some of them may have been eligible for HAART treatment were 
the study conducted today. All these limitations question the validity of their 
inferences, and the application of the findings to modern HIV patients.  
 
In summary, although much is known about how HIV pathogenesis is modulated, 
there still exists disease course variance that is unexplained. A promising line of 
research for exploring additional prognosis factors is HL, and has already been tested 
in a small sample of patients. The results of this study showed very clear associations 
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between HL and prospective CD4+ and CD8+ T-cell count changes in HIV patients, 
with converse relationships being described. However, this original study was subject 
to a number of methodological flaws – either in statistical control or sample selection. 
These flaws mean that the findings are very difficult to validly generalise to HIV+ 
people as a patient group. Therefore, a study was planned to advance these findings, 
in a larger, more representative sample of HIV patients, with stricter control for those 
variables identified as impacting upon HIV pathogenesis.  
 
 
THE ROLE OF HEMISPHERIC LATERALISATION IN HIV-1 
Objectives 
The present study was developed to examine the influence of the independent variable 
of HL on the dependent variable of CD4+ T-cell count, as a surrogate biomarker for 
HIV progression. The key differences to the original study by the Gruzelier 
workgroup are in methodological and statistical control. Methodologically, a larger 
sample of participants was sought from broader demographic profiles. Only right-
handed participants were recruited to eliminate the heterogeneity observed in HL 
amongst left handed and ambidextrous people. Additionally, strict exclusion factors 
were implemented to reduce confounds. These factors include the exclusion of 
pregnant women, those patients with other illnesses known to affect HIV progression 
or general immune system functioning (e.g., hepatitis, cancers, psychological 
morbidity, autoimmune and neurological disorders), and any patients who were also 
currently physiologically or psychologically dependent on addictive substances. 
Statistically, control for baseline immunity, mood, health behaviours and socio-
demographic variables were exacted to account for the impact these factors may have 
on the outcome. Potential confounding variables in the relationship were identified a 
priori from the existing literature on HIV progression, and will be discussed in detail 
later.  
 
The aims of the study were to 1) replicate and advance the findings of the Gruzelier 
workgroup using stricter methodology and a more representative sample of HIV+ 
patients; 2) identify and evaluate potential variables that may moderate or mediate the 
relationship between HL and HIV prognosis; and 3) explore the data to analyse the 
contribution of HL to HIV-relevant behaviours.  
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Hypotheses 
The major hypothesis of the present study was that HL would predict prognosis in 
HIV, as indicated by differential decline in CD4+ T-cells prospectively. This 
relationship was to be examined by controlling for baseline immunity, non-adherence 
to HIV medication and mean time between immunological assessments. Further, as a 
secondary (or minor) hypothesis, it was anticipated that left HL would predict a better 
prognosis, and right HL a worse prognosis.  
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PARTICIPANTS 
Sample 
The participant sample was drawn from a clinical population of HIV+ outpatients of 
the Universiteit Ziekenhuis Brussel (UZB), Belgium which is a hospital associated 
with the Vrije Universiteit Brussel. The hospital is a predominantly Flemish speaking 
organisation; however it services patients of all demographics within the local 
community of Jette and the surroundings near Brussels. HIV+ patients attend the 
internal medicine clinic as outpatients, at all stages of illness from initial diagnosis to 
long-term surveillance and monitoring. Consequently, a broad profile of patients was 
potentially available for candidacy. 
A total of 74 candidates were put forward for study inclusion by clinicians, using the 
inclusion criteria outlined below if the patients indicated willingness to participate. Of 
these, 72 became full participants, with two candidates being excluded on medical 
grounds (one had a diagnosis of cerebral toxoplasmosis, the other was diagnosed with 
a Hepatitis virus and was receiving Interferon treatment). Recruitment spanned a three 
month period. After full follow-up data had been collected, 68 participants remained 
with sufficient data to carry out analyses. 
 
Sample Size Calculation 
Preliminary power calculations provided a target sample size of between 64 and 74 
participants. This sample size was calculated following two assumptions; 1) a total of 
two neuropsychological and six background variables will be predictive of immune 
outcomes (CD4+ T-cell and viral load counts); and 2) assuming a statistical power of 
0.80, a statistical significance of p<.05, and a contribution of 9% of the variance by 
neuropsychological tests to immune-outcomes, beyond the contribution of 30%-40% 
by the background measures (Cohen & Cohen, 1983).  
General Recruitment Criteria 
General guidelines for candidacy were to recruit right-handed adult men and women 
between the ages of 18 and 70 years old, in good general health. All candidates were 
to have a formal diagnosis of HIV, but not AIDS. Doctors were advised only patients 
with a CD4+ T-cell count of over 200/mm3 should be approached for candidacy. This 
rationale was implemented to ensure cognitive capability, as HIV is more likely to 
have infected the brain at this stage of disease, and because CD4+ T-cell loss 
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accelerates beyond this threshold (Weber, 2001). Only right-handed participants were 
required (discussed below), with a good level of literacy in French, Dutch or English. 
In order to provide true informed consent, candidates were required to have a good 
pre-assessed level of comprehension and cognition. Doctors were advised not to 
approach patients who had known cognitive deficits, or were otherwise similarly 
vulnerable. Cognitive capability was screened for in all participants, see below for 
further details. Patients were not offered an incentive (financial or otherwise) for 
participation, and were advised that the interview would take between 15 and 25 
minutes. Doctors at the Internal Medicine HIV clinic approached suitable candidate 
patients, and referred them to participate. Suitability was determined by the inclusion 
and exclusion criteria outlined below.  
Inclusion Criteria 
Eligible candidates for the study were those patients of UZB who were HIV+ and had 
not been diagnosed with an AIDS-defining condition at the time of study entry. Once 
the illness has developed to AIDS, neurological complications are prevalent which 
could corrupt the neuropsychological findings and impair cognition (Grant & De 
Cock, 2001; Hansasuta & Rowland-Jones, 2001; Simon et al., 2006). End-stage AIDS 
is characterised by multiple opportunistic infections, and renal and hepatic failure; all 
of which could alter the immune profile of the patient, thereby potentially obscuring 
the CD4+ T-cell and VL trajectory (Fine et al., 2008; Welch & Morse, 2002). Initially 
only patients not taking a HAART regimen were sought, in order to rule out 
medication effects. However, due to relatively slow study uptake and time constraints, 
it was decided to include HIV patients taking a HAART regimen. 
Only right-handed people were selected for recruitment. It is known that left handed 
individuals exhibit atypical inter-hemispheric communication (Iwabuchi & Kirk, 
2009), and atypical hemispheric specialisation (Toga & Thompson, 2003), which may 
interfere with the indices of HL. It has also been suggested that functional and 
biochemical cerebral asymmetries may be less pronounced in left-handed individuals 
(Previc, 1996; Zhavoronkova, 2000). 
In order that the participants were able to fulfill all of the study criteria, they were also 
required to read, speak and write a good level of Dutch, French or English. 
Participants were advised of their language options for carrying out the study, and 
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were advised to conduct the study using the language with which they felt most 
comfortable.  
 
Exclusion Criteria 
The exclusion criteria for the present study were based on three research 
requirements. Firstly, as full informed consent was required, cognitive capability 
screening was conducted to ensure the candidates were functioning to a minimum (but 
high) standard, with a cut-off score applied to the screening (see below). Secondly, as 
the study examined factors relating to prognosis in HIV, a number of extraneous 
factors, which are known to affect the pathogenesis of HIV beyond its natural course, 
were identified a priori for exclusion. These factors are listed below.  
Finally, as the research focussed on the functioning of the brain and its relationship to 
disease prognosis; a number of factors that are known to interact with the relationship 
between the brain and the immune system required identification. It should be noted 
that some factors that relate to HIV disease course also relate to the relationship 
between the brain and the immune system. The main exclusion measures are now 
described and explained below.  
Cognitive Capability 
Candidates were assessed for cognitive impairment using the Mini Mental State 
Examination (MMSE) (Folstein et al., 1975). This test is a widely-used cognitive 
screening tool with good specificity for identifying dementia and mild cognitive 
impairment in a variety of patient samples (Mitchell, 2009). The MMSE has a total 
score of 30. It is suggested that those exhibiting no cognitive impairments will score 
between 25 and 30, those with mild to moderate impairment 18 to 24, and those with 
severe impairment will score below 17 (Folstein et al., 1975). There has been some 
criticism levelled at the MMSE in being able to confirm a diagnosis of impairment, 
however a meta-analytic review has suggested that it is a valid tool for ruling out 
these cognitive deficits in a variety of samples (Mitchell, 2009).  
In order to avoid inclusion of those patients who may be even slightly cognitively 
impaired, the cut-off score of 25 was adopted. Any participants that attained a score 
lower than 25 were advised they would not be able to continue with the study. The 
MMSE was available as a standardised version in all three study languages and so no 
additional translation was required. 
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Factors Relating to Atypical or Accelerated HIV Pathogenesis 
Clinical morbidity of psychiatric illness is known to increase the pathogenesis of HIV, 
exacerbate HIV related symptoms, and impact on the adherence to HIV treatments 
(Evans et al., 1997; Ickovics et al., 2001; Mijch et al., 1999). Any candidates who had 
received a clinical diagnosis of a psychological or psychiatric disorder (such as major 
depressive disorder, bipolar affective disorder, schizophrenia, personality disorder, 
anxiety or dementia) were excluded from participation.  
Current dependence on addictive substances, both illicit and legal or prescription can 
cause earlier onset of AIDS-defining conditions in the HIV+ patient (Basso & 
Bornstein, 2000), and therefore those candidates who were classed as dependent on 
any addictive substance were unable to participate. 
 
Factors Relating to Atypical Brain to Immune Communication 
Historic dependence to and abuse of alcohol, cocaine and methamphetamine in HIV+ 
patients has been associated with neurological interference and decreased cerebral 
functioning (Basso & Bornstein, 2000; Chang et al., 2005; Jernigan et al., 2005; 
Pfefferbaum et al., 2007; Schulte et al., 2008). Any such neurological interference 
would potentially have affected the measures of lateralisation (HL), and so any 
participants reporting such dependencies were excluded from research. 
Autoimmune disorders such as arthritis and systemic lupus erythmatosus were 
screened for as they are indicative of atypical immune system functioning. Equally, 
patients with a chronic medical condition that significantly influences the normal 
functioning of the immune system, such as cancer, cardiovascular diseases, 
respiratory disease, glaucoma, or any form of hepatitis were also excluded.  
Medications administered for less severe, and perhaps acute rather than chronic, 
medical conditions have modulating effects on the autonomic nervous system (ANS), 
which in turn is suggested to modulate the functioning of the immune system 
(Bellinger et al., 2008; Quan & Banks, 2007; Wrona 2006). Patients prescribed 
sympathomimetics, anxiolytics, antihistamines or steroids were therefore excluded 
from candidacy consideration.  
In women, pregnancy is known to create atypical functioning of the ANS (Pickel et 
al., 2008) and so pregnant women were not invited to participate. 
Any pre-existing medical condition or incident which would have resulted in 
clinically meaningful damage to the brain would not only interfere with the 
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relationship between the brain and the immune system, but could also have affected 
the neuropsychological assessment of HL. Patients with history of traumatic brain 
injury, surgery to the head or brain or who had suffered any periods of cerebral 
hypoxia were excluded.  
 
MATERIALS 
The independent variable of HL was assessed with two neuropsychological tests, and 
a number of other instruments were implemented to assess other factors identified as 
being associated with HIV disease progression. In order to isolate the effect of HL on 
the dependent variables (immunological and virological outcome), variables identified 
previously in the literature as being associated with these outcome variables were 
measured to provide confounder and moderator assessment. These items are listed 
below, along with the methodological considerations surrounding their selection and 
purpose. Copies of all instruments can be found in Appendix B. 
Neuropsychological Measures 
To assess HL, two neuropsychological tests were used. Two tests were selected due to 
the associated problems involved in collecting neuropsychological data on 
lateralisation (discussed below). It was decided that two assessments that index 
laterality in different manners could provide a means of inter-test reliability should the 
two indices produce different effects, by assessing correlation between the data from 
the two. Both tests have strengths and weaknesses, and it was hoped that by using two 
the conceptual strength of each assessment would be bolstered.  
Neuropsychological tests like the line bisection task (LBT) require visuospatial 
negotiation, as well as motor skills in physically completing the task. The task itself is 
supposed to utilise the right side of the brain, at least in right handed individuals 
(Flöel et al., 2005; Foxe et al., 2003), and as such may present a left-sided bias 
(pseudoneglect), which is observed more strongly in women (Ciçek et al., 2003; 
Milner et al., 1992). As the purpose of this thesis was to examine overall HL of 
activity, rather than HL of specialisation, examining just this aspect of HL was 
considered to be a potentially insufficient composite of HL.  
Questionnaire-based assessment of HL such as that levelled by the Hemispheric 
Preference Test (HPT) (Zenhausern, 1978) can provide a way to overcome 
operational cognitive bias. The HPT assesses laterality by means of surveying the 
 101 
respondent’s behaviours and cognitions as opposed to relying on perceptual and 
attentional processes. However, there are also affective states which correlate with the 
responses of the HPT, with suggestions that the scale relates directly to anxiety 
(Russo et al., 2001), phobia and depression (Merckelbach et al., 1990).  
 
Line Bisection Task 
The second measurement of HL was conducted by a computerised online version of 
the Line Bisection task (LBT) (Milner et al., 1992). The test was held on a secure 
server with password protected entry (within www.brunelhivresearch.org). This task 
presents participants with a series of pre-bisected lines for a period of one second; the 
participant must then decide whether the line bisects more to the left or right. This 
task also correlates with resting EEG activation asymmetry (Nash et al., 2010). The 
current format of this test provided ten genuine and five randomly-generated sham 
trials, with presentation order randomised for each participant. Sham trials were very 
obviously bisected to one side; genuine trials were bisected exactly at the median. An 
example of a genuine trial and response entry are provided in figures five (a and b). 
(a)  
 
(b)  
 
Figure 5. Examples of the computerised LBT trials.  
Above shown are: (a) a genuine LBT trial; and (b) a trial response input. 
 
 
Hemispheric Preference Test 
The HPT (Zenhausern, 1978) is a 20-item self-report test that measures the amount of 
preference for either right hemisphere-based cognitions (e.g. “How vivid are your 
dreams?”) or left hemisphere-based operations (e.g. “How quickly do you read?”). 
The respondent answers to their individual preference and an index of lateralisation 
can be ascertained from those answers.  
 102 
This inventory is scored on the basis of one to ten for each item of the scale. 
However, due to an error in encoding the first five participants were scaled only on 
one or ten. A further ten participants were administered this questionnaire with a one-
to-six scale for response. The remainder of the participants were surveyed with the 
correct one-to-ten scale. Adjustments for these errors were made in statistical 
analysis, detailed below. 
This scale has been validated against EEG measures of hemispheric activation 
(Genovese, 2005; Merckelbach et al., 1997). This test was developed originally in the 
Dutch language, and an English version already existed; thus only one translation 
(French) was required.  
Immune Parameters 
The HIV-specific immune parameters being assessed were CD4+ T-cells and viral 
load (VL) counts, in both their whole and log10 form. VL was available in both 
formats, and so was collected with both formats. Clinicians often collect the VL data 
in both formats in order to describe the change of VL between measurements. 
Because log conversions allow the recoding of very large numbers in to more small, 
manageable figures, it is often easier to assess the significance of VL change using the 
log expression  - with a change of at least 0.5 log10 being classed as a clinically 
significant change in HIV medicine (Ginocchio, 2001). Although both figures are 
essentially expressing the same value, it was decided to use both as they are 
incrementally different, and one may provide more sensitivity to change within this 
context.     
International guidelines for the monitoring of HIV disease are that patients should 
undergo immunological and virological survey testing every three to four months 
(AIDS Education & Training Centers National Resource Center, 2009); however this 
is dependent upon the patient’s own vigilance of their health. Participants were 
advised that their immunological and virological data were to be collected from their 
medical records, and therefore did not require any additional serological testing. Data 
collection of immune parameters was conducted three months after the last participant 
had completed their baseline interview. Three points of immunological and 
virological data were sought, spanning the longest period of time where possible. 
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Mood  
In order to assess levels of anxious and depressive mood the participants were given 
the Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983). The 
HADS has been validated in a self-report format in factor structure, item analysis and 
internal consistency (Mykeltun & Stordal, 2001). Many other scales used for the 
assessment of anxiety and depression rely on the measurement of somatic variables, 
whereas the HADS does not. HIV and its treatment create many of the somatic 
symptoms also present with depression and anxiety (e.g. restlessness, nausea, 
anorexia) (Farinpour et al., 2003; Ickovics et al., 2001), so assessment of anxiety and 
depression in the HIV+ patient must be done without relying on somatic 
symptomatology.  In the HIV setting, the HADS has been found to have “excellent” 
internal consistency, convergent validity and test-retest reliability (Savard et al., 
1998). The scale has also been assessed using symptomatic and asymptomatic HIV 
patients, and has been suggested to be unaffected by the presence of HIV symptoms 
due to its reliance on cognitive-affective (as opposed to somatic) symptoms, 
particularly in reference to depression (Savard et al., 1998).  
This scale was obtained in standardised forms in French, Dutch and English and so no 
translation was required.  
 
Medication Adherence 
Treatment of HIV involves the implementation of a regimen of highly active 
antiretroviral therapy (HAART), which can be administered and altered in accordance 
with many different factors (Grant & De Cock, 2001; Harris & Bolus, 2008). The 
present study included patients both HAART-naïve (N=20) and HAART treated 
(N=49). In HIV+ patients, treatment adherence is a key issue to pathogenesis.  
The Morisky Medication Adherence Scale (MMAS) (Morisky et al., 1986) is a four-
item scale, which asks respondents to indicate a yes or no answer to the questions and 
also considers reasons why participants may not adhere (e.g., since they feel better). 
The scale is negatively weighted, so in order to confirm a positive behaviour, a 
negative response is given (e.g. Do you ever forget to take your medicine?). It was 
designed purposefully to overcome what the developers term a “yes-saying bias”, as 
patients are most used to answering questions that require an affirmative answer to 
indicate compliance (Morisky et al.¸ 1986). This scale has been validated in HIV+ 
 104 
population samples (Pratt et al., 2001). This scale was only obtainable in English, and 
so required translation in to both French and Dutch. 
 
Health Behaviour 
General Health Behaviour 
Some health behaviours have been found to be particularly relevant to HIV 
pathogenesis and general health in the HIV+ patient. Due to the associated interactions 
of drug use and HIV pathogenesis and HAART adherence (Baum et al., 2009; Cabral, 
2006; Feldman et al., 2006; Pfefferbaum et al., 2007), tobacco, marijuana, alcohol 
and cocaine use were surveyed for the last month. Candidates were initially screened 
for substance dependence or addiction, however casual use has less of an impact on 
the health of the individual, and so this information was collected to be accounted for, 
rather than ruled out. Participants were asked how frequently they used each 
substance in the last month, in the stratification of: no use, once or twice, once a 
week, several times a week, and daily. This survey was designed to allow exploration 
of potential confounding, moderating or mediating factors. The evidence is 
contentious as to whether these substances have a significant impact upon HIV 
progression, but there is sufficient evidence to suggest they may be confounding 
variables.  
 
Sexual Health Behaviour 
The participants were surveyed for sexual health behaviours (number of sexual 
partners, frequency of condom use) in the prior 12 months. Coinfection with multiple 
HIV strains or other sexually transmitted viruses can profoundly alter the disease 
course of HIV, and so condom use was assessed (Chan, 2004; Gore-Felton & 
Koopman, 2008). Although condom use does not necessarily indicate the presence of 
coinfection, it is an extrapolation of potential risk of coinfection – which may not 
have been medically apparent at the time of interview (and therefore evident to the 
screening doctors). This information works synergistically with the number of sexual 
partners the individual has and their relationship status; insomuch as the combined 
picture of these factors provides a more comprehensive index of risk. For example, 
the relative risk of coinfection of someone who reports no condom use, but is in a 
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relationship with only one sexual partner would be very different to someone who 
reports little condom use, no relationship and many sexual partners.  
 
The participants were asked how many sexual partners they had in the prior 12 
months, and how often they used condoms (always, often, sometimes, never). This 
scale was devised originally as a simple surveillance strategy of this type of health 
behaviour, but after conducting the interviews with the participants it became 
apparent that there were more phenomenologically relevant strata for this information. 
For example, there were frequent reports of no condom use, but the other 
circumstances that each individual reported mitigated the level of risk they apparently 
were prepared to engage in. These responses were then therefore re-coded according 
to their potential impact upon HIV progression; those responding “never” were 
categorised in to those with no relationship or sexual partners (thus representing the 
most minimal risk of multiple infection); those in a relationship but did not have sex; 
and those who did have a relationship or sexual partners and did not use condoms 
(representing the highest risk of multiple infection). This scale was thus transformed 
and scored in the following manner:  
1 – no relationship, no sex, “never” on condom use; 
2 – a relationship, no sex, “never” on condom use  
3 – “always”  
4 – “often”  
5 – “sometimes”  
6 – reported sexual activity (either within or without a relationship) and “never” on 
condom use.  
This information was collected as part of the demographic questionnaire, detailed 
below. 
Socio-demographic Factors 
A two-part survey-style questionnaire was devised to collate information about the 
participants’ socio-demographic background and historic information relating to their 
HIV+ status. The socio-demographic section of the questionnaire documented age, 
gender, ethnicity, educational level, employment status, sexual orientation and 
relationship status– these have all been associated as being related to HIV disease 
prognosis (Eich-Höchli et al., 1997; de la Hera et al., 2004). The second half of the 
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questionnaire related directly to HIV, and information concerning mode of 
contraction, duration of illness or diagnosis, and duration and type of antiretroviral 
treatment. Again, all of these factors have been related to HIV prognosis (Eich-Höchli 
et al., 1997; Kitahata, 2010; Wood et al., 2003) and had been identified as some of the 
potential key factors of covariance for the present study.  
 
PROCEDURE 
All candidate and participant interviews were conducted in a private room in the 
internal medicine clinic. This room was equipped with a desk, several chairs and a 
desktop computer to conduct the LBT. Participants were provided with writing 
materials and paper questionnaires. Some patients attended the clinic with partners, 
and were permitted their partners presence at interview; but were advised of the 
personal nature of the questions and were advised to conduct the interview alone. 
Only one participant chose to remain with their partner for the process of the 
interview.  
Following being put forward for candidacy by their doctor, the candidate would then 
be provided a detailed information sheet and consent form. If the candidate opted to 
participate, they were then screened using the MMSE. If the candidate scored over 25 
on this item they were then considered a participant. Those that scored less than 25 
were advised that they could not continue, and were thanked for their time. 
Participants were then verbally taken through the demographic survey questionnaire. 
If there were items that the participant could not answer, these were logged as a null 
response. Both the HADS and HPT were provided to the participant for self-
completion. The participants were advised that they could ask for clarification of the 
questions if necessary, but that they should answer as accurately as possible. The 
HADS versions provided instructions for completion, and the participants were 
advised on how to respond to the HPT questions verbally. The required response for 
the HPT was to circle, or otherwise mark, one number of the likert scale that they felt 
corresponded to their own perspective on the question. Any participants that could not 
respond to just one of the multiple-choice responses for the HADS, or one of the 
inventories on the likert scale for the HPT were advised to indicate a group response 
(i.e. circling two responses); the median of this response was then recorded for 
analysis.  
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Upon completion of the study-proper, participants were provided with a contact card 
detailing their participant number and contact details of the main researcher. They 
were then invited to ask any questions they had and were thanked for their time. A 
flow-chart of the study procedure can be found in figure six.  
 
C a n did at e  id e nt if ie d  
a n d ap p roa c he d  
b y  d o c to rs .
I n f o rm ed
c o ns e n t
M M S E D e br ie f
D e m o gra ph ic
S urv e y  &
q ue s t io nn a ire s
H P T  &  
C om p u te r  
L B T
F ol low -u p 
m e d ic a l
rec o rd  d at a
c o lle c tion
<2 5
> 2 5
 
Figure 6. A flow-chart of study procedure from candidacy to completion. 
 
Data collection was initially carried out by the principal researcher (RS). Due to time 
and financial constraints, the remaining data collection was conducted by two 
research assistants. Follow-up data collection was completed solely by the principal 
researcher. The research assistants were suitably qualified for and experienced in the 
collection of psychological data and suitably adept with all three languages being 
used. The principal researcher coached the research assistants in the procedure, and 
assistants were advised of potential procedural problems and how to overcome them 
(e.g. participants becoming distressed or wishing to terminate participation). Two 
participants became significantly distressed during data collection. At the point of the 
distress becoming apparent the interviews were suspended and the participants were 
counselled in relation to their rights to withdraw. Both participants were repeatedly 
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offered the opportunity to discontinue participation; however they both decided to 
continue with the interview after a brief period of suspension.  
Follow-up Data Collection 
Follow-up data was collected using the computerised medical records held at UZB. 
Information collected at this juncture was CD4+ T-cell count and VL; and the dates at 
which the patient attended the clinic for these readings. Whilst the attendance of these 
clinics is guided by the clinicians, it is ultimately the patient’s responsibility to return 
and so the frequency of return visits varied. As not all patients attended the clinic with 
the same frequency, time points for which there were data for both immune (T-cells) 
and virion (VL) cell were prioritised over duration of time between visits. This was 
prioritised in order to preserve these cross-sections of immunological status to provide 
discrete “snapshots” of the disease course. In some instances there were only data for 
either immune or virion cell data; which could skew data and potentially make the 
analysis of visit frequency (a health behaviour in itself) redundant. Immunological 
data was collected for three time points; an artificial baseline, one clinic visit 
retrospective to the original baseline data collection (T1); first follow-up which 
corresponded with baseline interview (T2), and second follow-up one clinic visit 
prospective to the original baseline interview (T3). Time-points were sought 
approximately three months apart where possible (i.e., true baseline (T2) ≈ at 
interview; artificial baseline (T1) ≈ T2-3months; follow-up (T3) ≈ T2+3 months). In 
the case of new patients, who had not had immunological surveillance before the 
interview, only prospective data was collected. As the frequency of clinic visits varied 
between participants a mean was taken of the time between clinic visits, so that it 
could be controlled for in statistical analysis. 
 
DATA CLARIFICATION 
One participant represented an outlier for the HPT variable. Using scatterplot analysis 
of the correlation distribution between HPT and CD4+ T3 it became apparent that this 
participant was heavily skewing the distribution of the HPT data and the pattern of 
this correlation. Therefore it was decided to exclude this participant’s data for the 
entirety of the data analysis.  
Three participants were demographic outliers. The majority of participants were of 
European or African descent, aside from one who was of South American extraction. 
 109 
Equally, the majority of participants reported themselves to be either homosexual or 
heterosexual, but two reported being bisexual. In order to include these outliers in 
covariable and moderator analyses it was decided that they be adjusted to fit in to one 
of the larger groups. This decision was made in order to retain the maximum number 
of participants for analyses, as the sample (N=68) was within the minimum limits 
delineated by the a priori statistical projection (N=64-74). This adjustment was done 
by the means of analysing each participant’s specific demographic information and 
aligning them to the group that they corresponded to in other demographic 
characteristics (e.g. age, gender, sexuality, education level and employment status). 
The South American participant was included in the European group. One bisexual 
participant was sorted to the heterosexual group, the other to the homosexual group. 
Data analyses were conducted with these participants in their unsorted and re-sorted 
groups to ensure there was no significant change in effect size for the main analyses. 
As these analyses were unaffected by the resorting of these participants, they 
remained in their re-sorted groups. 
Those participants with missing data were still included provided there were sufficient 
reported data for the independent and dependent variables. If participants were not 
definitive with their answers on continuous variables, and instead supplied a range or 
selected two responses to an inventory question, a mean value was recorded.  
 
ETHICAL CONSIDERATIONS AND APPROVAL 
Informed consent and debrief protocols were designed in line with British 
Psychological Society code of ethics and conduct (British Psychological Society, 
2006). All methods, materials and instruments were disclosed to and approved by the 
Brunel School of Health Sciences and Social Care Research Ethics Committee, as 
well as the Vrije Universiteit Brussel/UZB Medical Research Ethics Committee, 
where the study took place. Any amendments to protocol were also subject to ethical 
approval by each of the stated committees. Examples of ethical clearance notifications 
and amendment approvals can be found in Appendix A.  
Due to the nature of recruitment (referral by Doctor) extra care was taken to ensure 
candidates were ensured of their rights in voluntary participation, with relevance to 
potential coercion that could be inherent in being selected by an authority figure such 
as a clinician. A section was added to the informed consent information sheet 
explicitly stating that their participation, or declination to participate, would have no 
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bearing on their access to or standard of care from the Hospital and its staff. An 
example of the participant information sheet can be found in Appendix B. In Belgium, 
where patients were recruited, doctors see it as their ethical and clinical responsibility 
toward patients to support recruitment into scientific studies; hence they and not the 
research staff recruited patients.  
Medical record data retrieval was collected using the participants’ patient numbers (in 
an alphanumeric code), provided by the head of the Internal Medicine department at 
UZB. This request was made for all candidates put forward by the clinicians, in order 
to maintain confidentiality in those who declined to participate or required study 
exclusion. A key linking participant names and their patient number was retained by 
the principal investigator (RS) only, to ensure anonymity and in the event of a 
withdrawal request. This data was collected by the principal investigator from UZB’s 
computer systems, which are held in the Dutch language, using only the alphanumeric 
patient code. Due to the investigator’s limited familiarity with the Dutch language, it 
would not have been possible to examine any other parts of the participants’ medical 
files. The clinician provided training with the computer system to obtain study-
relevant data only (CD4+, VL). Participants were advised from the outset of the study 
in the information sheet (Appendix B) that all members of the research team were 
bound by confidentiality and only the CD4+ and VL data would be sought by the 
investigator. The collection of this data was undertaken in a private room within the 
clinic.  
 
LANGUAGE CONSIDERATIONS 
All scales were initially obtained in English. In order to cater for a multi-lingual 
population, all instruments were sought in standardised forms in French and Dutch. If 
scales could not be obtained in an official standardised version for the relevant 
language, translation was carried out. Those materials that were translated from 
English were either done so, or were validated by, a native speaker of that language.  
The participant interviews at baseline were conducted in the participant’s native 
language where at all possible. There were two participants whose native languages 
were not French, Dutch or English (one Scandinavian, one South American 
participant), and they were advised that they could complete the study in whichever of 
the three study languages they felt most comfortable with, or were advised that they 
should not participate if they were not sufficiently proficient in any of these 
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languages. Both participants chose to continue with the study; one chose English (the 
Scandinavian participant) and the other chose French.  
 
STATISTICAL ANALYSIS 
HL and immunity 
In order to assess the main relationship between HL (HPT and LBT separately) and 
the outcome measure of CD4+ T-cell count (T3); a linear multiple regression analysis 
was used.  All data analyses were run using the calculated left hemispheric 
lateralisation index (LHL) of the Log10 transformation of the HPT, and a 
corresponding LHL index of the LBT. A “left” index of the HPT was calculated using 
the formula LHL= 100 x (L-R)/(L+R).  The errors in encoding for the HPT data were 
overcome by excluding the first five participants (coded 1 or 10), and then performing 
z score transformations for the remaining data set in order to standardise the one-to-
six and one-to-ten scores. The data from the LBT were uncorrupted, and so analyses 
including this variable were conducted with the full participant sample. Due to data 
skewness and kurtosis present in HPT data, both square-root and log10 transformations 
were tested. The log10 transformations presented the least skewness and so were 
employed for the analyses; however there was still significant skewness apparent in 
this variable (see Appendix C). Additional analyses were conducted using Spearman’s 
rho correlation in order to counteract bias due to outliers within the dataset. To ensure 
that one of the key objectives of the study – to control for confounding variables – 
was preserved,  and since the Spearman’s test does not permit controlling for 
confounders, the T3 CD4+ scores (dependent variable) were residualised on T1 CD4+ 
data and medication variables. 
 
Confounding variables 
Potential confounding variables for the main data analysis were identified from the 
literature a priori, for both the outcome and independent variables. Those variables 
that were identified from the literature as being potential confounding variables for 
HIV variables were baseline immunity (CD4+ T-cell count at artificial baseline), 
HAART use, HAART adherence and duration of HIV infection, as all of these 
variables have the capacity to significantly alter, or predict, outcome CD4+ T-cell 
count (Deeks, 2006; Pratt et al., 2001; Simon et al., 2006).  
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A set of subsequent tests were conducted to identify true, statistically confounding 
variables identified in the present sample. The significance of each potential 
confounding variable was assessed against the  outcome variable (CD4+ T-cell count 
at T3) using bivariate Pearson’s correlation (continuous data) and t test or ANOVA 
(categorical data). Those variables that presented significant (p<.05) associations were 
used as covariates in each multiple regression or correlation.  
 
Moderators 
Moderators were identified observationally (ethnicity) and through methodological 
contingency (HAART treatment). It became apparent during data collection that the 
sample comprised of two groups: male, homosexual Europeans, and female, 
heterosexual Africans. This clinical separation is similar to that observed in other 
studies (Anastos et al., 2000; Jarrin et al., 2008; Smith et al., 2007), yet its implication 
in immune outcomes has not yet been analysed in such a way. Analysis of HAART as 
a moderator served a methodological purpose, to understand whether the inclusion of 
a mixed-treated sample would modify the potential results. Further, as HAART is a 
immunomodulating medical treatment, it is possible that its presence may attenuate, 
or even abrogate, the effects of HL on immunity in HIV+ patients. Additionally, the 
investigation of the moderation of HAART in this context presents clinical 
significance to the interpretation of the findings. Analyses comparing sub-samples 
were undertaken using t tests for continuous data and X2 tests for categorical data. As 
splitting the sample according ethnicity and medication resulted in smaller sample 
sizes for the main analysis Spearman’s rho correlation tests were used to assess the 
HL-immune relationship for each separate sub-sample.  
 
Post-hoc tests 
Exploratory analysis of behavioural data was conducted in the split dataset using two-
tailed bivariate correlations. Both measures of HL (HPT and LBT) were employed to 
fully explore the available data. Exploratory analyses were run in both the whole 
sample and the ethnicity-split subsamples to ascertain further implications of the 
moderator.   
 
 
 
 113 
Statistical tools & parameters 
Statistical analyses were conducted using SPSS Statistics (IBM SPSS, version 17.0), 
with p values <0.05 indicating statistical significance. Raw data output can be found 
in Appendix C.  
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PARTICIPANT SUMMARY STATISTICS 
 
The original sample size was 72, and four participants had to be excluded from final 
analyses. Three of these participants were excluded due to comprehension problems, 
which became apparent during interview, the other was excluded due to outlying HPT 
scores (see previous chapter).  
Of the remaining participants several demographic outliers required re-classification 
in order to maximise the dataset potential. As outlined in the previous chapter, one 
non-African non-European participant, and two bisexual participants were re-
classified into other subcategories in accordance with their other demographic 
characteristics. Each of these participants was compared to the other profiles of 
participants (either by ethnicity or sexuality) and was re-sorted to the category that fit 
their other reported variables. This reclassification was conducted as both ethnicity 
and sexuality could have potentially been important confounding or moderating 
variables, and these participants would have been lost in those analyses without 
reclassification. 
 
Table 4. Descriptive statistics of continuous data with mean, standard deviation and number of 
respondents. 
 
Characteristic Mean  SD N 
Age (years) 43.30 8.95 68 
Duration of HIV (years) 6.32 6.36 64 
MMSE (maximum range 25-30) 29.03 1.25 68 
Mean period between clinic visits (days) 109.97 33.98 65 
Non-Adherence (maximum range 0-4, 4 indicating maximum non-
adherence) 
.55 .77 47 
Number of sexual partners (prior 12 months) 7.28 13.38 68 
HADS Anxiety (maximum range 0-21) 7.22 4.37 68 
HADS Depression (maximum range 0-21) 4.13 3.54 68 
Line Bisection Index of Left Lateralisation (maximum range 0-10) 5.46 2.64 68 
HPT Left Lateralisation Index Z Score (based on log 
transformation) 
3.05 .073 61 
 
Sample Description 
The full participant dataset comprised 68 individuals (50 male, 18 female; mean age= 
43.30, SD ±8.95 (years)). The mean self-reported duration of illness was 6.32 years 
(SD= ±6.36 years), with just over 70% (N=48) currently taking a HAART regimen. 
The majority reported contracting HIV through sexual contact (N=43). Within this 
dataset the majority were of European extraction (N=45), were homosexual (N=38), 
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were not in a relationship (N=33), had attained an academic level of education 
(N=35), and were employed full time (N=41). Non-adherence was low amongst those 
taking a HAART regimen. The dispersion of the HL scores was very large. Before z 
score transformations were conducted, the dataset showed a majority of left lateralised 
participants (i.e. scoring higher on “left” versus “right” items). 
Full details of summary statistics can be found in tables 4 and 5. 
 
Table 5. Descriptive statistics of categorical data with number of respondents and percentage of total 
respondents for that category.  
 
Characteristic N % 
Male 50 73.5 Gender 
Female 18 26.5 
European 45 66.2 Ethnicity 
African 23 33.8 
Primary 5 7.5 
Secondary 23 34.3 
Vocational 4 6.0 
Academic 35 52.2 
Education 
Missing/Undisclosed 1  
Employed full time (FT) 41 60.3 
Employed part time (PT) 4 5.9 
Homemaker/Full time parent 1 1.5 
Unemployed due to health 3 4.4 
Unemployed 17 25.0 
Employment Status 
Retired 2 2.9 
Heterosexual 30 44.1 Sexual Orientation 
Homosexual 38 55.9 
Single 33 49.3 
Married/Cohabiting 11 16.4 
In a Relationship 23 34.3 
Relationship Status 
Missing/Undisclosed 1  
HAART treated 48 70.6 HAART* Medication 
Untreated 20 29.4 
Sexual Contact 43 64.2 
Injection Drug Use 1 1.5 
Medical Contact 5 7.5 
Unknown 18 26.9 
Mode of Contraction 
Missing/Undisclosed 1  
Never – No relationship, No sex 10 14.9 
Never – Relationship, No sex 4 6.0 
Always 37 55.2 
Often 4 6.0 
Often-Sometimes (both responses 
given) 
1 1.5 
Sometimes 7 10.4 
Never – Sexually active 4 6.0 
Condom use (12 
months) 
Missing/Undisclosed 1  
*HAART= Highly Active Antiretroviral Treatment 
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Immunological Data 
Of the final participants, 66 had full immunological data (CD4, VL (absolute and 
log10 copies)) at interview (T2) time, 61 had full immunological data for artificial 
baseline (T1), 60 had CD4 prospective follow-up data and 62 had VL (absolute and 
log10 copies) prospective follow-up data at T3 (see table 6). Please see previous 
chapter for delineation between VL measures. 
 
Table 6. Summary of immunological data, with mean, standard deviation and total number of 
respondents. 
 
Cell Type & Data Collection Point Mean SD N 
T1: Retrospective data point 571.31 251.92 61 
T2: Baseline 567.64 263.29 66 
CD4+ 
(cells/mm3) 
T3: Prospective data point 545.90 242.28 60 
T1 28461.67 90153.67 61 
T2 62015.48 3.39 66 
Viral Load 
(Absolute 
Copies) T3 39453.66 2.12 62 
T1 1.85 2.03 61 
T2 1.79 2.08 66 
Viral Load 
(Log10 Copies) 
T3 1.37 1.92 62 
 
 
The mean values of CD4+ T-lymphocyte cells suggests a sample of relatively healthy 
HIV+ individuals, however there is a large variation in these values exhibited in the 
dataset. Viral load (VL) data also suggests broad variation, however this can be 
explained by the inclusion of participants both receiving and not receiving 
antiretroviral treatment. From mere inspection, one can see trends towards reduced 
CD4+ levels over time. This represents a normal pattern of disease progression in 
these patients. VL data represents more variance, possibly due to the inclusion of a 
mixed-treated sample. 
Tables of all zero-order associations between the dependent variable (CD4+ T3) and 
all variables (continuous and categorical) conducted with two-tailed significance can 
be found in tables 7, 8 and 9. Tables 10 and 11 detail the one-tailed correlation 
between the HL measures and each immunological data collection point. Skewness 
and kurtosis in the independent and dependent variables can be found in Appendix C.  
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Table 7. Zero-order associations between the dependent variable (CD4+ T3) and variables with 
continuous data. 
 
CD4+ T3 Continuous Variable 
r p N 
CD4+ T1 .811* <.01 59 
CD4+ T2 .797* <.01 61 
Age .055 .676 61 
Duration of HIV .257 .054 57 
MMSE .157 .234 59 
VL log10 T1 -.312* .016 59 
VL copies T1 -.238 .069 59 
VL log10 T2 -.309* .016 61 
VL copies T2 -.232 .072 61 
VL log10 T3 -.298* .020 61 
VL copies T3 -.241 .062 61 
HADS – Anxiety .078 .553 61 
HADS - Depression -.024 .853 61 
Line Bisection Index of Left Lateralisation -.118 .367 61 
HPT Left Lateralisation Index Z Score (based on log transformation) -.229 .095 54 
Non-adherence Index (MMAS) -.275 .071 44 
Mean period between clinic visits .213 .100 61 
Number of sexual partners (prior 12 months) -.027 .837 61 
Condom use (12 months) .066 .618 60 
Alcohol use (prior 1 month) .210 .104 61 
Cigarette or Tobacco use (prior 1 month) .205 .112 61 
Marijuana use (prior 1 month) .101 .436 61 
Cocaine use (prior 1 month) .118 .365 61 
 
Table 8. Zero-order associations between the dependent variable (CD4+ T3) and variables with 
categorical data with only two levels (employing t test) 
 
Categorical Variable t df p 
Gender .463 58 .645 
Ethnicity 1.749 58 .086 
Sexual Orientation -.892 58 .376 
HAART Medication 1.556 58 .125 
 
 
Table 9. Zero-order associations between the dependent variable (CD4+ T3) and variables with 
categorical data with more than two levels (employing ANOVA) 
 
Categorical Variable F df p 
Education .092 3, 58 .964 
Employment Status 2.183 5, 59 .070 
Relationship Status .501 2, 58 .608 
Mode of Contraction .820 2, 59 .445 
Condom Use .210 6, 58 .972 
Alcohol use (prior 1 month) 1.364 4, 59 .258 
Cigarette or Tobacco use (prior 1 month) .690 3, 59 .562 
Marijuana use (prior 1 month) .384 2, 59 .683 
Cocaine use (prior 1 month) .690 2, 59 .506 
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Table 10. Zero-order associations between the HPT and all CD4+ T-cell data collection points. 
 
CD4+ T1 CD4+ T2 CD4+ T3 HPT Sample 
r p r p r p 
Whole sample 
 
-.130 .173 -.080 .273 -.054 .349 
European -.147 .193 -.073 .330 -.150 .196 Ethnicity 
Split African -.006 .490 .091 .351 .389 .055 
Yes -.227 .075 -.138 .186 -.162 .156 HAART 
Split No .240 .215 .057 .420 .402 .098 
 
Table 11. Zero-order associations between the HPT and all CD4+ T-cell data collection points. 
 
CD4+ T1 CD4+ T2 CD4+ T3 LBT Sample 
r p r p r p 
Whole sample 
 
-.017 .449 -.022 .429 -.086 .257 
European -.037 .410 -.004 .490 -.108 .256 Ethnicity 
Split African -.025 .458 -.136 .269 -.154 .253 
Yes -.057 .357 .020 .447 -.114 .231 HAART 
Split No .133 .305 -.087 .362 .023 .466 
 
 
HEMISPHERIC LATERALISATION AND IMMUNITY IN HIV 
First, simple bivariate correlations were conducted to assess the relationship between 
HL and the immunity outcome variables (at the prospective data collection point). A 
summary of the correlation coefficients and their relevant one-tailed probabilities are 
provided in table 12. It can be seen that the only significant relationship observed in 
this battery of tests is between the HPT and prospective VL copies. Whilst this 
relationship is encouraging, and is in the hypothesised direction, there were too many 
covariables with the VL data to adequately analyse this relationship further. This was, 
for the mostpart, because a mixed-treated sample (i.e. HAART-treated and HAART-
naïve) was included, and therefore the effects of HAART on these outcome variables 
could not be appropriately controlled for. No further analyses for VL data were 
conducted. 
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Table 12. A summary of simple bivariate correlations (one-tailed) between left indices of the 
hemispheric lateralisation tests and outcome (prospective: T3) immunological and virological 
assessments.  
 
CD4+  VL log10  VL copies HL Measure 
r p r p r p 
LBT -.086 .257 .020 .439 .075 .282 
HPT -.054 .351 -.139 .158 -.241* .038 
 
 
In order to assess the impact of hemispheric lateralisation on disease progression in 
HIV, linear multiple regression (MR) analysis was applied. A MR analysis, with the 
prospective CD4+ T-cell measurement as the dependent variable and retrospective 
CD4+ T-cell measurement (artificial baseline), duration of HIV, mean time between 
clinic visits, non-adherence (using the Moriskey Medication Adherence Scale) and the 
log10 transformation of the Hemispheric Preference Test as predictors for the reduced 
whole sample (due to the errors of encoding for this variable) gave R2=.76 (F change 
(1,30)=.438, p=.513). This analysis indicated that the left index of the HPT contributed 
an additional, and non-significant, 0.3% of CD4+ follow-up variance, beyond the 
contribution (76%) of the confounders.  
 
CONFOUNDING VARIABLES 
After completing the MR and finding no significant effect, it was decided further 
testing was required to assess confounding variables. Of those identified a priori from 
the literature only one proved to provide a significant relationship – baseline 
immunity. For outcome CD4+ (T3), significant relationships were observed for 
HAART use (t(51.36)= 2.23, p=.030); and baseline CD4+ (r(56)= .84, p<.001).  
Due to the lack of significance of this main MR, further tests were run including the 
covariables identified statistically. A MR analysis, with the prospective CD4+ T-cell 
measurement as the dependent variable and retrospective CD4+ measurement (T1) 
and HAART medication, log10 transformation of the Hemispheric Preference Test 
(log10 HPT) and the left index of the Line Bisection Test (left LBT) as predictors for 
the reduced whole sample gave R2=.73 (F change (2, 46)=.785, p=.462). This indicates 
that the two HL tests contributed 0.7% of the variance observed in follow-up CD4+ T-
cell count beyond the contribution (71.6%) of the confounders, and were non-
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significant. Table 13 summarises the original MR employing the covariables 
identified a priori, and the final MR employing both HL measures and the statistically 
identified covariables. 
 
Table 13. A summary of the multiple regression (MR) analyses employed, their predictor and outcome 
variables, and covariables used. Outcome R2 change and probability (p) value are provided. 
All MRs were conducted with the reduced whole sample.  
  
Predictor 
Variable 
Covariables Outcome 
Measure 
R2 
change 
p 
Retrospective CD4+ (T1) 
Duration of HIV 
Mean time between clinic visits 
Log10 HPT 
– Index of 
LHL Non-adherence to HAART medication 
Prospective 
CD4+ 
.003 .513 
Retrospective CD4+ Log10 HPT 
LBT  HAART medication 
Prospective 
CD4+ 
.009 .462 
 
Due to the presence of skewness and possible outliers in the dataset, a nonparametric 
Spearman’s rho correlation was conducted between the standardised prospective 
CD4+ T-cell measurement (CD4+ T3, residualised on CD4+ T1 and HAART 
medication as covariates) and the log10 transformation of the Hemispheric Preference 
Test (log10 HPT). There was a statistically significant correlation between left 
lateralisation (left HPT) and standardised outcome CD4+ T-cell count (rho=.234, 
p=.047, one tailed test, N=61). 
 
MODERATING VARIABLES  
Moderating variables were sought for further analysis of the dataset. To test the 
moderating relevance of these variables with other categorical data variables, chi-
square (X2) tests were conducted and t tests were conducted for continuous data 
variables. All analyses were conducted with two-tailed significance as they were 
unhypothesised assessments. 
 
Ethnicity 
An observed split in the data was ascertained between the two ethnicity groups 
(African and European). Descriptive statistics of the two sub-samples can be found in 
table 14.  
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Table 14. Descriptive statistics of the continuous data for the ethnicity-split sample, with mean and 
standard deviation values for each category. 
 
Africans Europeans Characteristic 
Mean SD Mean SD 
Age (years) 42.82 8.37 43.53 9.31 
Duration of HIV (years) 6.22 5.30 6.36 6.90 
MMSE (maximum range 25-30) 28.54 1.37 29.27 1.12 
Mean period between clinic visits (days) 111.15 30.50 109.32 36.07 
Non-Adherence (maximum range 0-4, 4 indicating maximum 
non-adherence) 
.56 .89 .55 .72 
Number of sexual partners (prior 12 months) 1.17 1.19 10.40 15.57 
HADS Anxiety (maximum range 0-21) 6.91 4.32 7.37 4.44 
HADS Depression (maximum range 0-21) 4.91 3.69 3.73 3.43 
Line Bisection Index of Left Lateralisation (maximum range 0-
10) 
4.91 2.62 5.73 2.63 
HPT Left Lateralisation Index Z Score (based on log 
transformation) 
3.07 .05 3.04 .08 
Follow-up (T3) CD4+ T-cell Count 472.62 282.62 585.36 211.03 
 
Significant differences were found between the two ethnicity groups for: gender (x2(1, 
N=68)=21.13, p<.001); level of education (x2(3, N=67)=13.15, p=.004); employment status 
(x2(5, N=68)=24.01, p<.001); sexual orientation (x2(1, N=68)=31.39, p<.001); mode of HIV 
contraction (x2(3, N=67)=13.24, p=.004); MMSE (t(64)= 2.29, p=.025); and number of 
sexual partners in the prior 12 months (t(45.01)=3.95, p<.001). A summary table of 
these significant categorical characteristics can be found in table 15. No significant 
difference was observed between outcome (T3) CD4+ counts for these two groups 
(t(58)= 1.75, p=.086). 
 
The dataset was split by ethnicity: African (N=23) and European (N=45). Due to the 
reduced sample sizes Spearman’s rho correlations were implemented. Spearman’s rho 
correlations were conducted between the standardised prospective CD4+ T-cell 
measurement (CD4+ T3, residualised on CD4+ T1 and HAART medication) and the 
log10 transformation of the Hemispheric Preference Test (log10 HPT) as predictor, 
split by ethnicity group. There were no statistically significant correlations between 
left lateralisation (left HPT) and standardised outcome CD4+ T-cell count for the 
European sub-sample (rho=.241, p=.081, one tailed test, N=35) or for the African 
sub-sample (rho=.402, p=.055, one tailed test, N=17). 
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Table 15. Descriptive statistics of the categorical data for the ethnicity-split sample, with number of 
respondents and percentage of total respondents for each category. 
 
Africans  Europeans Characteristic 
N % N % 
Male 9 39.1 41 91.1 Gender 
Female 14 60.9 4 8.9 
Primary 4 17.4 1 2.3 
Secondary 12 52.2 11 25.0 
Vocational 7 30.4 4 9.1 
Education 
Academic 0 0 28 63.6 
Employed FT 6 26.1 35 77.8 
Employed PT 2 8.7 2 4.4 
Homemaker 1 4.3 0 0 
Unemployed (Health) 1 4.3 2 4.4 
Unemployed 13 56.5 4 8.9 
Employment 
Status 
Retired 0 0 2 4.4 
Heterosexual 21 91.3 9 20.0 Sexual 
Orientation Homosexual 2 8.7 36 80.0 
Single 11 47.8 22 50.0 
Married/Cohabiting 4 17.4 7 15.9 
Relationship 
Status 
In a Relationship 8 34.8 15 34.1 
HAART treated 16 69.6 32 71.1 HAART 
Medication Untreated 7 30.4 13 28.9 
Sexual Contact 10 43.5 33 75.0 
Injection Drug Use 0 0 1 2.3 
Medical Contact 5 21.7 0 0.0 
Mode of 
HIV 
Contraction Unknown 8 34.8 10 22.7 
Never – No relationship, No 
sex 
5 21.7 5 11.4 
Never – Relationship, No sex 1 4.3 3 6.8 
Always 12 52.2 25 56.8 
Often 1 4.3 3 6.8 
Often-Sometimes (both 
responses given) 
0  1 2.3 
Sometimes 3 13.0 4 9.1 
Never – Sexually active 1 4.3 3 6.8 
Condom use 
(12 months) 
Missing/Undisclosed 0  1  
 
 
HAART 
Additionally, the moderating variable of HAART medication was identified for 
testing. The inclusion of HAART-treated patients potentially confounded the results 
of the main analysis due to HAART’s effects on general immunity in HIV patients. 
By analysing the implication of HAART as a moderator it would have been possible 
to ascertain whether including these patients corrupted the overall findings. Further, it 
was possible that there would be a medical significance of HL moderation of 
immunity in HIV patients either side of this clinically important milestone. After 
testing differences between the HAART-treated and HAART-untreated sub-samples, 
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very few significant differences were found between the groups in continuous or 
categorical variables. A significant difference was found between the two treatment 
groups for condom use (x2(1, N=68)=14.03, p=.029) and duration of HIV (t(62)= 2.35, 
p=.022) only. A significant difference was also observed between treatment groups 
and outcome (T3) CD4+ counts in these two groups (t(50.80)= 2.06, p=.045). See tables 
16 and 17 for group differences in continuous and categorical variables 
 
Table 16. Descriptive statistics of the continuous data for the treatment-split sample, with mean and 
standard deviation values for each category. 
 
HAART 
Treated 
Untreated Characteristic 
Mean SD Mean SD 
Age (years) 43.83 8.93 42.00 9.07 
Duration of HIV (years) 7.53 6.10 3.64 6.23 
MMSE (maximum range 25-30) 28.91 1.28 29.31 1.15 
Mean period between clinic visits (days) 114.29 34.01 99.5 32.40 
Non-Adherence (maximum range 0-4, 4 indicating maximum 
non-adherence) 
.55 .77 - - 
Number of sexual partners (prior 12 months) 5.54 8.68 11.45 20.47 
HADS Anxiety (maximum range 0-21) 7.6 4.53 6.3 3.91 
HADS Depression (maximum range 0-21) 4.29 3.73 3.75 3.09 
Line Bisection Index of Left Lateralisation (maximum range 0-
10) 
5.29 2.44 5.85 3.08 
HPT Left Lateralisation Index Z Score (based on log 
transformation) 
3.05 .08 3.04 .07 
Follow-up (T3) CD4+ T-cell Count 574.90 265.94 466.13 137.45 
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Table 17. Descriptive statistics of the continuous data for the treatment-split sample, with number of 
respondents and percentage of total respondents for each category. 
 
HAART Treated Untreated Characteristic 
N % N % 
Male 35 72.9 15 75.0 Gender 
Female 13 27.1 5 25.0 
Primary 2 4.3 3 15.0 
Secondary 17 36.2 6 30.0 
Vocational 4 8.5 - - 
Education 
Academic 24 51.1 11 55.0 
Employed FT 25 52.1 16 80.0 
Employed PT 3 6.3 1 5.0 
Homemaker 1 2.1 - - 
Unemployed (Health) 3 6.3 - - 
Unemployed 14 29.2 3 15.0 
Employment 
Status 
Retired 2 4.2 - - 
Heterosexual 20 41.7 10 50.0 Sexual 
Orientation Homosexual 28 58.3 10 50.0 
Single 22 46.8 11 55.0 
Married/Cohabiting 9 19.1 2 10.0 
Relationship 
Status 
In a Relationship 16 34.0 7 35.0 
European 32 66.7 13 65.0 Ethnicity 
African 16 33.3 7 35.0 
Sexual Contact 30 62.5 13 68.4 
Injection Drug Use 1 2.1 - - 
Medical Contact 3 6.3 2 10.5 
Mode of 
HIV 
Contraction Unknown 14 29.2 4 21.1 
Never – No relationship, No 
sex 
9 18.8 1 5.3 
Never – Relationship, No sex 4 8.3 - - 
Always 24 50.0 13 68.4 
Often 4 8.3 - - 
Often-Sometimes (both 
responses given) 
1 2.1 - - 
Sometimes 2 4.2 5 26.3 
Never – Sexually active 4 8.3 - - 
Condom use 
(12 months) 
Missing/Undisclosed - - - - 
 
 
The dataset was split by HAART medication status: those taking HAART (N=48) and 
those not taking HAART (N=20). Spearman’s rho correlations were conducted 
between the standardised prospective CD4+ T-cell measurement (CD4+ T3 
residualised on CD4+ T1) and the log10 transformation of the Hemispheric Preference 
Test (log10 HPT) as predictor split by treatment group. There was no statistically 
significant correlation between left lateralisation (left HPT) and standardised outcome 
CD4+ T-cell count for the HAART treated sub-sample (rho=.153, p=.170, one tailed 
test, N=41).  
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Figure 7. A scatterplot showing the correlation between left lateralisation (HPT log10 transformation) 
and standardised CD4+ T-cell follow-up for the HAART treated sub-sample. 
 
There was a statistically significant correlation between left lateralisation (left HPT) 
and standardised outcome CD4+ T-cell count for the untreated sub-sample (rho=.627, 
p=.019, one tailed test, N=11). Scatterplots of these correlations can be found in 
figures seven (HAART treated sub-sample) and eight (untreated sub-sample).  
 
  
Figure 8. A scatterplot showing the correlation between left lateralisation (HPT log10 transformation) 
and standardised CD4+ T-cell follow-up for the untreated sub-sample. 
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POST-HOC EXPLORATORY ANALYSES – BEHAVIOUR 
Due to the large volume of behavioural data taken we had a unique opportunity to 
examine the relation between HL and health behaviours. As these analyses were not 
hypothesised, only two-tailed bivariate correlations were employed to explore the 
possibility of LHL relating to the behavioural data collected in this HIV+ sample. 
Both indices of LHL (the HPT and the line bisection task (LBT)) were used for this 
exploration, in both the full sample and the sub-samples split by ethnicity. The 
African sub-sample unanimously reported no cigarette/tobacco, marijuana or cocaine 
use. 
 
Whole Sample 
In the whole sample, LHL (LBT) was shown to have a significant relationship with 
self-reported marijuana use in the last month (r(66)= -.26, p=.035). A trend was also 
identified in the whole sample, between LHL (LBT) and the number of sexual 
partners reported in the prior 12 months (r(66)= -.22, p=.071). A summary of all 
correlations for the whole sample can be found in table 18. 
 
Table 18. Summaries of the correlations for behavioural data in the whole sample. Correlation (r) and 
probability (p) values are provided. Those statistically significant correlations are denoted 
with *. 
 
 
 
 
Number 
of sexual 
partners 
(prior 12 
months) 
Mean 
period 
between 
clinic 
visits 
Condom 
use (12 
months) 
Alcohol 
use (prior 
1 month) 
Cigarette 
or 
Tobacco 
use (prior 
1 month) 
Marijuana 
use (prior 
1 month) 
Cocaine 
use (prior 
1 month) 
r .028 -.035 -.046 -.103 .030 -.015 .177 HPT 
p .831 .796 .729 .430 .818 .911 .172 
r -.220 -.035 .132 .174 -.097 -.256* .130 LBT 
p .071 .784 .287 .157 .430 .035 .290 
 
 
Split Sample 
Europeans 
In the split sample, two significant relationships were observed in the European sub-
sample. A significant relationship was found between LHL (LBT) and number of 
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sexual partners in the past 12 months (r(43)= -.36, p=.017; 2-tailed test); and LHL 
(LBT) and marijuana use in the past month (r(43)= -.36, p=.016; 2-tailed test). 
Summaries of the correlations for behavioural data in the European subsample can be 
found in table 19.  
 
Table 19. Summaries of the correlations for behavioural data in the European sub-sample. Correlation 
(r) and probability (p) values are provided. Those statistically significant correlations are 
denoted with *. 
 
 
 
 
Number 
of sexual 
partners 
(prior 12 
months) 
Mean 
period 
between 
clinic 
visits 
Condom 
use (12 
months) 
Alcohol 
use (prior 
1 month) 
Cigarette 
or 
Tobacco 
use (prior 
1 month) 
Marijuana 
use (prior 
1 month) 
Cocaine 
use (prior 
1 month) 
r .092 -.051 -.137 -.151 .128 .022 .252 HPT 
p .568 .761 .400 .345 .427 .890 .112 
r -.356* .115 .108 .024 -.211 -.357* .120 LBT 
p .017 .468 .487 .876 .163 .016 .432 
 
 
Africans 
In the African sub-sample, a trend was identified between LHL (LBT) and the mean 
time between clinic visits for HIV surveillance (r(21)= -.36, p=.092; 2-tailed test). 
Summaries of the correlations for the behavioural data in the African subsample can 
be found in table 20.  
 
Table 20. Summaries of the correlations for behavioural data in the African sub-sample. Correlation (r) 
and probability (p) values are provided. Those correlations with no data are denoted with -. 
 
 
 
 
Number 
of sexual 
partners 
(prior 12 
months) 
Mean 
period 
between 
clinic 
visits 
Condom 
use (12 
months) 
Alcohol 
use (prior 
1 month) 
Cigarette 
or 
Tobacco 
use (prior 
1 month) 
Marijuana 
use (prior 
1 month) 
Cocaine 
use (prior 
1 month) 
r .262 -.017 .349 .315 - - - HPT 
p .264 .942 .131 .176 - - - 
r .078 -.360 .148 .334 - - - LBT 
p .725 .092 .502 .119 - - - 
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THE EFFECTS OF HEMISPHERIC LATERALISATION ON PROGNOSIS IN 
HIV 
The present study sought to examine the relationship between hemispheric 
lateralisation (HL) and prognosis in right-handed HIV-1+ patients without a clinical 
diagnosis of AIDS. A recent review suggests that HL has a discernable relationship 
with immunity both in cross-sectional and prospective analyses, concluding that 
increased left HL is associated with better immune function (Sumner et al., 2011). A 
prior study examining the effects of HL on immunity in HIV patients (CD4+ and 
CD8+ T-cells) showed that left HL predicted a better prognosis and right HL a poorer 
prognosis prospectively at 30 months (Gruzelier et al., 1996). Despite the encouraging 
results from this earlier study, there was very little control for potential confounding 
variables, most notable of which was baseline immunity. It was the objective of the 
present study to replicate and advance these findings in a more diverse sample of 
HIV+ patients, with more rigorous control for potential confounding variables, 
relating either to the disease, immunity or those neurological factors that may impact 
upon the assessment of HL. It was hypothesised that left HL would predict a better 
immune-specific prognosis in HIV, as indicated by a relatively higher prospective 
CD4+ T-lymphocyte count. In order to assess this relationship, a number of potential 
covariables were also identified and analysed. These variables included those 
pertaining to potential psychosocial factors contributing to HIV prognosis (levels of 
depressive and anxious mood, relationship status, level of education and ethnicity), 
and those biomedical factors related to, or potentially causing factors related to, HIV 
prognosis (medication use and adherence, duration of illness, mode of contraction, 
condom use, frequency of condom use, addictive substance use and baseline 
immunity). Confounding variables for this relationship were selected a priori from 
indications from the literature, to be included in the main multiple regression analysis 
of the whole sample. The finding of this main multiple regression analysis examining 
the relationship between left HL and immunological outcome did not attain statistical 
significance. However, the dataset presented significant skewness (see Appendix C), 
with outliers being identified amongst the main independent variable of HL. Further 
analysis employing a simplified statistical strategy (Spearman’s rho correlation), but 
retaining the objective of covariable control by way of using standardised residuals 
for outcome (T3) CD4+ count, showed a significant, positive relationship between left 
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HL (HPT) and prospective CD4+ T-cell count, independent of baseline CD4+ level 
and HAART status. This analysis indicated that approximately 5.5% of the variance 
observed in outcome CD4+ levels could be attributed to LHL, controlling for baseline 
CD4+ counts and medication use, providing a small (r ≥.1) to medium (r ≥.3) effect 
size as designated by Cohen (1988). This finding, albeit relatively modest, is in line 
with those found in previous HIV+ patient samples (Gruzelier et al., 1996) and 
amongst the wider literature describing a relationship between left HL and better 
immunity (Sumner et al., 2011).  
 
Moderation Effects 
Ethnicity 
A potential moderating factor was identified in ethnicity, by the observation of 
potential relationships between this variable and several other confounding variables 
(e.g. gender, level of education, employment status, sexual orientation, mode of HIV 
contraction, cognitive function and number of sexual partners). Statistical analyses of 
these potential confounding variables showed significant relationships between CD4+ 
T-cells, the artificial baseline (retrospective) CD4+ count and HIV medication status 
(Highly Active Antiretroviral Treatment; HAART). 
As the sample sizes were reduced for the moderator analyses, Spearman’s rho non-
parametric correlations were employed. No significant associations were observed in 
the European or African sub-samples, however both correlations were near statistical 
significance.  
These findings suggest that ethnicity may be a moderating factor in the HL-HIV 
progression relationship; however the data presented within this current sample were 
not of a sufficient size to adequately ascertain the extent of this moderation. The 
rationale behind ethnicity as a moderating factor has merit when considering the 
distribution of viral subtypes of HIV, the associations of HAART efficacy and viral 
virulence within these different subtypes. Subtype B is more commonly found in 
Europeans than other viral subtypes (Klimas et al., 2008; Roquebert et al., 2009). 
Africa has regional subtype prevalences, with the continent as a whole showing 
predominance of subtypes A, C, D and CRF02_AG (Klimas et al., 2008; Roquebert et 
al., 2009). It has been suggested that of all the main global HIV viral subtypes, clade 
B (most prevalent in Western Europe) presents a slower progression of HIV disease 
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than all other non-B subtypes (Spira et al., 2003). Additionally, the chemical agents in 
the spectrum of HAART have largely been designed for, and tested with, subtype B 
virus – making their efficacy most pertinent to those patients with this viral subtype 
(Spira et al., 2003) – mostly Western nations (Western Europe, North America and 
Australia). It is therefore possible that both ethnicity and HAART together may mask 
or moderate the HL-HIV prognosis relation. Thus, the examination of HAART as a 
moderator was conducted as well, however the sample was too small to test both 
factors as moderators together. 
 
Medication 
The examination of HAART medication as a potential moderating factor has clinical 
significance and practical value amongst the present dataset. The study was initially 
intended to only examine HL effects in HAART-naïve patients, and so examining the 
implication of including HAART-treated patients was a valid means of understanding 
this methodological compromise. Further, as the initiation of HAART treatment 
signifies a clinically distinct period in HIV disease (initiated once CD4+ T-cell levels 
decline below 350/mm3 (Hammer et al., 2006)), whether the HL-immune relationship 
differs in either side of this point can help to understand the biological mechanisms of 
the relationship and the practical application of targeted interventions.  
The Spearman’s rho strategy using standardised residuals to account for the 
confounding variable of baseline (T1) CD4+ count provided a significant, positive 
relationship between left HL (HPT) and prospective immunity only in those patients 
who were not receiving antiretroviral treatment. This analysis indicated that 
approximately 39.3% of the variance observed in outcome CD4+ levels could be 
attributed to LHL, controlling for baseline CD4+ counts, providing a large (r ≥.5) 
effect size as designated by Cohen (1988). 
These new findings present a new dimension to the current knowledge on HL in HIV 
disease. The Gruzelier group study (1996) included patients from an early-HIV 
Zidovudine drug trial, with 11 patients taking a placebo and 16 drug-treated patients, 
so the present findings are not entirely concordant. However, modern HAART 
comprises many new drug classes, being prescribed as combinations in either fixed 
doses or cocktails, therefore complicating the direct comparison from the Gruzelier 
study to the present findings. Whilst it was beyond the remit of the present study, it is 
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possible that there may be further differences amongst types of treatments within the 
HAART-treated group, with chemical classes being used to combat various different 
parts of the HIV virion life-cycle, from cell infiltration to reverse-transcription. It is 
also possible that the effects of HL on HIV progression in the Gruzelier study were 
only observed in those patients taking the placebo, and that this relationship (as it was 
measured over 36 months, and in a proportional placebo-to-treatment sample split 
(N=11:16)) was strong enough to withstand a null relationship in the treated sub-
sample, however this kind of testing was not reported. This theory is not entirely 
speculative, as it is how the findings appear in the present study, with overall 
statistical significance in the whole sample employing the same statistical test as that 
which described discrepant findings amongst treatment groups, in more unevenly split 
groups (non-treated versus HAART treated, N=11:41). 
Across the broader context of the literature, these findings support those of other 
studies that have examined the effects of HL on T-cells in patient groups (Ivashkova 
et al., 2002; Meador et al., 2004; Tarkowski et al., 1995; 1998). Further, the effect 
size observed (r=.627) was of similar magnitude (i.e. “large” in Cohen’s designation 
(1988)) to that reported as a mean effect size (r=.536) amongst the HL-immunity 
literature (Sumner et al., 2011); despite the present study’s higher degree of third 
variable control. However it should be noted that this sub-sample size (N=11) was 
significantly lower than the mean for the previously reviewed studies (N mean=39.72) 
and smaller sample sizes can, by their nature, produce larger effect sizes (Givens et 
al., 1997).  The lack of statistical significance for the relationship in the HAART-
treated sub-sample is in contravention to the literature, yet when considering the 
statistical significance of the whole group this finding may not be erroneous; however 
the findings will require replication.  
 
Differential predictive value of LHL in prospective immunity for non-treated 
HIV patients 
Why left HL is predictive of CD4+ outcome in treatment-naïve patients, but not 
HAART-treated patients, is not immediately clear. It is interesting that the non-
significance of the HAART-treated sample correlation is attenuated by the 
relationship in HAART-naïve patients when the sample is analysed as a whole. This is 
further complicated by the consideration of the mixed-treatment sample (albeit with a 
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less sophisticated monotherapy based treatment) in the Gruzelier group study (1996). 
It is possible that as HAART has a directly anti-viral action, with an indirect 
immunological action, and HL has an immunological action, with potentially indirect 
antiviral action, their presences may compete with each other in the overall outcome 
on HIV (see figure 9) or they may possibly interact with each other. As HAART 
controls HIV viraemia, the circulating numbers of immune cells (most notably T-
cells) are increased (Deeks, 2006; Simon et al., 2006). HL is suggested to modulate 
immunity at the system and cellular level (Koch et al., 2006; Tarkowski et al., 1995; 
1998), which could, in turn, help to control HIV viraemia. Equally, it could be 
possible that if both left HL and HAART are working in unison toward 
immunopotentiation, that the effects of HL in the presence of HAART may be 
nullified or masked. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. A proposed conflict of influence of HL and HAART in HIV prognosis. Both indirect and 
direct influences of HL and HAART can be possible on both T-cells and VL. 
 
When examined within the context of the broader literature, it is clear that HAART 
affects other aspects of immunology that are affected by HL. For example, induction 
of HAART treatment has been shown to affect plasma levels of interleukin (IL) -10, 
HIV Progression
VL T-Cells
HAART HL
 135 
neutrophil function and antigen-induced lymphocyte proliferation (Amirayan-
Chevillard et al., 2000; Lange et al., 2002; Mastroianni et al., 1999; Powderly et al., 
1998). When compared to HIV- controls, and untreated HIV+ patients, the elevated 
levels of plasma IL-10 observed in HIV disease have been described to return to 
levels comparable with healthy controls (Amirayan-Chevillard et al., 2000, Orsilles et 
al., 2006). Dziedzic et al. (2003) demonstrated that left-sided haemorrhagic stroke 
induced increases in circulating IL-10, suggesting that left HL effects on this anti-
inflammatory cytokine may be masked by HAART treatment, as they effectively both 
work to decrease circulating IL-10. Similarly, impaired lymphocyte proliferation to 
antigen observed in HIV disease has been seen to rebound after initiation of HAART, 
to levels analogous to healthy controls (Lange et al., 2002; Powderly et al., 1998), 
which has been associated with an increase in memory T-cells (Wendland et al., 
1999). Kang et al. (1991) and Ivashkova et al. (2002) both reported that left HL (in 
higher prefrontal EEG activation and right-hemispheric stroke respectively) was 
related to higher levels of lymphocyte proliferation to a T-cell specific mitogen 
(Phytohaemagglutinin), indicating that again HAART may mask left HL effects, as 
they both work in the same direction: to increase lymphocyte proliferation. The 
Ivashkova group (2002) also reported an increase in the function of neutrophils 
following right-sided stroke, with Koch et al. (2006) additionally reporting an 
increase in white blood cell count after stroke in the same hemisphere, these findings 
were inverse for stroke in the left-hemisphere in both studies. HAART has been 
demonstrated to increase the functional activity of neutrophils and monocytes in HIV 
patients, who classically exhibit a detriment in this index of immunity (Mastroianni et 
al., 1999).  
However, on examination of other immune indices demonstrated to be affected by 
HL, the pattern of HL and HAART working to influence immunity in the same 
direction does not consistently hold. The Koch group (2006) examined C-reactive 
protein (CRP) in patients after either left- or right-sided ischemic stroke. In this study 
they found that when the two groups were compared to each other, right-sided 
ischemic patients showed relatively lower levels of CRP than left-sided stroke 
patients (Koch et al., 2006). This marker of inflammation has been shown to be 
elevated in HIV patients, and this elevation is not ameliorated by the use of HAART 
(Regidor et al., 2011). Whilst CRP may be naturally elevated in a stroke patient, 
irrespective of location of ischemia, there is a differential observed from lateral 
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localisation that is not apparently mimicked by HAART in HIV. Similarly, natural 
killer cell activity (NKCA) has been demonstrated to be affected by HL, with the 
Kang (1991) and Davidson (1999) groups describing increases in NKCA in left-
lateralised participants, and Kang et al. also describing an inverse relationship for 
right-lateralised participants. In HIV disease, NKCA is markedly increased compared 
to healthy controls, and this increase normalises with HAART (Parato et al., 2002). 
Therefore, HAART does not seem to echo the actions of left-HL across all immune 
parameters thus far mutually researched. It is possible that the left hemisphere has 
more than just an immunopotentiating role. Given that these elevated levels of CRP 
and NKCA are above healthy parameters in HIV, there would be no need to increase 
them. Speculatively, it could be possible that the left hemisphere also serves as an 
allostatic decision maker, whereby it only acts to increase immunity if that increase is 
required.  
Whilst it was beyond the remit of the present study to evaluate other indices of 
immunity in this HIV sample, immune cells do not work in mutual exclusion, and so 
analysis of HL in relation to these other aspects of immunity would be beneficial. Not 
only would this help to understand why the presence of HAART may obliterate HL 
effects on HIV-specific immunity, it could also potentially serve to describe the 
mechanisms of how left HL provides a beneficial prognosis in untreated HIV disease. 
The chemical agents of HAART, whilst effective and crucial to prolonged survival 
with an HIV diagnosis, are nonetheless beleaguered with tolerance and toxicity effects 
and can cause potentially severe side-effects in patients (Deeks, 2006). The longer a 
patient can maintain a good standard of health before having to commence HAART 
treatment, the longer these negative consequences can be postponed, thereby 
increasing quality of life and potentially survival. Of equal merit is the consideration 
that if left-HL provides a better pre-treatment HIV prognosis, then this could become 
a potential target for intervention; crucially an intervention without financial burden, 
restriction of freedom (e.g. avoiding drug interactions, maintaining a strict pill 
regimen) or the necessity of further clinic attendance or medical monitoring. An 
interesting avenue of future research would be to examine the effects of activating 
left-HL in HAART-naïve HIV patients across multiple indices of immune activity and 
function.  
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Mediation Effect – The lack of contribution of mood 
The present study showed a lack of implication of mood in mediating the observed 
relationship between HL and HIV prognosis. In the present participant sample, neither 
indices of mood (anxiety and depression as measured by the Hospital Anxiety and 
Depression Scale; HADS) correlated significantly with HL or with outcome CD4+ T-
cell count. Previously, Gruzelier et al. found that mood impairment (measured by the 
HADS and the Profile of Mood States) predicted outcome helper T-cell counts in their 
sample, although did not correlate cross-sectionally at study commencement. 
Unfortunately the Gruzelier group did not report including mood in their HL-immune 
relation tests, so it is not possible to make a direct comparison here. Anxiety and 
depression are both known to have deleterious effects on HIV progression, in 
subjective experience and clinical prognostic markers (Chida & Vedhara, 2009; 
Hartzell et al., 2008; Leserman, 2003). Equally, mood has implications on HL, with 
overall activation being suggested to switch from left to right during certain adverse 
mood states or situations such as exam stress (Lewis et al., 2007). Furthermore, there 
are suggestions that prolonged states of stress may result in volumetric reductions in 
the left medial prefrontal cortex (Cerqueira et al., 2008), potentially physically 
altering the activational asymmetry of this region. 
Although it might be expected that there should be a mediation effect here, due to the 
well-documented relationship between mood and HIV prognosis, the present findings 
are not discrepant with the formerly reviewed HL-immunity studies. Of those studies 
that also examined mood alongside HL-immune assessments, there was a consensus 
that the observed HL-immune relationships were independent of mood or stress 
(Davidson et al., 1999; Kang et al., 1991; Meador et al., 2004). In fact, one of the 
studies examining prefrontal activation asymmetry found no significant differences in 
mood between left and right HL groups (Kang et al., 1991).  
In a range score of zero to 21 in both scales, the present sample attained a mean score 
of 7.32 (standard deviation= ±4.42) in the anxiety subscale and 4.15 (standard 
deviation= ±3.52) in the depression subscale. Although no concrete cut-off scores for 
indicative diagnosis have been set, the originators Zigmond and Snaith have 
suggested that a score of between seven and eight on either scale would indicate 
“possible” morbidity, and a minimum score of 10 or 11 indicates “probable” 
morbidity (Herrmann, 1997). With these guidelines, the present sample would 
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indicate a mean level of “possible” anxiety, and a sample mean below “possible” 
depression. In comparison to the sample from the Gruzelier group’s (1996) study, the 
present sample represented a more anxious and more depressed mean score; however 
the scores, and variance thereof, were comparable to others observed in HIV 
populations (Savard et al., 1998) and healthy populations (Crawford et al., 2001).  
 
 
HEMISPHERIC LATERALISATION & HIV-RELEVANT BEHAVIOUR 
Exploratory analyses were conducted to assess the implication of HL on behaviour 
relevant to HIV health. These analyses were conducted in order to understand 
potential behavioural mechanisms involved in the HL-immunity relationship within 
the HIV context. A number of significant associations were uncovered, as well as 
some potential trends amongst the whole sample, and ethnicity-split subsamples.  
High-Risk Sexual Behaviour & HL 
Number of Sexual Partners 
Of most relevance to HIV, a negative relationship trend was uncovered between LHL 
(as measured by the LBT) and the number of sexual partners reported in the prior 12 
months in both the whole sample and European subsample. In the whole sample the 
effect size of the relationship was between small (0.1) and medium (0.3) as designated 
by Cohen (1988), and was non-significant (p=.071); which once reduced to the 
European subsample increased to over a medium effect size and attained statistical 
significance (p=.017). This relationship suggests that left HL is associated with fewer 
sexual partners, most specifically in Europeans, and this is the first documented 
association of this sort in the contemporary literature on HL and health, to the best of 
my knowledge.  
This finding is important because of the associated risks for accelerated HIV 
progression following superinfection with more than one type of HIV virus (Blackard, 
et al., 2002; Smith et al., 2005), often associated with having multiple partners. It is 
also a high-risk behaviour for an individual to contract another sexually transmitted 
infection or blood-borne pathogen, such as Syphilis or Hepatitis, which has 
consequences not only for accelerated pathogenicity, but also for increased HIV 
transmission probability (Gore-Felton & Coopman, 2008; Kaul, et al., 2008; Soriano 
et al., 2010). Clearly more sexual partners do not necessarily suggest superinfection, 
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however the risk of superinfection is obviously higher for an individual who has many 
sexual partners in comparison to an individual who has none.  
There is currently no data on the impact of HL on high-risk behaviours such as the 
number of sexual partners, with or without implications of ethnicity. As it would be 
classified as approach behaviour, associated with left-HL (Coan & Allen, 2003; 
Davidson, 2003), it is curious that the relationship is not in the opposite direction. 
Additionally, risky behaviour is largely a left-brain cognitive process (Krain et al., 
2006), which one would again expect to result in an opposite correlation. It is possible 
that, as the left hemisphere is responsible for analytic processing (Bradshaw & 
Nettleton, 1981), this type of thinking may supersede approach, impulsive or risk-
taking behaviour.  
It should be noted that no such associations were observed for condom use in the 
whole sample or European subsample, which has a significant implication for this risk 
behaviour. Were there a similar association between HL and condom use, the 
implications of the present finding would be extremely clear. Furthermore, there was 
no observable relationship between number of sexual partners and condom use either.  
Condom Use 
The collection of condom use data was a synthesis of condom use surveillance 
weighed against sexual activity. The scoring of the scale was proportional to the risk 
of the behaviour (i.e. a score of 1 represented low risk sexual behaviour, a score of 6 
the highest risk sexual behaviour).  
In the African subsample a trend was observed for an inverse relation between LHL 
(as measured by the HPT) and condom use. Whilst this was only an observed trend, 
and the correlation did not attain statistical significance, the effect size was medium in 
accordance to Cohen’s (1988) guidelines. Sample size calculation, given the 
correlation coefficient, an alpha level of 0.05 and a beta level of 0.8 projected that 61 
participants would be required to attain a statistically significant result. However, the 
current sample consisted of just 23 African patients.  
Whilst it should be noted that the analyses for the whole sample and subsamples were 
not significant, it is worthwhile considering why these discrepant findings were 
observed in the present dataset. As condom use is relevant not only to the disease 
progression of the individual, but also to the development of the global pandemic of 
HIV (by the facilitation of transmission), it is an important factor to consider in HIV 
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behavioural medicine. Further studies need to investigate more clearly the HL-
condom-use relationship. 
Many variables have been uncovered as impacting upon condom use in a recent 
review by Sarkar (2008). This review details religion, ethnicity, sexuality, gender and 
social barriers to condom use; suggesting in synthesis that African women are one of 
the most vulnerable groups for condom non-use (Sarkar, 2008). The barriers 
presented to this demographic group come from societal conventions concerning 
modesty, submissiveness and the association of condoms with promiscuity; religious 
barriers (most specifically within Catholic communities) and social equality, whereby 
women have less opportunity or right to negotiate condom use (Sarkar, 2008).  
Addictive Substance Use & HL  
Amongst both the full sample and European subsamples, a negative association was 
observed between LHL (as measured by the LBT) and reported marijuana use in the 
prior month to interview. Amongst the whole sample this relationship constituted a 
small to medium effect size, which then grows to a medium effect size in the 
European sample (Cohen, 1988). It is worthwhile noting at this stage that no African 
patients in the present sample reported using marijuana in the past month, hence the 
lack of association among them. Similarly there were no reports of cigarette/tobacco 
or cocaine use amongst that subsample. In the European subsample, further 
relationship trends were uncovered between LHL (LBT) and cigarette/tobacco use 
(negative association), and LHL (HPT) and cocaine use (positive association) in the 
past month.  
Interestingly, the associations observed for the two stimulants (nicotine, cocaine) are 
divergent, with the cigarette/tobacco trend showing negative directionality and the 
cocaine trend showing positive directionality. Clearly further research in to these 
phenomena is required, both within and without the HIV context.  
HIV Clinic Attendance & HL 
Although not statistically significant, a trend was observed amongst the African 
subsample for the mean time between HIV clinic visits. This association (p=.092) 
provided a negative relationship between LHL and mean time between visits. This 
suggests that in the African subsample, LHL was predictive of smaller time gaps 
between visits to the clinic for HIV surveillance. Clinic attendance is important for 
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HIV surveillance, both in terms of the immunological assessments that are required, 
but also to assess the suitability and efficacy of HAART regimens. Previous studies 
have suggested that ethnic minority status predicts greater non-attendance to HIV 
clinics, amongst other variables (Catz, et al., 1999; Israelski et al., 2001), which could 
explain why this relationship was only found in the African subsample. The European 
subsample showed a mean time between visits of 109.32 days (standard deviation 
±36.08 days) and the African subsample showed a mean time of 111.15 (standard 
deviation ±30.49 days), differences between these means were not significant. Given 
that minorities may visit clinics less or manifest longer time gaps between visits, 
identifying those with low left-HL could possibly enable the identification in advance 
of those who may be at risk for poorer clinic attendance, and thus would require more 
reminders.  
It is possible that HL is associated with clinic attendance in the present subsample due 
to its associated effects on behaviour – with LHL being associated with approach 
behaviour (Davidson, 2003). However, it should be noted that less clinic attendance is 
associated with other factors, not just ethnicity. In fact, younger age, less severe 
illness, heterosexual orientation and lower perceived social support have also all been 
correlated with non-attendance to HIV clinics (Catz et al., 1999; Israelski et al., 
2001). In this regard, the present African sub-sample was comprised of more women, 
and more heterosexuals than the European sub-sample, however the duration of 
illness (a possible indicator of illness severity) and age were comparable between the 
sub-groups.  
 
THE ROLE OF HEMISPHERIC LATERALISATION IN IMMUNITY AND 
HIV-1 PROGNOSIS 
The synthesised literature review presented in chapter 3 and published (Sumner et al., 
2011) concerning HL and immunity provides compelling evidence for differential 
immunomodulation by the two hemispheres of the brain. All of the presently 
reviewed studies describe an immunopotentiating role of the left hemisphere and an 
immunosuppressant role of the right. The combined weight of the reviewed studies is 
such that the research focus must now shift from hypothesis testing to exerting more 
control in order to understand the depth and mechanistic dynamics of the relationship. 
Indeed, the next logical step in the field is to continue these examinations exerting 
more methodological control over potential confounding variables, and the 
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examination of moderating and mediating factors. One already nascent avenue of such 
research is the examination of specific areas of the brain that may drive the 
communication of immunomodulation to the periphery, and the associated chemical 
transmitters that provide this communication. The findings of the systematic review 
now suggest the discipline of HL-immunity research can be considered to be 
evidence-based, and must now expand to consider the broader context of health and 
disease consequences; such as the assessment of HL’s prognostic capability amongst 
other leading world health concerns (e.g. cardiovascular disease, cancer), vaccine 
efficacy and intervention strategy.  
One of the previously reviewed studies suggested that HL could explain some of the 
variance observed in HIV pathogenesis (Gruzelier et al., 1996). HIV pathogenesis is 
known to vary greatly between individuals, and whilst some risk factors for this 
variance are known, much of the variance observed is still unexplained (Lama & 
Planelles, 2007; Langford et al., 2007; Leserman, 2003). In the spirit of the future 
research indications of the systematic review conducted, the present study sought to 
advance those findings in a contemporary sample of HIV patients, while exerting 
more control over confounding variables than Gruzelier et al. (1996) to assess 
whether these findings would withstand more rigourous testing. The present study 
provides some support for HL influencing HIV progression, and furthers this support 
to describe a moderator - HIV medication. However the findings are far from resolute, 
and will require replication and further advancement to incorporate more 
comprehensive immunological analyses in order to stand amongst the existing 
literature.  
In line with the synthesised findings of the wider literature, the present analyses 
support the argument of an immunopotentiating role of the left hemisphere. In 
accordance to the studies of Ivashkova et al. (2002), via transcranial electromagnetic 
stimulation to the ischemic left hemisphere, Gruzelier et al. (1996), via prospective 
association, and Meador et al. (2004), via post right-hemispheric surgery prospective 
association, the current analyses suggest left HL predicts upregulated CD4+ T-cell 
populations. Critically, the present research has extended these previous findings by 
exerting more methodological control over potential confounding variables associated 
with both HIV-immunity and laterality, and including a broader (perhaps more 
representative) profile of HIV+ patients, all of which the former study did not do. 
However these findings do need to be viewed with a degree of caution. Crucially, not 
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all analyses provided significant results for the whole sample, or moderator-analysed 
sub-samples. The planned multiple regression analysis yielded no significant results, 
but the more simple correlational analysis did, for both the full sample relationship 
and the HAART-moderated sub-sample analysis, but not for the ethnicity-moderated 
analysis. It is possible that the large amount of skewness present in the main 
independent variable is responsible for this discrepancy, and therefore that there was a 
critical methodological flaw in the research design – namely the measures of HL 
employed. Of the previously reviewed studies that required HL assessment (i.e. HL 
was not created by cerebral trauma), all of the studies used EEG assessments with or 
without accompanying neuropsychological evaluation.  
 
Neurobiological Pathways for HL Driven Immunomodulation 
Although specific exploration of the potential neuroimmune pathways that facilitate 
this relationship was beyond the remit of the present work, there still exists literature 
which could elucidate the relationship between HL and immunity. The main findings 
of the studies relating HL to immune function are further elaborated when including 
research that has looked into specific areas of the brain and immune function. One of 
the previously reviewed studies already took that step. The Davidson research group 
related their findings not just to HL patterns but also to the areas of HL-brain activity, 
highlighted by EEG, most strongly related to peripheral immunity. This study 
revealed that the HL-differences at mid-sensorimotor and anterior temporal regions 
were the differences most strongly related to natural killer cell activity (NKCA) 
(Davidson et al., 1999). These results have been echoed in other studies using 
positron-emission tomography (PET) in various samples of participants, with the 
addition of more specific areas that are discoverable with such methodology 
(Lekander et al., 2000; Matsunaga et al., 2008; Ohira et al., 2008; Tashiro et al., 
2001; Wik et al., 1998). These studies have also found that greater immune function 
(NKCA and lymphocyte proliferation) is related to activity in the secondary visual, 
motor and sensory cortices; hippocampus; putamen; thalamus; anterior cingulate 
cortex; posterior parietal cortex; and several areas of the prefrontal cortex (Lekander 
et al., 2000; Matsunaga et al., 2008; Ohira et al., 2008; Tashiro et al., 2001; Wik et 
al., 1998).   
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One PET study by Matsunaga et al. (2008) examined the relationship between areas 
of cerebral activation and immune indices in positive and neutral affect. They found a 
positive correlation between NKCA and dopamine (DA). The increases in NKCA and 
DA were related to increased activity in areas of the brain such as the medial 
prefrontal cortex, thalamus, hypothalamus, cerebellum, posterior cingulate cortex, 
subcallosal gyrus and superior temporal gyrus during experience of positive affect 
(Matsunaga et al., 2008). This echoes the findings of the Davidson work group who 
demonstrated, also under conditions of positive affect, that regions in the mid-frontal 
brain (medial prefrontal gyrus) and mid-temporal region (medial temporal gyrus) on 
the left side of the brain correlated with NKCA (Davidson et al., 1999). DA receptors 
have also been described on T-cells, B-cells, granulocytes and 
monocytes/macrophages as well as NK cells (Basu & Dasgupta, 2000; Levite, 2008; 
Wrona, 2006). Studies using mouse models have also found lateralised effects on T-
lymphocyte proliferation and NKCA after unilateral lesions to dopaminergic brain 
regions such as the nucleus accumbens and striatum, with left-sided lesions 
decreasing NKCA (Deleplanque et al., 1994). In synthesis, this suggests that left-
sided dopaminergic areas of the brain are related to higher levels of NKCA, meaning 
DA could serve as a neurotransmitter in brain-to-immune communication.  
Further, associations have been made between dopaminergic areas of the brain, such 
as the mesostriatum and substantia nigra, and the production of Substance P (SP) in 
rats and humans (Gerfen et al., 1991; Mai et al., 1986). This could potentially impact 
upon the HL-HIV immunity relationship with relevance to the previously discussed 
implications of SP in HIV. To recapitulate, SP has a reciprocal relationship with HIV 
virus in vivo, creating a feed-forward cycle where the existence of one upregulates the 
other (Ho et al., 2002; Kopnisky et al., 2004; Leserman, 2003). The presence of SP 
stimulates the release of proinflammatory cytokines such as Tumour Necrosis Factor 
(TNF), which promote the release of new target cells for infection (Ho & Douglas, 
2004; Kopnisky et al., 2004; Li et al., 2001). Moreover, SP promotes the activation of 
CCR5 on target immune cells – a particularly relevant factor for R5-tropic HIV virus 
(Li et al., 2001), and can activate cells latently infected with HIV (Ho & Douglas, 
2004; Li et al., 2001). HIV virus also increases the blood levels of SP, thereby 
creating this positive feedback cycle (Ho et al., 2002). Therefore, if dopaminergic 
regions of the brain can impact upon the generation of SP, which can then in turn 
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impact the availability of HIV target cells, there is the possibility that DA and SP may 
have a synergistic impact upon HIV virology and pathogenesis. However, the 
directionality of the relationship between DA and HIV is not altogether clear, given 
its relationship to SP, and so this postulation requires deeper investigation.  
Another potential means of explaining the mechanisms behind the HL-immunity 
relationship is via the autonomic nervous system (ANS). The cholinergic anti-
inflammatory pathway is a well described interface between the brain and the immune 
system, and relies on the parasympathetic cascade of acetylcholine to inhibit the 
proinflammatory response originating in monocytes (Tracey, 2002). More well-
documented is the relationship between the sympathetic division of the ANS and 
immunity. The sympathetic nervous system (SNS) innervates primary and secondary 
lymphoid organs (Banks, 2004; Wrona, 2006). There are also receptors for β-
adrenergic (sympathetic) agents present on the surface of a wide range of immune 
system cells (Besedovsky & Del Ray, 1996; 2007; Taub, 2008). Recent evidence has 
suggested an immunomodulating effect of the SNS on CD8+ T-lymphocytes (Grebe et 
al., 2009). Further, an experiment involving the surgical sympathectomy of mice 
abolished the HL-immune relationship when the surgery was conducted at the T1 
vertebra (removing SNS activity), however sectioning at lower vertebrae did not have 
these effects (Moshel et al., 2005). It is therefore possible that the SNS has mediating 
effects in the HL-immune relationship.  
 
 
LIMITATIONS 
Whilst the present study was designed to replicate and extend the findings of the 
Gruzelier group using more meticulous methodology and strict control over third 
variables, there exist many limitations in this study as well. As an overall comment on 
limitation, the extensive statistical testing risked a type I error, it was however 
necessary given the initial lack of significance, and general paucity of research in this 
specific field. 
Sample Size & Composition 
Perhaps the most vital limitation to the present study is the sample size, further 
compounded by the previously discussed issues with encoding of the HPT. The initial 
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statistical projection suggested a sample of between 67 and 77 participants in order to 
adequately assess the relationship using multiple regression analysis. A total sample 
size of 68 was finally attained, after exclusion of three participants whose data could 
not be included due to comprehension problems. This sample was then further 
reduced to 63 for all analyses employing the HPT as a variable (due to encoding 
errors), bringing the total to just below that which was required. Furthermore, several 
patients’ immunological data were not available for all three data collection points, 
meaning those analyses that involved immunological parameters were further 
reduced. Whilst it is not being suggested that this issue was the only one responsible 
for the lack of statistical significance in the main analysis, it is a fundamental issue in 
statistical analyses, and as such, cannot be overlooked as having a potential impact. 
 
One of the main reasons for the difficulty in attaining an adequate sample was perhaps 
the amount of exclusion factors that were ascertained before recruitment. For 
example, by excluding substance-dependent patients the potential available sample 
could have been significantly reduced. It has been supposed that injection drug users 
constitute a significant proportion of HIV+ patients in Western samples alongside men 
who have sex with men (MSM) (UNAIDS, 2010). Moreover, there is a high 
prevalence of addictive-substance dependence amongst HIV samples outside of the 
injection drug use domain (Cabral, 2006; Fiellin, 2004). It was important to exclude 
all such cases in the present study due to the associated impact that addictive-
substance dependence has on both HIV progression, HIV medication adherence and 
cerebral function (Basso & Bornstein, 2000; Jernigan et al., 2005; Uldall et al., 2004). 
Similarly, the exclusion of patients with a clinical diagnosis of psychological 
morbidity may also have significantly reduced the potential sample size. There is a 
well-documented high prevalence of psychological comorbidity within HIV+ patients 
(Gibbie et al., 2006; McCain et al., 2003; Milam, 2006), with further well-
documented consequences for such comorbidities upon disease progression (Chida & 
Vedhara, 2009; Evans et al., 2002; Klis et al., 2011). Whilst these exclusion factors 
are considered to be one of the key strengths of the present study as they reflect 
methodological control, they could also have led to limiting the potential sample size 
and/or diversity. 
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The composition of the present sample is also an area for concern, and impacts upon 
the generalisability of the present findings. With the previously discussed issues of the 
high prevalence of substance dependence and psychological comorbidity within HIV 
patient samples, the present sample has limited generalisability to general HIV 
populations. Furthermore, although the present sample exhibited some ethnic 
diversity, the two subsamples of Europeans and Africans were neither equal in 
number nor composition. Moreover, as the sample was composed of mainly Africans 
and Europeans, the representation of various HIV viral subtypes will undoubtedly be 
disproportionate. As previously discussed, viral subtype has significant implications 
for viral virulence and HAART efficacy, and could be an important factor in the 
present study’s outcomes (Spira et al., 2003).  
HAART Use 
Despite the significant moderator analysis based around treatment group observed in 
the present research, HAART can still be considered to be a limitation. Including only 
HAART-naïve patients would have allowed a more sensitive analysis for the present 
study, and this was indeed the original recruitment protocol. However, due to the 
relative paucity of these patients at the time of recruitment, and the subsequent impact 
upon recruitment rate, it was decided that patients taking a HAART regimen should 
also be included, and the effects of this variable on outcomes were tested. HAART is 
designed to reduce VL counts to near-undetectable levels, and its efficacy is assessed 
on its ability to do so (Deeks, 2006). Therefore, the inclusion of HAART-taking 
patients effectively invalidated the use of VL data as an outcome for the main 
analysis. Moreover, the inclusion of HAART-taking patients presented further issues 
for analysis; for example the necessity of measuring HAART adherence. As 
adherence is vital to HAART efficacy, but is complicated by heavy pill-burden, 
unpleasant side-effects, drug toxicity and tolerance (Montessori et al., 2004; Wood et 
al., 2003); whether a patient adhered or not had potentially very large implications on 
the immunological assessments being recorded.  
Not only did the inclusion of HAART-taking patients present more methodological 
and statistical difficulties, it also compromised the validity of the present findings. 
Levelling a HAART-naïve patient against a HAART-experienced patient in analysis 
could be construed as at the very least impractical due to the associated effects that 
HAART has on HIV immunology (i.e. repopulation of T-cells and increasing VL 
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suppression) irrespective of the duration of HIV infection (Autran, 1999; Deeks, 
2006). The trajectory of immune cell loss versus VL increase would be markedly 
different between a non-treated and a treated patient, which is a potential explanation 
for the marginal significance of the main effect. Nevertheless, the effects of both 
HAART and adherence to it were examined in the present study. The inclusion of 
HAART-treated patients was nonetheless identified as a moderating factor, which has 
ultimately added to current knowledge on HL-immunity research, and so although it 
was a limitation in terms of the original intended protocol, it has provided a novelty to 
the present research.  
There may be additional implications for including a HAART-treated sample, in 
terms of whether the patient is taking a first- or second-line regimen, what chemical 
classes of drugs they are taking and whether or not they have had treatment 
interruptions. It was beyond the scope of the present study to analyse the respective 
regimens of each patient in detail and to consider this in the analysis, due to the 
sample size. Thus it is possible that several between-subjects differences on these 
important issues could have impacted upon the overall findings. For example, 
immunological outcomes of someone who has just started their first HAART regimen 
may be markedly different from those of an individual who has been on the same 
regimen for a few months even during that same period of time. Similarly, an 
individual who is taking a second-line HAART regimen (i.e. after first-line treatment 
fails) may not have the same immune reconstitution potential as someone who is 
about to start their first line of treatment. Further research employing both HAART-
treated and HAART-naïve patients is clearly needed, in addition to more exacting 
control over the line, type and duration of the treatment.  
Circumstantial Limitations 
The time constraints for the present study resulted in several compromises to the 
methodological ideal. Firstly, the period of study was significantly shorter than that 
which has been indicated by prior research (e.g. Gruzelier et al., 1996); and indeed 
that which was originally intended. The precedent for 30 months from the Gruzelier 
study may perhaps not have been necessary; however a follow-up period of 12 
months would have permitted not only more data collection points, but also a greater 
observable change. As previously outlined, HIV treatment guidelines suggest patients 
should be monitored every three to four months to adequately monitor HIV 
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pathogenesis trajectory and treatment efficacy (AIDS Education & Training Centers 
National Resource Center, 2009). Therefore, the use of three data collection points 
spanning approximately 6 months was not necessarily inadequate, but would 
constitute a minimum for assessing disease progression in HIV.    
Moreover, due to the restricted actual follow-up time, it was necessary to employ a 
retrospective artificial baseline to establish a longer total surveillance period. The 
largest methodological compromise for this restricted data collection period was in 
the use of a medically retrospective baseline (i.e. using medical data that predated the 
baseline collection of all other measures). The statistical tests employed for the 
present data analyses relied heavily upon the factoring-in of baseline immune 
parameters, which did not coincide with the true baseline for all other parameters, and 
therefore the findings must be viewed with caution. For example, it is possible that the 
previously discussed relations between mood and HIV progression were not found 
because of the discrepancy between the time when the immunological surveillance 
began and the time when the mood measurement was conducted.   
 
Future Directions 
Whilst the present findings suggest some support for the hypothesis of HL predicting 
prognosis in HIV-1, with the important moderator of HAART-treatment, the 
discussed observations and study limitations necessitate further research into the 
relationship between HL and immunity in HIV. The consideration of ethnicity within 
the context of HIV research is imperative, as Africans disproportionately represent the 
majority of HIV cases worldwide, as well as having some of the least financial and 
infrastructural capabilities to cope with the virus burden. Whilst the ethnicity-based 
moderator analysis ultimately yielded non-significant results, the basis for conducting 
that analysis was sound, and could potentially provide significant results in a larger 
sample. Further, and perhaps in accordance with that line of enquiry, analysis of these 
effects in different viral subtypes could provide an interesting avenue of research; not 
least to understand why some viral subtypes present more virulence than others. It is 
possible that these interact with HL in relation to outcomes. Identifying a moderator 
in HAART treatment has provided new knowledge in to the clinical relevance of HL 
in HIV disease; however the interpretation of these findings is far from clear-cut. 
What is not clear is why HAART-treated patients may not be subject to HL influence, 
and whether different stages in HAART treatment (i.e. first- or second-line, or even 
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salvage treatment) may present even further differences. Further analysis in to those 
immune indices that are affected in the same way by both HL and HAART (e.g. 
lymphocyte proliferation, neutrophil function, or circulating IL-10) together with 
HIV-specific immune outcomes (CD4+, CD8+, VL) could provide further insight in to 
why we would not see HL effects on patients treated with HAART. Outside of the 
HIV context, it may also be interesting to evaluate the influence of HL on CRP and 
NKCA due to the discrepant effects of left HL and HAART on these immune 
measures in HIV patients. Does the role of the left hemisphere also incorporate a 
“decision-taking” action in immunological allostasis?  
Of most importance is the need for replication of the present study with a larger 
sample, for a longer period of follow-up, with a broader profile of ethnicities and a 
more detailed account of HAART-treatment amongst patients.  
The exploratory analyses conducted with the present data also imply further effects of 
HL in the disease course of HIV, via behaviour. Although the present analyses did not 
yield any significant effects, it would also be interesting to assess the implication of 
HL on HAART adherence, which could perhaps be attainable with a larger sample of 
HAART-treated participants. The observed relationship between HL and the reported 
number of sexual partners is a new finding, and has important implications for HIV 
prevention strategies and sexual health initiatives outside of HIV. The reported 
associative trend with HL and condom use extends the importance of this new finding 
and its applications in health psychology. The assessment of the effects of a left-HL 
enhancing cognitive exercise on adherence to condom use, or medication, could prove 
an interesting and relatively simple interventional strategy, and could be of relevance 
to CD4+ T-cell counts if the present findings are replicated. Equally, the observed 
associations between HL and addictive-substance use behaviour could provide an 
interesting insight in to addiction and rehabilitation sciences.  
The reliance on neuropsychological tests for the assessment of HL in the present 
study provides some circumspection to the results, as they rely on either cognitive or 
behavioural assessments of this variable. Further, the performance of the line 
bisection task (LBT) has been argued to rely more on the cerebral organisation of 
cognitive processes, rather than on unilateral hemispheric activation (Floël et al., 
2005).  The use of neuroimaging or electroencephalogram (EEG) could provide 
further clarification of the validity of these measures in this context, as well as 
providing a potentially more detailed analysis of HL for a replication of the present 
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study. Indeed, the basis for the present study – the research conducted by the 
Gruzelier workgroup – employed EEG analyses alongside neuropsychological tests. 
However, other studies examining the relationship between HL and immunity have 
also employed neuropsychological approaches with success (e.g. Davidson et al., 
1999). 
 
Extraneous to the context of the present study, the field of HL and immunity has been 
shown to offer a variety of applications in other disease paradigms (Sumner et al., 
2011). Applying lateralisation theory to other disease models such as cancer could 
help to elucidate differential prognosis outside of those factors already identified as 
being related to disease outcome, given the role of cellular immunity in cancer 
prognosis (Galon et al., 2006). Furthermore, there is the potential for lateralisation-
immunity theory to provide interventions to ameliorate disease outcomes. If, under 
better conditions, HL can be seen to have a significant impact upon the prognosis of a 
disease such as HIV, targeted interventions could be devised and implemented in 
order to attenuate the effects of an unfavourable lateral balance. An interesting 
example of this comes from a study examining the effects of unilateral rTMS on 
salivary immunoglobulin A (S-IgA) (Clow et al., 2003). This small study described 
immunopotentiation (in increased S-IgA concentration) after application of left-sided 
rTMS, and could have far-reaching effects if it can be replicated in larger samples, 
and if the role of LHL in HIV observed here, is replicated. Neuropsychological 
“training” could also be possible to enhance the functioning of one hemisphere, and 
has already been described in the rehabilitation of stroke patients (Thimm et al., 2009) 
and the increasing of neural plasticity in older adults (Erickson et al., 2007). Finally, 
the implication of HL in understanding the efficacy of vaccines may also be another 
interesting avenue of research. One study has already described increased antibody 
responses to influenza vaccine in participants given mindfulness meditation, as a 
function of increased LHL (Davidson et al., 2003). This obviously not only has 
implications for vaccine development, but also suggests that HL can be enhanced in a 
clinically meaningful way outside of physical alteration (i.e. rTMS) or 
neuropsychological training, and may synergistically interact with medical 
interventions, possibly for the benefit of HIV patients as well. 
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THE ROLE OF HEMISPHERIC LATERALISATION IN 
IMMUNTITY AND HUMAN IMMUNODEFICIENCY VIRUS 
(HIV) -1 
The present thesis sought to evaluate the role of hemispheric lateralisation (HL) in 
immunity and HIV by the compilation of a systematic review and the execution of an 
empirical prospective study. To date, a systematic review of human research in to HL 
and immunity had not been conducted, and so a quasi-meta-analytic review was 
carried out to evaluate the current available data and the relative strengths of 
evidence. An empirical research was conducted to examine the relation between HL 
and the prognosis of an HIV+ outpatient sample, modelled on a prior study (Gruzelier 
et al., 1996) that indicated a relationship despite some key methodological confounds. 
 
Since the first studies into the immunomodulating effects of handedness conducted by 
Geschwind and Behan (1982), many other research groups have sought to understand 
the implications of HL on immunity in disease and health. These initial studies of 
handedness, although conceptually different to HL, provided an insight in to the 
differential management of the immune system by the brain and inspired research 
spanning the proceeding three decades. From these initial descriptions of immunity 
differences between left- and right-handed individuals, animal research conducted by 
Pierre Neveu and his colleagues expanded these associations from handedness to 
cerebral asymmetry (Neveu, 1988, 1991, 1992; Neveu et al., 1991; Neveu & Merlot, 
2003). Detailing immunological consequences of cortical ablation in animals with 
paw preference assessment (right- or left-pawed) the extensive studies of Neveu and 
his workgroups showed asymmetrical, and in some cases opposite, control over 
interleukin (IL)-1, IL-2, natural killer cell and T-cell proliferation as well as 
macrophage activation and T-cell mitogenesis (Neveu, 1988, 1991, 1992; Neveu et 
al., 1991; Neveu & Merlot, 2003). In so doing, he and his colleagues opened up a new 
field of research combining laterality theory with neuroimmunology. Since then many 
studies have been conducted with human participants, in both disease and health 
models using either a handedness or HL paradigm. Some contention has arisen as to 
the distinction between immunomodulation by handedness effects, and by HL effects; 
resulting in the separation of these two phenomena in research.  
 154 
The previously described review of the current literature concerning HL and 
immunity in humans provided support for differential modulation of the immune 
system by each hemisphere (Sumner et al., 2011). Amongst the 11 studies evaluated, 
there was a cumulative consensus that the left hemisphere is immunopotentiating and 
the right, immunosuppressing. The studies employed a variety of methods to assess 
the relationship between HL and immunity, in cross-sectional, prospective and 
experimental examinations. In order to assess the relative strength of the HL-
immunity relation in each study, effect size analyses were conducted, which revealed 
strong statistical HL-immunity associations overall. Summary remarks included the 
necessity of more rigourous control over third variables in testing the HL-immunity 
relationship (pertaining to each of the three disciplines contributing to 
psychoneuroimmunology), the need for replication in larger, more generalisable 
samples, and indications for more detailed research in locating those areas or 
processes of the brain that may cause these effects.  
 
One of the reviewed studies examined the effects of HL on immunity prospectively in 
a disease context (Gruzelier et al., 1996), helping to illustrate an application of 
laterality-immunity theory in HIV. By examining the effects of HL on immunity in 
HIV patients, Gruzelier and colleagues described differences in T-lymphocyte levels 
longitudinally; providing the first insight in to how HL can affect the long-term 
outcomes of a disease. This finding was important and timely, as it was conducted just 
before (1996) the advent of the era of highly-active antiretroviral therapy (HAART - 
1997) when HIV represented an aggressive, and rapidly fatal illness. During this era, 
HIV was largely uncontrolled by effective medication, and the epidemic continued to 
expand across the world, seemingly unabated. Since its discovery HIV has generated 
a wealth of research to understand its pathogenesis, with a wide variation of disease 
course being described between individuals (Lama & Planelles, 2007; Langford et al., 
2007; Leserman, 2003). A variety of explanations for this variability has been 
proposed; with psychological, host biological and virological factors all being 
described as contributing to disease course variability. However, despite three decades 
of research, these contributing factors have not accounted for all of the variance 
observed in the disease course of HIV.  
The findings from the Gruzelier study, and the combined findings of HL-immunity 
studies (Sumner et al., 2011), provided another potential factor to explain the 
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variability in HIV pathogenesis, namely HL. However, the Gruzelier investigation 
suffered from two key problems in being appropriately applied to HIV disease; 
several important methodological flaws and its pre-HAART era status. One of the 
most important methodological short-comings was the lack of control for baseline 
immunity and other confounders (such as duration of illness, age, gender etc.); a 
necessity in immunological research. Lack of control for confounders was a key 
limitation in all the reviewed studies, and indications were made to bring HL-
immunity research away from identification, and in to the realms of description – 
providing control for confounders, and analysing moderating and mediating factors. 
Further, the Gruzleier study suffered from a small sample size (N=27), comprised of 
only white, homosexual men; with no control for biological or neurological factors 
which could have impacted upon either HIV or the measurement of HL, or 
psychological aspects known to impact upon immunity in HIV (i.e. depression, 
anxiety) (Chida & Vedhara, 2009). Moreover, the study was conducted before the 
advent of HAART (1997), the most important “game-changer” in HIV since the 
epidemic began (Simon et al., 2006). This factor is important because although the 
Gruzelier study only used asymptomatic HIV patients, had the study been conducted 
more recently some participants may have been within the diagnostic guidelines for 
HAART treatment. It should be noted that the Gruzelier study sample was drawn 
from a larger sample of the clinical trials for Zidovudine (one of the first antiretroviral 
treatments), using both drug- and placebo-taking participants. Although this parallels 
the present study, insomuch as there is a mixture of drug-taking and drug-naïve 
patients, HAART is now comprised of many other drug types and classes aside from 
Zidovudine. Thus it is difficult to use the knowledge gained from their study in 
today’s HIV epidemic, which represents patients from every continent, being treated 
with some of the most sophisticated batteries of chemical agents developed in recent 
times (De Clerq, 2009).  
 
Given the strong cumulative evidence of HL’s effects on immunity and the precedent 
for studying HL in HIV patients, a study was devised to extend the findings of the 
Gruzelier group. Using a larger and more diverse sample of HIV-1+ patients (N=68), 
and employing strict controls for potential psychological, biological and neurological 
influences on the study outcome (CD4+ T-cells), the present study sought to extend 
current knowledge concerning laterality-immunity theory, and variability of HIV 
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prognosis. The analyses provided some support for the hypothesis of HL predicting 
HIV prognosis in the whole sample, and an important moderating factor was 
identified: HAART medication. A significant positive association between left HL 
and outcome CD4+ T-cell count was observed in the whole sample, independent of 
confounders (baseline CD4+ T-cell count, HAART medication) employing a basic 
nonparametric correlation, applying standardised residualisation of CD4+ counts to 
retain confounder contribution. This finding is in line with the Gruzelier group’s study 
(1996) and with the wider HL-immunity literature (Sumner et al., 2011). However, 
the initial statistical analysis employing linear multiple regression was unable to 
provide a significant result for this assessment, which is suggested to be due to 
skewness within the HL measurement variables, but due to this discrepancy further 
research is required. Employing HAART medication as a separation factor 
(moderator) in the participant pool, prospective associations between HL and CD4+ T-
cells were observed in patients not taking a HAART regimen, independent of the 
confounder of baseline CD4+ T-cell count. This important observation was the first of 
its kind, and its absence in the HAART-treated sub-sample is suggested to be resultant 
from HAART masking HL effects, as HAART is an immunomodulator in its own 
right. 
Another potential moderator was identified, namely ethnicity, with suggestions that 
left-HL is predictive of outcome CD4+ count in African, rather than European, 
patients. It is not possible at this stage to support the notion that ethnicity may be a 
true moderator in the HL-immune relationship in HIV, as the initially significant 
results yielded from the multiple regression analyses were not echoed by the 
subsequent nonparametric correlational analyses. The suggestion of ethnicity being a 
moderator in the HL-immune relationship is also a new implication, and although it 
will require more testing before it can be supported as a moderating factor, it has 
important implications in a global epidemic that is overwhelmingly over-represented 
in Africa.  
Proposed explanations for the conflicting significance of the main analyses (multiple 
regression versus Spearman’s rho correlation) include the sample size (which was 
ultimately slightly under that which was projected as required for such analysis a 
priori), the presence of outliers amongst the HL variable data, and significant 
skewness and kurtosis amongst these same variables even after outlier exclusion. 
Additionally, the measures of HL in the present study (self-report and 
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neuropsychological tests) not only differed from the preceding study, but also from 
those employed by former studies within the broader discipline that required HL 
assessment (i.e. not through stroke or surgery) as these all used Electroencephalogram 
(EEG). It is possible that the two measures employed for the present study may not be 
as sensitive to activational HL as measured by EEG examination, but may be more 
representative of functional HL only. For example, the Line Bisection Task (LBT) 
relies on cognitive cerebral organisation for perceptual and motor skills rather than on 
overall hemispheric activation, creating potential operational and interpretation biases 
(Flöel et al., 2005). Equally, the Hemispheric Preference Test (HPT) relies on the 
self-report of behaviours and preferences, which have been suggested to be modulated 
by affective states (Merckelbach et al., 1990; Russo et al., 2001).  
Despite the short-comings of the present study, it still fits within the framework of the 
existing literature concerning laterality and immunity; with left HL being observed to 
predict a slower decline in T-cells amongst HIV patients. Crucially, the present 
findings help to understand some proportion of variance between patients in terms of 
differences in time to morbidity and mortality in HIV disease. Further, the study adds 
to the current knowledge in the discipline of laterality-immunity research by 
describing a moderating factor of HAART medication; which has clinical significance 
in potentially providing a way to identify those patients that may require HAART 
initiation earlier (i.e. people low on left-HL) as well as identifying groups that would 
benefit from other targeted interventions. Neuropsychological interventions to 
increase left hemisphere activity could be implemented with sufficient ease as to be 
available to people in all areas of the world without relying on costly equipment, 
further medical involvement, or access to sophisticated clinics or treatment centres. 
Additionally, the hint toward ethnicity being a moderator in the HL-HIV-immunity 
relationship is another new suggestion in HL and HIV research. Whilst this 
suggestion is not a substantiated finding per se, it merits further research due to its 
near-significance and the disproportionate weight of HIV infections, with the equally 
disproportionate lack of resources to cope with HIV seen, in Africa. Thus, future 
research needs to test whether cognitive tasks which activate the left hemisphere 
improve CD4+ T-cell levels in non-medicated HIV patients. Additionally, the 
exploratory analyses concerning HL and behaviour uncover important implications 
for sexual health behaviour, HIV clinic attendance and substance misuse. These 
associations and trends are again new findings within the discipline, and warrant 
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further exploration, with potential significance to deepen our understanding of these 
behaviours, their antecedents, and potentially their prevention.  
 
The complitation of a systematic review to analyse the cumulative evidence of HL-
immunity research allows the discipline to assess the current knowledge, and advance 
that knowledge in areas of methodological limitation. The strength of evidence of the 
reviewed studies suggests that the time for mere observation of this relationship has 
ended. There is now the need to describe the HL-immune relationship by way of 
analysing moderating and mediating factors and controlling for known confounders, 
as well as looking in to the neurobiological mechanisms that facilitate and drive the 
lateralised brain-to-immune communication. Moreover, the combined suggestions of 
these data permit a more credible perspective of this often contentious subject area. 
Whilst it was not possible to conduct a full meta-analysis of the available data, the 
inclusion of effect size analysis afforded a higher level of scientific application than a 
simple review, and can be implemented relatively easily if the appropriate data are 
reported.  
 
In summation, the present thesis contributes a synthesised description of laterality-
immunity research in humans, in the systematic review and the advancement of 
existing research into the effect of HL on HIV progression. The systematic review 
provides the first cumulative perspective on the current evidence in the laterality-
immunity domain of psychoneuroimmunology in humans. Moreover by employing 
effect size analysis it provides meaningful, empirical weight to the sometimes 
contested role of HL within the field. The advancement of the one study within the 
literature to examine the practical implications of HL in immunity (i.e. Gruzelier et 
al., 1996) not only provides further evidence for the immunomodulating effects of 
HL, but also expands the knowledge to suggest the moderating factor of medication, 
namely HAART treatment, and the potential moderator of ethnicity. Importantly, the 
present work may have implications for other immune-mediated diseases, to 
eventually help guide interventions for diseases without a current cure, and to 
understand some of the variation observed in disease course, wellness and behaviour.  
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Can Differences in Brain Function Predict HIV Prognosis? 
 
 
The study you are being asked to take part is conducted by Rachel Sumner, a PhD 
student at Brunel University in West London. The study is being used as the main 
research to complete this course. The Brunel School of Health Sciences and Social 
Care ethics committee has approved this research. The study is being supervised by 
Dr Alex Nowicky of Brunel University and is being run in conjunction with Professor 
Yori Gidron and the cooperation of University Hospital of Brussels.  
 
The contact details of the main researcher, her supervisor and the chair of the research 
ethics committee are supplied below; please make a note of them for future reference.  
 
 
• What is it about? 
The current study concerns whether it is possible to predict how people progress in 
their course of HIV by looking at differences in brain functioning. In order to assess 
this we will be asking you to complete some questionnaires and some simple tests to 
look at how your brain works. In order to assess how this impacts upon your 
prognosis we will need to collect your CD4+ and viral load at three and six months 
after you have completed the initial part of the study. Please note that we will only 
count on reports of these measures and will not be asking you to undergo any 
additional blood tests. The easiest way for us to do this is to access your medical 
records when you have your normal check ups.  
In order to carry out the study we must have access to your medical record. We will 
only collect information concerning your CD4+ and viral load, and that information 
will only be collected by a member of the research team. All of your medical 
information will be kept strictly confidential, however if you do not feel comfortable 
allowing us access to your medical records then please do not participate.  
 
 
• What will I need to do? 
The first part of the study will involve completing questionnaires to assess your 
suitability to take part in the study. As we are looking for some very specific 
relationships between your brain functioning and your illness there are certain 
conditions whereby you may not be suitable to participate, this is nothing to be 
alarmed about it is purely a reflection of the very early stages of this line of research.  
 
The main study involves answering a questionnaire about your background and the 
various aspects of your illness, such as how and when you contracted HIV, what 
symptoms you have and what types of treatment you access.  The questions on this 
questionnaire are personal, but will remain confidential and are only included because 
they are essential to our being able to understand the relationship between any other 
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personal factors (eg. health behaviour, duration of illness etc.) and the course of your 
illness.  
The next part of the study involves completing questionnaires and computer-based 
tests which look at your mood, your health behaviours and how your brain functions. 
There are two types of neuropsychological test for you to complete; one presents you 
with a bisected line and asks you to indicate which half of the line is greater: the left 
or the right. The other test asks questions concerning your thoughts and activities and 
you are asked to select one of the two statements that most applies to you.  
 
These questionnaires and tests should take between 20 and 30 minutes to complete. If 
you are not sure you have time to complete them all in one sitting then please book an 
appointment with the researcher. Should you wish, it may be possible for you to 
complete this study at home, using our secure web server for the tests and having a 
brief telephone call. However, as this study originates from the UK you should be 
confident in your ability to speak, read and understand English if you choose this 
option.  
 
The questionnaires are intended for us to collect information only, and as such we 
cannot use them to provide you with any form of diagnostic information. If there is 
anything in the tests that causes you concern you are urged to speak to your doctor or 
clinician. You are also asked to stop your participation if you feel any type of distress 
during the proceedings of this research. 
 
• What next? 
As mentioned previously, we will need to obtain your CD4+ count and viral load at 
three and six months after your initial visit with the researcher. With your permission 
this will be done directly with the staff at the hospital. Please note that all members of 
the research team, including those who are assisting us at the hospital, are bound by 
confidentiality and no other details aside from your CD4 and viral load will be 
disclosed.   
Because we are trying to examine a relationship between your brain function and the 
course of your illness, we may also want to collect information about your CD4 and 
viral load up to six months prior to you beginning the study. Again, this is the only 
information we will collect from your medical records and it will remain strictly 
confidential.  
 
• Ethical conduct & your rights in research 
You have the right at any time during or after this research to withdraw yourself and 
your data from the study. This right is comprehensive and enduring; should you wish 
to discontinue your participation you can do so at any time and without providing a 
reason. If you choose to withdraw yourself from the study you can request your data 
or you can request that it be destroyed.  
All the information you provide us is confidential and anonymous. You will be given 
a “participant identification code” when you agree to take part, which will ensure your 
anonymity and allows us to identify your data should you wish to withdraw. All of the 
data you provide us will include this unique code, and only one file will include a link 
between this code and your name. This file will be kept in a locked box in the 
researcher’s home.  
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The information gleaned from this research will be prepared in to a doctoral thesis, 
scientific journals and conference presentations. At no point will any individual 
personal information be made available to the public.  
 
 
 
 
We are conducting this study with the generous cooperation of the University 
Hospital Brussels. Whether or not you decide to participate in this research will have 
no bearing whatsoever on your access to their facilities or the quality or degree of care 
that you receive from them. Any member of staff at The University Hospital Brussels 
who is not a member of the research team will not be notified of any individuals’ 
participation in the research, but they are aware of the content and background of the 
study should you wish to discuss any aspects of the study with them. If you feel any 
degree of concern about the impact this study may have on your illness or your use of 
clinical services we urge you to discuss this with the experimenter or your clinician. 
 
If you have any doubts about any part of the research, or you do not feel 
completely comfortable in carrying out what we ask you to do then please do not 
take part. We understand that we are asking you to take part in research about 
something that is deeply personal to you, and we respect your right to privacy. 
 
This study has been approved by the Brunel University School of Health 
Sciences and Social Care Research Ethics Committee. 
 
 
• Contact Information 
 
Rachel Sumner, MSc. - Researcher 
rachel.sumner@brunel.ac.uk 
rachel.c.sumner@googlemail.co.uk 
 
Dr Alex Nowicky Ph. D. - Supervisor 
Alex.nowicky@brunel.ac.uk 
 
Elizabeth Cassidy – Chair of Ethics Committee, Brunel University School of Health 
Sciences and Social Care 
Elizabeth.Cassidy@brunel.ac.uk 
 
School of Health Sciences & Social Care 
Brunel University 
Uxbridge 
Middlesex  
UB8 3PH 
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Informed Consent 
 
Research Consent 
(Please tick as appropriate) 
 
1. I have received sufficient information about this research to understand what 
my participation will involve. 
 
YES □ 
  NO □ 
 
2. I give consent for the research team to access my medical records to obtain 
information about my CD4 count and viral load  
 
YES □ 
  NO □ 
 
 
3. I understand that any information I provide will be anonymous and 
confidential. 
 
YES □ 
NO □ 
 
4. I understand that I have the right to withdraw myself and my data from this 
research at any time and without necessarily providing reason for doing so. 
 
YES □ 
NO □ 
 
 
By completing the below information as indication of the above declarations I 
confirm that I am willing to participate in this research based on the information I 
have received. I understand that my personal information will be completely 
confidential and that any data collected from me will be anonymous. I also understand 
that I have the right to withdraw myself and my data from this research at any point 
during the research or after it has finished. 
 
 
 
Please provide us with your name and date of birth. This will not be attached to any of 
the information you provide us, but will need to be retained should you at any point 
wish to withdraw yourself and your data from the research. 
 
Name………………………… 
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Date of Birth ………………. (DD/MM/YYYY) 
 
 
 
 
This study has been approved by the Brunel University School of Health Sciences and 
Social Care Research Ethics Committee. 
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Demographic Questionnaire 
 
Age……………………… 
 
Gender :  Male  Female 
 
Ethnicity: 
 
Education: 
 
Employment status: 
 
Sexual orientation: 
 
Relationship status: 
 
 
(a) How many sexual partners have you had in the last 12 months? 
 
 
(b) Condom use: 12 months?  
 
Always Often  Sometimes Never 
 
(c) STI? – last 12 m? 
 
 
 
Frequency of use in the last month  
No use Once or 
twice 
Once a 
week 
Several 
times a 
week 
Daily 
Alcohol      
Cigarettes/Tobacco      
Marijuana      
Cocaine      
 
 
 
 
HIV for ……………………….years and ……………months 
MoC: 
Moriskey:  
Meds: 
 
 
 191 
Hospital Anxiety & Depression Scale 
Please read the statements and tick which response best suits your experience. 
 
 
 
 
 Yes 
definitely 
Yes 
sometimes 
No, not 
much 
No, not at 
all 
1. I wake up early and then sleep 
badly for rest of the night. 
    
2. I get very frightened or have 
panic feelings for apparently 
no reason at all. 
    
3. I feel miserable and sad.     
4. I feel anxious when I go out 
of the house on my own. 
    
5. I have lost interest in things.     
6. I get palpitations, or 
sensations of “butterflies” in 
my stomach or chest. 
    
7. I have a good appetite.     
8. I feel scared or frightened.      
9. I feel life is not worth living.     
10. I still enjoy the things I used 
to. 
    
11. I am restless and can’t keep 
still. 
    
12. I am more irritable than usual.     
13. I feel as if I have slowed 
down. 
    
14. Worrying thoughts constantly 
go through my mind.  
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Hemispheric Preference Test 
1. How often are your decisions based on objective facts rather than feelings? 
Never (1)  Always (10) 
 
2. Are you psychic? 
Never (1)  Always (10) 
 
3. Do you like using symbols and/or images in solving problems? 
Never (1)  Always (10) 
 
4. How good are you at teaching and/or explaining by manipulating objects? 
Never (1)  Excellent (10) 
 
5. Are you artistically or musically creative? 
Never (1)  Always (10) 
 
6. Are you logical? 
Never (1)  Always (10) 
 
7. How good are you at solving crossword puzzles? 
Poor (1)  Excellent (10) 
 
8. How quickly can you read? 
Very slowly (1)  Very Quickly (10) 
 
9. How vivid are your daydreams? 
Not at all vivid (1)  Extremely vivid (10) 
 
10. How good is your ability to think of synonyms for words? 
Poor (1)  Excellent (10) 
 
11. Do you remember your dreams often? 
Never (1)  Always (10) 
 
12. How vivid are your dreams? 
Not at all vivid (1)  Extremely vivid (10) 
 
13. Are you fluent in using words? 
Never (1)  Always (10) 
 
14. Do you use a playful approach to solving problems? 
Never (1)  Always (10) 
 
15. Do you use a serious, all-business approach to solving problems? 
Never (1)  Always (10) 
 
16. Do you like experiences to be planned and structured? 
Never (1)  Always (10) 
 
17. Do you like to think or read while sitting upright? 
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Never (1)  Always (10) 
18. How often does your thinking consist of words? 
Never (1)  Always (10) 
 
19. How often does your thinking consist of mental pictures or images? 
Never (1)  Always (10) 
 
20. Do you like teaching or explaining by visual presentation? 
Never (1)  Always (10) 
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Moriskey Medication Adherence Scale (Moriskey et al., 1986) 
 
 
 YES NO 
a) Do you ever forget to take your medicine?   
b) Are you careless at times about taking your medicine?   
c) When you feel better do you sometimes stop taking your 
medicine? 
  
d) Sometimes if you feel worse when you take the medicine, 
do you stop taking it? 
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APPENDIX C 
 
 
RAW DATA 
 
 
 
Skewness and Kurtosis reports for HL and CD4+ collections 
 
Multiple Regression analyses – for the whole and moderator-
split samples 
 
Exploratory behavioural analyses 
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1. Skewness and Kurtosis in HL variables and CD4+ collections 
 
Variable Skewness (Std. Error) Kurtosis (Std. Error) 
Left HPT (Log10 transformation) -2.455 (.306) 14.55 (.604) 
Left LBT -.257 (.291) -.730 (.574) 
CD4+ T1 .823 (.306) .452 (.604) 
CD4+ T2 .572 (.295) .137 (.582) 
CD4+ T3 .766 (.309) 1.094 (.608) 
 
 
 
 
2) Multiple Regression analysis – whole sample, using confounders identified a 
priori for the outcome measure of CD4+ 
 
 
Warnings 
For models with dependent variable CD4 +1, the following variables are constants or have missing 
correlations: HAART. They will be deleted from the analysis. 
 
 
Variables Entered/Removedb 
Model Variables Entered Variables Removed Method 
1 Mean Clinic Visit, 
Non_Adh_2, CD4 -
1, Duration of HIVa 
. Enter 
2 LHPT_Log_2a . Enter 
a. All requested variables entered. 
b. Dependent Variable: CD4 +1 
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ANOVAc 
Model Sum of Squares df Mean Square F Sig. 
Regression 1907392.731 4 476848.183 24.898 .000a 
Residual 593712.825 31 19152.027   
1 
Total 2501105.556 35    
Regression 1915933.654 5 383186.731 19.645 .000b 
Residual 585171.902 30 19505.730   
2 
Total 2501105.556 35    
a. Predictors: (Constant), Mean Clinic Visit, Non_Adh_2, CD4 -1, Duration of HIV 
b. Predictors: (Constant), Mean Clinic Visit, Non_Adh_2, CD4 -1, Duration of HIV, LHPT_Log_2 
c. Dependent Variable: CD4 +1 
 
 
 
 
Model Summary 
Change Statistics 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate R Square Change F Change df1 df2 Sig. F Change 
1 .873a .763 .732 138.39085 .763 24.898 4 31 .000 
2 .875b .766 .727 139.66292 .003 .438 1 30 .513 
a. Predictors: (Constant), Mean Clinic Visit, Non_Adh_2, CD4 -1, Duration of HIV 
b. Predictors: (Constant), Mean Clinic Visit, Non_Adh_2, CD4 -1, Duration of HIV, LHPT_Log_2 
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Coefficientsa 
Unstandardized Coefficients 
Standardized 
Coefficients 
Model B Std. Error Beta t Sig. 
(Constant) -407.397 175.662  -2.319 .027 
CD4 -1 .889 .098 .831 9.088 .000 
Duration of HIV .552 4.708 .011 .117 .907 
Non_Adh_2 53.775 37.041 .131 1.452 .157 
1 
Mean Clinic Visit 2.485 .847 .257 2.934 .006 
(Constant) -1045.837 980.977  -1.066 .295 
CD4 -1 .911 .104 .851 8.748 .000 
Duration of HIV -.107 4.855 -.002 -.022 .982 
Non_Adh_2 57.023 37.702 .138 1.512 .141 
Mean Clinic Visit 2.485 .855 .257 2.907 .007 
2 
LHPT_Log_2 202.409 305.886 .062 .662 .513 
a. Dependent Variable: CD4 +1 
 
 
 
Excluded Variablesb 
Collinearity 
Statistics 
Model Beta In t Sig. Partial Correlation Tolerance 
1 LHPT_Log_2 .062a .662 .513 .120 .878 
a. Predictors in the Model: (Constant), Mean Clinic Visit, Non_Adh_2, CD4 -1, Duration of HIV 
b. Dependent Variable: CD4 +1 
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3) Multiple Regression analysis – whole sample, using confounders identified statistically for the outcome measure of CD4+. 
 
 
Variables Entered/Removed 
Model 
Variables 
Entered 
Variables 
Removed Method 
1 HAART, CD4 -1a . Enter 
2 LB_LHL, 
LHPT_Log_2a 
. Enter 
a. All requested variables entered. 
 
 
 
Model Summary 
Change Statistics 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
R Square 
Change F Change df1 df2 Sig. F Change 
1 .846a .716 .704 138.07832 .716 60.569 2 48 .000 
2 .852b .726 .702 138.70150 .009 .785 2 46 .462 
a. Predictors: (Constant), HAART, CD4 -1 
b. Predictors: (Constant), HAART, CD4 -1, LB_LHL, LHPT_Log_2 
 
 
 201 
 
ANOVAc 
Model Sum of Squares df Mean Square F Sig. 
Regression 2309575.283 2 1154787.642 60.569 .000a 
Residual 915149.893 48 19065.623   
1 
Total 3224725.176 50    
Regression 2339772.333 4 584943.083 30.405 .000b 
Residual 884952.843 46 19238.105   
2 
Total 3224725.176 50    
a. Predictors: (Constant), HAART, CD4 -1 
b. Predictors: (Constant), HAART, CD4 -1, LB_LHL, LHPT_Log_2 
c. Dependent Variable: CD4 +1 
 
 
Coefficientsa 
Unstandardized Coefficients 
Standardized 
Coefficients 
Model B Std. Error Beta t Sig. 
(Constant) 172.218 82.534  2.087 .042 
CD4 -1 .850 .081 .820 10.514 .000 
1 
HAART -72.759 49.378 -.115 -1.474 .147 
(Constant) -293.632 841.962  -.349 .729 
CD4 -1 .860 .083 .830 10.396 .000 
HAART -60.863 50.890 -.096 -1.196 .238 
LHPT_Log_2 160.093 266.439 .048 .601 .551 
2 
LB_LHL -7.956 7.782 -.080 -1.022 .312 
a. Dependent Variable: CD4 +1 
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Excluded Variablesb 
Collinearity 
Statistics 
Model Beta In t Sig. 
Partial 
Correlation Tolerance 
LHPT_Log_2 .058a .724 .473 .105 .933 1 
LB_LHL -.085a -1.107 .274 -.159 .989 
a. Predictors in the Model: (Constant), HAART, CD4 -1 
b. Dependent Variable: CD4 +1 
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4) Bivariate correlations for exploratory behavioural analyses using the Line Bisection Test (LBT) 
 
 
Correlations 
  
Non_Adh_2 
12m No. Sexual 
Partners 
Condom Use 
12m Alcohol use 1m 
Cigarette/Tobacc
o use 1m 
Marijuana use 
1m Cocaine use 1m Mean Clinic Visit 
Pearson Correlation .020 -.220 .132 .174 -.097 -.256* .130 -.035 
Sig. (2-tailed) .895 .071 .287 .157 .430 .035 .290 .784 
LB_LHL 
N 47 68 67 68 68 68 68 65 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
 
 
5) Bivariate correlations for exploratory behavioural analyses using the LBT, with the sample split by ethnicity 
 
Correlations 
Ethnicity Non_Adh_2 
12m No. Sexual 
Partners 
Condom Use 
12m Alcohol use 1m 
Cigarette/Tobacc
o use 1m 
Marijuana use 
1m Cocaine use 1m Mean Clinic Visit 
Pearson Correlation .127 -.356* .108 .024 -.211 -.357* .120 .115 
Sig. (2-tailed) .495 .017 .487 .876 .163 .016 .432 .468 
European LB_LHL 
N 31 45 44 45 45 45 45 42 
 204 
Pearson Correlation -.161 .078 .148 .334 .a .a .a -.360 
Sig. (2-tailed) .551 .725 .502 .119 . . . .092 
African LB_LHL 
N 16 23 23 23 23 23 23 23 
*. Correlation is significant at the 0.05 level (2-tailed). 
a. Cannot be computed because at least one of the variables is constant. 
 
 
6) Bivariate correlations for exploratory behavioural analyses using the Hemispheric Preference Test (HPT) for the whole sample. 
 
 
 
Correlations 
  
Non_Adh_2 
12m No. Sexual 
Partners 
Condom Use 
12m Alcohol use 1m 
Cigarette/Tobacc
o use 1m 
Marijuana use 
1m Cocaine use 1m Mean Clinic Visit 
Pearson Correlation -.020 .032 -.046 -.104 .030 -.015 .177 -.034 
Sig. (2-tailed) .899 .808 .730 .430 .823 .910 .176 .800 
LHPT_Log_2 
N 44 60 59 60 60 60 60 57 
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7) Bivariate correlations for exploratory behavioural analyses using the HPT, with the sample split by ethnicity 
 
 
Correlations 
Ethnicity Non_Adh_2 
12m No. Sexual 
Partners 
Condom Use 
12m Alcohol use 1m 
Cigarette/Tobacc
o use 1m 
Marijuana use 
1m Cocaine use 1m Mean Clinic Visit 
Pearson Correlation -.017 .094 -.137 -.151 .130 .023 .253 -.052 
Sig. (2-tailed) .931 .566 .406 .351 .425 .889 .115 .760 
European LHPT_Log_2 
N 30 40 39 40 40 40 40 37 
Pearson Correlation -.004 .262 .349 .315 .a .a .a -.017 
Sig. (2-tailed) .990 .264 .131 .176 . . . .942 
African LHPT_Log_2 
N 14 20 20 20 20 20 20 20 
a. Cannot be computed because at least one of the variables is constant. 
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